Patent Grant
11911387
The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.
The present invention further relates to certain DPP-4 inhibitors for treating and/or preventing endothelial dysfunction.
The present invention further relates to certain DPP-4 inhibitors for use as antioxidants and/or anti-inflammatories.
The present invention further relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction (e.g. in diabetes or non-diabetes patients), particularly independently from or beyond glycemic control.
The present invention further relates to certain DPP-4 inhibitors for treating and/or preventing hyperglycemia-induced or -associated oxidative stress (e.g. beyond glycemic control), as well as to the use of such DPP-4 inhibitors in antidiabetic therapy.
The present invention further relates to certain DPP-4 inhibitors for treating and/or preventing metabolic diseases, such as diabetes, especially type 2 diabetes mellitus and/or diseases related thereto (e.g. diabetic complications), particularly in patients having or being at risk of oxidative stress, vascular stress and/or endothelial dysfunction, or diseases or conditions related or associated therewith.
Further, the present invention relates to certain DPP-4 inhibitors for treating and/or preventing metabolic diseases, such as diabetes, especially type 2 diabetes mellitus and/or diseases related thereto (e.g. diabetic complications), in patients having or being at risk of cardiovascular and/or renal disease, such as e.g. myocardial infarction, stroke or peripheral arterial occlusive disease and/or diabetic nephropathy, micro- or macroalbuminuria, or acute or chronic renal impairment.
Further, the present invention relates to certain DPP-4 inhibitors for treating and/or preventing metabolic diseases, such as diabetes, especially type 2 diabetes mellitus and/or diseases related thereto, in patients having or being at risk of micro- or macrovascular diabetic complications, such as e.g. diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, or cardio- or cerebrovascular diseases (such as e.g. myocardial infarction, stroke or peripheral arterial occlusive diasease).
Further, the present invention relates to certain DPP-4 inhibitors for modulating, blocking or reducing deleterious metabolic memory effect of (chronic or transient episodes of) hyperglycemia, particularly on diabetic complications.
Further, the present invention relates to certain DPP-4 inhibitors for treating, preventing or reducing risk for micro- or macrovascular diseases which may be induced, memorized by or associated with exposure to oxidative stress.
Furthermore, the present invention relates to a certain DPP-4 inhibitor for treating and/or preventing metabolic diseases, such as diabetes, especially type 2 diabetes mellitus and/or diseases related thereto (e.g. diabetic complications), in patients with or at risk of cardiovascular and/or renal disease, particularly in those type 2 diabetes patients being at risk of cardio- or cerebrovascular events, such as type 2 diabetes patients with one or more risk factors selected from A), B), C) and D):
A) previous or existing vascular disease (such as e.g. myocardial infarction (e.g. silent or non-silent), coronary artery disease, percutaneous coronary intervention, coronary artery by-pass grafting, ischemic or hemorrhagic stroke, congestive heart failure (e.g. NYHA class I or II, e.g. left ventricular function<40%), or peripheral occlusive arterial disease),
B) vascular related end-organ damage (such as e.g. nephropathy, retinopathy, neuropathy, impaired renal function, chronic kidney disease, and/or micro- or macroalbuminuria),
C) advanced age (such as e.g. age>/=60-70 years), and
D) one or more cardiovascular risk factors selected from
Moreover, the present invention relates to a certain DPP-4 inhibitor for use in a method of preventing, reducing the risk of or delaying the occurrence of cardio- or cerebrovascular events, such as cardiovascular death, (fatal or non-fatal) myocardial infarction (e.g. silent or non-silent MI), (fatal or non-fatal) stroke, or hospitalisation (e.g. for acute coronary syndrome, leg amputation, (urgent) revascularization procedures, heart failure or for unstable angina pectoris), preferably in type 2 diabetes patients, particularly in those type 2 diabetes patients being at risk of cardio- or cerebrovascular events, such as type 2 diabetes patients with one or more risk factors selected from A), B), C) and D):
A) previous or existing vascular disease (such as e.g. myocardial infarction (e.g. silent or non-silent), coronary artery disease, percutaneous coronary intervention, coronary artery by-pass grafting, ischemic or hemorrhagic stroke, congestive heart failure (e.g. NYHA class I or II, e.g. left ventricular function<40%), or peripheral occlusive arterial disease),
B) vascular related end-organ damage (such as e.g. nephropathy, retinopathy, neuropathy, impaired renal function, chronic kidney disease, and/or micro- or macroalbuminuria),
C) advanced age (such as e.g. age>/=60-70 years), and
D) one or more cardiovascular risk factors selected from
Yet moreover, the present invention relates to a certain DPP-4 inhibitor for use in a method of preventing, reducing the risk of or delaying the occurrence of cardio- or cerebrovascular events, such as cardiovascular death, (fatal or non-fatal) myocardial infarction (e.g. silent or non-silent MI), (fatal or non-fatal) stroke, or hospitalisation (e.g. for acute coronary syndrome, leg amputation, (urgent) revascularization procedures, heart failure or for unstable angina pectoris) in type 2 diabetes patients with vascular related end-organ damage, particularly nephropathy, impaired renal function, chronic kidney disease, micro- or macroalbuminuria, said method comprising administering a therapeutically effective amount of the DPP-4 inhibitor, optionally in combination with one or more other therapeutic substances, to the patient.
Yet moreover, the present invention relates to a certain DPP-4 inhibitor for use in a method of improving cognitive function (e.g. attenuating, reversing or treating cognitive decline), improving β-cell function (e.g. improving insulin secretion rate derived from a 3 h meal tolerance test, improving long term β-cell function), improving diurnal glucose pattern (e.g. improving ambulatory glucose profile, glycemic variability, biomarkers of oxidation, inflammation or endothelial function), and/or improving durability of glucose control according to β-cell autoantibody status (e.g., glutamic acid decarboxylase GAD), said method comprising administering a therapeutically effective amount of the DPP-4 inhibitor, optionally in combination with one or more other therapeutic substances, to the patient.
Yet moreover, the present invention relates to a certain DPP-4 inhibitor for use in a method of preventing, reducing the risk of, slowing the progression of, delaying the onset of, attenuating, reversing or treating cognitive dysfunction or cognitive decline, said method comprising administering a therapeutically effective amount of the DPP-4 inhibitor, optionally in combination with one or more other therapeutic substances, to the patient.
Yet moreover, the present invention relates to a certain DPP-4 inhibitor for use in a method of preventing, reducing the risk of, slowing the progression of, delaying the onset of, attenuating, reversing or treating latent autoimmune diabetes in adults (LADA), said method comprising administering a therapeutically effective amount of the DPP-4 inhibitor, optionally in combination with one or more other therapeutic substances, to the patient.
Further, the present invention relates to a certain DPP-4 inhibitor for use in a method (with the joint aims) of
preventing, reducing the risk of, slowing the progression of, delaying the onset of, attenuating, reversing or treating cardio- or cerebrovascular disease or events (such as e.g. those described herein), and
preventing, reducing the risk of, slowing the progression of, delaying the onset of, attenuating, reversing or treating diabetic nephropathy,
in a patient in need thereof (such as e.g a patient as described herein, especially a type 2 diabetes patient),
said method comprising administering a therapeutically effective amount of the DPP-4 inhibitor, optionally in combination with one or more other therapeutic substances, to the patient.
Further, the present invention relates to one or more of the following methods of
Further, the present invention relates to a certain DPP-4 inhibitor for use in a method of preventing, reducing the risk of, slowing the progression of, delaying the onset of, attenuating, reversing or treating diabetic nephropathy,
in a patient (such as e.g a patient as described herein, especially a type 2 diabetes patient), who does not adequately respond to therapy with an angiotensin receptor blocker (ARB such as e.g. telmisartan),
said method comprising administering a therapeutically effective amount of the DPP-4 inhibitor, optionally in combination with one or more other therapeutic substances (e.g. an ARB such as e.g. telmisartan), to the patient.
Features of diabetic nephropathy may include hyperfiltration (in early stage), micro- or macroalbuminuria, nephrotic syndrome, proteinuria, hypertension, fluid retention, edema, and/or progressively impaired or decreased kidney and renal filter function (e.g. glomerular filitration rate GFR) leading finally to renal failure or end-stage renal disease. Further features may include diffuse or nodular glomerulosclerosis, afferent and efferent hyaline arteriolosclerosis, and/or tubulointerstitial fibrosis and atrophy. Further features may include abnormal albumin/creatinine or protein/creatinine ratio and/or abnormal glomerular filtration rate.
The present invention further relates to a certain DPP-4 for use in a method of preventing or treating diabetic nephropathy in a patient with inadequate response to therapy with an angiotensin receptor blocker (ARB such as e.g. telmisartan). The method may comprise administering a therapeutically effective amount of the DPP-4 inhibitor and telmisartan to the patient.
Accordingly, in a particular embodiment, a preferred DPP-4 inhibitor within the meaning of this invention is linagliptin.
Pharmaceutical compositions or combinations for use in these therapies comprising the DPP-4 inhibitor as defined herein optionally together with one or more other active substances are also contemplated.
Further, the present invention relates to the DPP-4 inhibitors, optionally in combination with one, two or more further active agents, each as defined herein, for use in the therapies as described herein.
Further, the present invention relates to the use of the DPP-4 inhibitors, optionally in combination with one, two or more further active agents, each as defined herein, for preparing pharmaceutical compositions which are suitable for the treatment and/or prevention purposes of this invention.
Further, the present invention relates to a therapeutic (treatment or prevention) method as described herein, said method comprising administering an effective amount of a DPP-4 inhibitor as described herein and, optionally, one or more other active or therapeutic agents as described herein to the patient in need thereof.
Oxidative stress represents an imbalance between the production of reactive oxygen species (which include free radicals, which typically have an oxygen- or nitrogen based unpaired electron in their outer orbitals and peroxides) and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage. Disturbances in the normal redox state of tissues can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipides and nucleic acid/DNA. Oxidative stress can target many organs (such as blood vessels, eyes, heart, skin, kidney, joints, lung, brain, immune system, liver, or multi-organs) and can be involved in many diseases and conditions. Examples of such diseases or conditions associated with oxidative stress include atherosclerosis (e.g. platelet activation and atheromatous plaque formation), endothelial dysfunction, restenosis, hypertension, peripheral occlusive vascular disease, ischemia-reperfusion injuries (e.g. renal, hepatic, cardiac or cerebral ischemia-reperfusion injuries), fibrosis (e.g. renal, hepatic, cardiac or pulmonary fibrosis); macular degeneration, retinal degeneration, cateracts, retinopathy; coronary heart disease, ischemia, myocardial infarction; psoriasis, dermatitis; chronic kidney disease, nephritis, acute renal failure, glomerulonephritis, nephropathy; rheumatoid arthritis, osteoarthritis; asthma, COPD, respiratory distress syndrome; stroke, neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease, Huntington's disease), schizophrenia, bipolar disorder, obsessive compulsive disorder; chronic systemic inflammations, perivascular inflammation, autoimmune disorders, multiple sclerosis, lupus erythematosus, inflammatory bowel disease, ulcerative colitis; NAFLD/NASH; chronic fatigue syndrome, polycystic ovary syndrome, sepsis, diabetes, metabolic syndrome, insulin resistance, hyperglycemia, hyperinsulinemia, dyslipidemia, hypercholesterolemia, hyperlipidemia, etc. In addition to their original pharmacological properties, certain drugs used clinically, including, without being limited, anti-hypertension agents, angiotensin receptor blockers and antihyperlipidemic agents such as statins, protect various organs via anti-oxidative stress mechanisms.
Patients with or at risk of oxidative and/or vascular stress can be diagnosed by determining patient's oxidative stress markers, such as e.g. oxidized LDL, markers of inflammatory status (e.g. pro-inflammatory interleukins), 8-OHdG, isoprostanes (e.g. F2-isoprostanes, 8-iso-prostaflandin F2alpha), nitrotyrosine, or N-carboxymethyl lysine (CML).
Endothelial dysfunction, commonly assessed clinically as impaired endothelium-dependent vasomotion (e.g. imbalance between vasodilating and vasoconstricting), is a physiological disability of endothelial cells, the cells that line the inner surface of blood vessels, arteries and veins, that prevents them from carrying out their normal biochemical functions. Normal endothelial cells are involved in mediating the processes of coagulation, platelet adhesion, immune function, control of volume and electrolyte content of the intravascular and extravascular spaces. Endothelial dysfunction is associated with proinflammatory, pro-oxidative and prothrombotic changes within the arterial wall. Endothelial dysfunction is thought to be a key event in the development and progression of atherosclerosis and arterial stiffness, and predates clinically obvious vascular complications. Endothelial dysfunction is of prognostic significance in detecting vascular disease and predicting adverse vascular events.
Risk factors for atherosclerosis and vascular disease/events are associated with endothelial dysfunction. Endothelial damage also contributes to the development of renal injury and/or chronic or progressive kidney damages, such as e.g. tubulointerstitial fibrosis, glomerulonephritis, micro- or macroalbuminuria, nephropathy and/or chronic kidney disease or renal failure. There is supporting evidence that oxidative stress does not only contribute to endothelial dysfunction or damage but also to vascular disease.
Type 2 diabetes mellitus is a common chronic and progressive disease arising from a complex pathophysiology involving the dual endocrine effects of insulin resistance and impaired insulin secretion with the consequence not meeting the required demands to maintain plasma glucose levels in the normal range. This leads to hyperglycaemia and its associated micro- and macrovascular complications or chronic damages, such as e.g. diabetic nephropathy, retinopathy or neuropathy, or macrovascular (e.g. cardio- or cerebro-vascular) complications. The vascular disease component plays a significant role, but is not the only factor in the spectrum of diabetes associated disorders. The high frequency of complications leads to a significant reduction of life expectancy. Diabetes is currently the most frequent cause of adult-onset loss of vision, renal failure, and amputation in the Industrialised World because of diabetes induced complications and is associated with a two to five fold increase in cardiovascular disease risk.
Large randomized studies have established that intensive and tight glycemic control during early (newly diagnoses to 5 years) stage diabetes has enduring beneficial effects and reduces the risk of diabetic complications, both micro- and macrovascular. However, many patients with diabetes still develop diabetic complications despite receiving intensified glycemic control.
Epidemiological and prospective data support a long-term influence of early (newly diagnosed to 5 years) metabolic control on clinical outcomes. It has been found that hyperglycemia has long-lasting deleterious effects both in type 1 and type 2 diabetes and that glycemic control, if not started at a very early stage of the disease or not intensively or not tightly provided, may not be enough to completely reduce complications.
It has been further found that transient episodes of hyperglycemia (e.g. hyperglycemic events), can induce molecular changes, and that these changes can persist or are irreversible after return to normoglycemia.
Collectively, these data suggest that metabolic memories are stored early in the course of diabetes and that, in certain diabetic conditions, oxidative and/or vascular stresses can persist after glucose normalization. This phenomenon that early glycemic environment, and/or even transient hyperglycemia, is remembered with clinical consequences in the target end organs (e.g. blood vessels, retina, kidney, heart, extremities) has recently been termed as ‘metabolic memory.’
Potential mechanisms for propagating this ‘memory’ are certain epigenetic changes, the non-enzymatic glycation of cellular proteins and lipids (e.g. formation of advanced glycation end-products), oxidatively modified atherogenic lipoproteins, and/or an excess of cellular reactive oxygen and nitrogen species (RONS), in particular originated at the level of glycated-mitochondrial proteins, perhaps acting in concert with one another to maintain stress signalling.
Mitochondria are one of major sources of recative oxygen species (ROS) in cells. Mitochondrial dysfunction increases electron leak and the generation of ROS from the mitochondrial respiratory chain (MRC). High levels of glucose and lipids impair the activities of MRC complex enzymes. For example, the MRC enzyme NADPH oxidase generates superoxide from NADPH in cells. Increased NADPH oxidase activity can be detected in diabetic patients.
Further, there is evidence that overproduction of free radicals, such as e.g. reactive oxygen species (ROS), contributes to oxidative and vascular stress after glucose normalization and to developing and/or maintaining the metabolic memory, and thus to the unifying link between hyperglycemia and cellular memory effects, such as e.g. in endothelial dysfunction or other complications of diabetes.
Thus, mainly related to persisting (long-term) oxidative stress induced by or associated with (chronic, early or transient episodes of) hyperglycemia, there are certain metabolic conditions in that, even normalizing glycemia, a long-term persitent activation of many pathways involved in the pathogenesis of diabetic complications can still be present. One of the major findings in the course of diabetes has thereby been the demonstration that even in normoglycemia and independent of the actual glycemic levels an overproduction of free radicals can still be evident. For example, endothelial dysfunction (a causative marker of diabetic vascular complications) can persist even after normalizing glycemia. However, there is evidence that combining antioxidant therapy with normalization of glycemia can be used to almost interrupt endothelial dysfunction.
Therefore, treating oxidative and/or vascular stress particularly beyond glycemic control, such as by the reduction of cellular reactive species and/or of glycation (e.g. by inhibition of the production of free oxygen and nitrogen radicals), preferably independently of glycemic status, may beneficially modulate, reduce, block or protect against the memory' effect of hyperglycemia and reduce the risk, prevent, treat or delay the onset of long-term diabetic complications, particularly such ones which are associated with or induced by oxidative stress, in patients in need thereof.
The treatment of type 2 diabetes typically begins with diet and exercise, followed by oral antidiabetic monotherapy, and although conventional monotherapy may initially control blood glucose in some patients, it is however associated with a high secondary failure rate. The limitations of single-agent therapy for maintaining glycemic control may be overcome, at least in some patients, and for a limited period of time by combining multiple drugs to achieve reductions in blood glucose that cannot be sustained during long-term therapy with single agents. Available data support the conclusion that in most patients with type 2 diabetes current monotherapy will fail and treatment with multiple drugs will be required. But, because type 2 diabetes is a progressive disease, even patients with good initial responses to conventional combination therapy will eventually require an increase of the dosage or further treatment with insulin because the blood glucose level is very difficult to maintain stable for a long period of time. Although existing combination therapy has the potential to enhance glycemic control, it is not without limitations (especially with regard to long term efficacy). Further, traditional therapies may show an increased risk for side effects, such as hypoglycemia or weight gain, which may compromise their efficacy and acceptability.
Thus, for many patients, these existing drug therapies result in progressive deterioriation in metabolic control despite treatment and do not sufficiently control metabolic status especially over long-term and thus fail to achieve and to maintain glycemic control in advanced or late stage type 2 diabetes, including diabetes with inadequate glycemic control despite conventional oral or non-oral antidiabetic medication.
Therefore, although intensive treatment of hyperglycemia can reduce the incidence of chronic damages, many patients with type 2 diabetes remain inadequately treated, partly because of limitations in long term efficacy, tolerability and dosing inconvenience of conventional antihyperglycemic therapies.
This high incidence of therapeutic failure is a major contributor to the high rate of long-term hyperglycemia-associated complications or chronic damages (including micro- and makrovascular complications such as e.g. diabetic nephrophathy, retinopathy or neuropathy, or cerebro- or cardiovascular complications such as e.g. myocardial infarction, stroke or vascular mortality or morbidity) in patients with type 2 diabetes.
Oral antidiabetic drugs conventionally used in therapy (such as e.g. first- or second-line, and/or mono- or (initial or add-on) combination therapy) include, without being restricted thereto, metformin, sulphonylureas, thiazolidinediones, glinides and α-glucosidase inhibitors.
Non-oral (typically injected) antidiabetic drugs conventionally used in therapy (such as e.g. first- or second-line, and/or mono- or (initial or add-on) combination therapy) include, without being restricted thereto, GLP-1 or GLP-1 analogues, and insulin or insulin analogues.
However, the use of these conventional antidiabetic or antihyperglycemic agents can be associated with various adverse effects. For example, metformin can be associated with lactic acidosis or gastrointestinal side effects; sulfonylureas, glinides and insulin or insulin analogues can be associated with hypoglycemia and weight gain; thiazolidinediones can be associated with edema, bone fracture, weight gain and heart failure/cardiac effects; and alpha-glucosidase blockers and GLP-1 or GLP-1 analogues can be associated with gastrointestinal adverse effects (e.g. dyspepsia, flatulence or diarrhea, or nausea or vomiting) and, most seriously (but rare), pancreatitis.
Therefore, it remains a need in the art to provide efficacious, safe and tolerable antidiabetic therapies.
Further, within the therapy of type 2 diabetes, it is a need for treating the condition effectively, avoiding the complications inherent to the condition, and delaying disease progression, e.g. in order to achieve a long-lasting therapeutic benefit.
Furthermore, it remains a need that antidiabetic treatments not only prevent the long-term complications often found in advanced stages of diabetes disease, but also are a therapeutic option in those diabetes patients who have developed or are at risk of developping complications, such as renal impairment.
Moreover, it remains a need to provide prevention or reduction of risk for adverse effects associated with conventional antidiabetic therapies.
The enzyme DPP-4 (dipeptidyl peptidase IV) also known as CD26 is a serine protease known to lead to the cleavage of a dipeptide from the N-terminal end of a number of proteins having at their N-terminal end a prolin or alanin residue. Due to this property DPP-4 inhibitors interfere with the plasma level of bioactive peptides including the peptide GLP-1 and are considered to be promising drugs for the treatment of diabetes mellitus.
For example, DPP-4 inhibitors and their uses are disclosed in WO 2002/068420, WO 2004/018467, WO 2004/018468, WO 2004/018469, WO 2004/041820, WO 2004/046148, WO 2005/051950, WO 2005/082906, WO 2005/063750, WO 2005/085246, WO 2006/027204, WO 2006/029769, WO2007/014886; WO 2004/050658, WO 2004/111051, WO 2005/058901, WO 2005/097798; WO 2006/068163, WO 2007/071738, WO 2008/017670; WO 2007/128721, WO 2007/128724, WO 2007/128761, or WO 2009/121945.
In the monitoring of the treatment of diabetes mellitus the HbA1c value, the product of a non-enzymatic glycation of the haemoglobin B chain, is of exceptional importance. As its formation depends essentially on the blood sugar level and the life time of the erythrocytes the HbA1c in the sense of a “blood sugar memory” reflects the average blood sugar level of the preceding 4-12 weeks. Diabetic patients whose HbA1c level has been well controlled over a long time by more intensive diabetes treatment (i.e. <6.5% of the total haemoglobin in the sample) are significantly better protected from diabetic microangiopathy. The available treatments for diabetes can give the diabetic an average improvement in their HbA1c level of the order of 1.0-1.5%. This reduction in the HbA1C level is not sufficient in all diabetics to bring them into the desired target range of <7.0%, preferably <6.5% and more preferably <6% HbA1c.
Within the meaning of this invention, inadequate or insufficient glycemic control means in particular a condition wherein patients show HbA1c values above 6.5%, in particular above 7.0%, even more preferably above 7.5%, especially above 8%. An embodiment of patients with inadequate or insufficient glycemic control include, without being limited to, patients having a HbA1c value from 7.5 to 10% (or, in another embodiment, from 7.5 to 11%). A special sub-embodiment of inadequately controlled patients refers to patients with poor glycemic control including, without being limited, patients having a HbA1c value ≥9%.
Within glycemic control, in addition to improvement of the HbA1c level, other recommended therapeutic goals for type 2 diabetes mellitus patients are improvement of fasting plasma glucose (FPG) and of postprandial plasma glucose (PPG) levels to normal or as near normal as possible. Recommended desired target ranges of preprandial (fasting) plasma glucose are 70-130 mg/dL (or 90-130 mg/dL) or <110 mg/dL, and of two-hour postprandial plasma glucose are <180 mg/dL or <140 mg/dL.
In one embodiment, diabetes patients within the meaning of this invention may include patients who have not previously been treated with an antidiabetic drug (drug-naïve patients). Thus, in an embodiment, the therapies described herein may be used in naïve patients. In another embodiment, diabetes patients within the meaning of this invention may include patients with advanced or late stage type 2 diabetes mellitus (including patients with failure to conventional antidiabetic therapy), such as e.g. patients with inadequate glycemic control on one, two or more conventional oral and/or non-oral antidiabetic drugs as defined herein, such as e.g. patients with insufficient glycemic control despite (mono-)therapy with metformin, a thiazolidinedione (particularly pioglitazone), a sulphonylurea, a glinide, GLP-1 or GLP-1 analogue, insulin or insulin analogue, or an α-glucosidase inhibitor, or despite dual combination therapy with metformin/sulphonylurea, metformin/thiazolidinedione (particularly pioglitazone), sulphonylurea/α-glucosidase inhibitor, pioglitazone/sulphonylurea, metformin/insulin, pioglitazone/insulin or sulphonylurea/insulin. Thus, in an embodiment, the therapies described herein may be used in patients experienced with therapy, e.g. with conventional oral and/or non-oral antidiabetic mono- or dual or triple combination medication as mentioned herein.
A further embodiment of diabetic patients within the meaning of this invention refers to patients ineligible for metformin therapy including
A further embodiment of the diabetes patients which may be amenable to the therapies of this invention may include, without being limited, those diabetes patients for whom normal metformin therapy is not appropriate, such as e.g. those diabetes patients who need reduced dose metformin therapy due to reduced tolerability, intolerability or contraindication against metformin or due to (mildly) impaired/reduced renal function (including elderly patients, such as e.g. ≥60-65 years).
A further embodiment of diabetic patients within the meaning of this invention refers to patients having renal disease, renal dysfunction, or insufficiency or impairment of renal function (including mild, moderate and severe renal impairment), e.g. as suggested by elevated serum creatinine levels (e.g. serum creatinine levels above the upper limit of normal for their age, e.g. ≥130-150 μmol/l, or ≥1.5 mg/dl (≥136 μmol/l) in men and ≥1.4 mg/dl (≥124 μmol/l) in women) or abnormal creatinine clearance (e.g. glomerular filtration rate (GFR)≤30-60 ml/min).
In this context, for more detailed example, mild renal impairment may be e.g. suggested by a creatinine clearance of 50-80 ml/min (approximately corresponding to serum creatine levels of ≤1.7 mg/dL in men and ≤1.5 mg/dL in women); moderate renal impairment may be e.g. suggested by a creatinine clearance of 30-50 ml/min (approximately corresponding to serum creatinine levels of >1.7 to ≤3.0 mg/dL in men and >1.5 to ≤2.5 mg/dL in women); and severe renal impairment may be e.g. suggested by a creatinine clearance of <30 ml/min (approximately corresponding to serum creatinine levels of >3.0 mg/dL in men and >2.5 mg/dL in women). Patients with end-stage renal disease require dialysis (e.g. hemodialysis or peritoneal dialysis).
For other more detailed example, patients with renal disease, renal dysfunction or renal impairment include patients with chronic renal insufficiency or impairment, which can be stratified according to glomerular filtration rate (GFR, ml/min/1.73 m2) into 5 disease stages: stage 1 characterized by normal GFR≥90 plus either persistent albuminuria or known structural or hereditary renal disease; stage 2 characterized by mild reduction of GFR (GFR 60-89) describing mild renal impairment; stage 3 characterized by moderate reduction of GFR (GFR 30-59) describing moderate renal impairment; stage 4 characterized by severe reduction of GFR (GFR 15-29) describing severe renal impairment; and terminal stage 5 characterized by requiring dialysis or GFR<15 describing established kidney failure (end-stage renal disease, ESRD).
A further embodiment of diabetic patients within the meaning of this invention refers to type 2 diabetes patients with or at risk of developing micro- or macrovascular diabetic complications, such as e.g. described herein (e.g. such at-risk patients as described as follows).
A further embodiment of diabetic patients within the meaning of this invention refers to type 2 diabetes patients with or at risk of developing renal complications, such as diabetic nephropathy (including chronic and progressive renal insufficiency, albuminuria, proteinuria, fluid retention in the body (edema) and/or hypertension).
A further embodiment of the diabetes patients which may be amenable to the therapies of this invention may include, without being limited, those type 2 diabetes patients with or at risk of developing retinal complications, such as diabetic retinopathy.
A further embodiment of the diabetes patients which may be amenable to the therapies of this invention may include, without being limited, those type 2 diabetes patients with or at risk of developing macrovascular complications, such as myocardial infarction, coronary artery disease, ischemic or hemorrhagic stroke, and/or peripheral occlusive arterial disease.
A further embodiment of the diabetes patients which may be amenable to the therapies of this invention may include, without being limited, those type 2 diabetes patients with or at risk of cardio- or cerebrovascular diseases or events (such as e.g. those cardiovascular risk patients described herein).
A further embodiment of the diabetes patients which may be amenable to the therapies of this invention may include, without being limited, those diabetes patients (especially type 2 diabetes) with advanced age and/or with advanced diabetes disease, such as e.g. patients on insulin treatment, patients on triple antidiabetic oral therapy, patients with pre-existing cardio- and/or cerebrovascular events and/or patients with advanced disease duration (e.g. >/=5 to 10 years).
A further embodiment of the diabetes patients which may be amenable to the therapies of this invention may include, without being limited, those diabetes patients (especially type 2 diabetes patients) with one or more cardiovascular risk factors selected from A), B), C) and D):
A) previous or existing vascular disease (such as e.g. myocardial infarction (e.g. silent or non-silent), coronary artery disease, percutaneous coronary intervention, coronary artery by-pass grafting, ischemic or hemorrhagic stroke, congestive heart failure (e.g. NYHA class I or II, e.g. left ventricular function<40%), or peripheral occlusive arterial disease),
B) vascular related end-organ damage (such as e.g. nephropathy, retinopathy, neuropathy, impaired renal function, chronic kidney disease, and/or micro- or macroalbuminuria),
C) advanced age (such as e.g. age>/=60-70 years), and
D) one or more cardiovascular risk factors selected from
In certain embodiments, the patients which may be amenable to to the therapies of this invention may have or are at-risk of one or more of the following diseases, disorders or conditions: type 1 diabetes, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting blood glucose (IFG), hyperglycemia, postprandial hyperglycemia, postabsorptive hyperglycemia, latent autoimmune diabetes in adults (LADA), overweight, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperNEFA-emia, postprandial lipemia, hypertension, atherosclerosis, endothelial dysfunction, osteoporosis, chronic systemic inflammation, non alcoholic fatty liver disease (NAFLD), polycystic ovarian syndrome, metabolic syndrome, nephropathy, micro- or macroalbuminuria, proteinuria, retinopathy, cataracts, neuropathy, learning or memory impairment, neurodegenerative or cognitive disorders, cardio- or cerebrovascular diseases, tissue ischaemia, diabetic foot or ulcus, atherosclerosis, hypertension, endothelial dysfunction, myocardial infarction, acute coronary syndrome, unstable angina pectoris, stable angina pectoris, peripheral arterial occlusive disease, cardiomyopathy (including e.g. uremic cardiomyopathy), heart failure, cardiac hypertrophy, heart rhythm disorders, vascular restenosis, stroke, (renal, cardiac, cerebral or hepatic) ischemia/reperfusion injuries, (renal, cardiac, cerebral or hepatic) fibrosis, (renal, cardiac, cerebral or hepatic) vascular remodeling; a diabetic disease, especially type 2 diabetes, mellitus may be preferred (e.g. as underlying disease).
In a further embodiment, the patients which may be amenable to to the therapies of this invention have a diabetic disease, especially type 2 diabetes mellitus, and may have or are at-risk of one or more other diseases, disorders or conditions, such as e.g. selected from those mentioned immediately above.
Within the scope of the present invention it has now been found that certain DPP-4 inhibitors as defined herein, optionally in combination with one or more other therapeutic substances (e.g. selected from those described herein), as well as pharmaceutical combinations, compositions or combined uses according to this invention of such DPP-4 inhibitors as defined herein have properties, which make them suitable for the purpose of this invention and/or for fulfilling one or more of above needs.
The present invention thus relates to a certain DPP-4 inhibitor as defined herein, preferably linagliptin (Bl 1356), for use in the therapies described herein.
The present invention further relates to a certain DPP-4 inhibitor as defined herein, preferably linagliptin (Bl 1356), in combination with metformin, for use in the therapies described herein.
The present invention further relates to a certain DPP-4 inhibitor as defined herein, preferably linagliptin (Bl 1356), in combination with pioglitazone, for use in the therapies described herein.
The present invention further relates to a certain DPP-4 inhibitor as defined herein, preferably linagliptin (Bl 1356), in combination with telmisartan, for use in the therapies described herein.
The present invention further relates to a pharmaceutical composition comprising a certain DPP-4 inhibitor as defined herein, preferably linagliptin (Bl 1356), for use in the therapies described herein.
The present invention further relates to a pharmaceutical composition comprising a certain DPP-4 inhibitor as defined herein, preferably linagliptin (Bl 1356), and metformin, for use in the therapies described herein.
The present invention further relates to a pharmaceutical composition comprising a certain DPP-4 inhibitor as defined herein, preferably linagliptin (Bl 1356), and pioglitazone, for use in the therapies described herein.
The present invention further relates to a combination comprising a certain DPP-4 inhibitor (particularly Bl 1356) and one or more other active substances selected from those mentioned herein, e.g. selected from other antidiabetic substances, active substances that lower the blood sugar level, active substances that lower the lipid level in the blood, active substances that raise the HDL level in the blood, active substances that lower blood pressure, active substances that are indicated in the treatment of atherosclerosis or obesity, antiplatelet agents, anticoagulant agents, and vascular endothelial protective agents, e.g. each as described herein; particularly for simultaneous, separate or sequential use in the therapies described herein.
The present invention further relates to a combination comprising a certain DPP-4 inhibitor (particularly Bl 1356) and one or more other antidiabetics selected from the group consisting of metformin, a sulphonylurea, nateglinide, repaglinide, a thiazolidinedione, a PPAR-gamma-agonist, an alpha-glucosidase inhibitor, insulin or an insulin analogue, and GLP-1 or a GLP-1 analogue, particularly for simultaneous, separate or sequential use in the therapies described herein, optionally in combination with telmisartan.
The present invention further relates to a method for treating and/or preventing metabolic diseases, especially type 2 diabetes mellitus and/or conditions related thereto (e.g. diabetic complications) comprising the combined (e.g. simultaneous, separate or sequential) administration of an effective amount of one or more other antidiabetics selected from the group consisting of metformin, a sulphonylurea, nateglinide, repaglinide, a thiazolidinedione, a PPAR-gamma-agonist, an alpha-glucosidase inhibitor, insulin or an insulin analogue, and GLP-1 or a GLP-1 analogue, and of an effective amount of a DPP-4 inhibitor (particularly BI 1356) as defined herein, and, optionally, of an effective amount of telmisartan, to the patient (particularly human patient) in need thereof, such as e.g. a patient as described herein, including at-risk patient groups.
The present invention further relates to therapies or therapeutic methods described herein, such as e.g. a method for treating and/or preventing metabolic diseases, especially type 2 diabetes mellitus and/or conditions related thereto (e.g. diabetic complications), comprising administering a therapeutically effective amount of linagliptin (Bl 1356) and, optionally, one or more other therapeutic agents, such as e.g. antidiabetics selected from the group consisting of metformin, a sulphonylurea, nateglinide, repaglinide, a thiazolidinedione, a PPAR-gamma-agonist, an alpha-glucosidase inhibitor, insulin or an insulin analogue, and GLP-1 or a GLP-1 analogue, and/or telmisartan, to the patient (particularly human patient) in need thereof, such as e.g. a patient as described herein (e.g. at-risk patient as described herein).
The present invention further relates to therapies or therapeutic methods described herein, such as e.g. a method for treating and/or preventing metabolic diseases, especially type 2 diabetes mellitus and/or conditions related thereto (e.g. diabetic complications), comprising administering a therapeutically effective amount of linagliptin (Bl 1356) to the patient (particularly human patient) in need thereof, such as e.g. a patient as described herein, including at-risk patient (particularly such a patient with or at-risk of cardio- or cerebrovascular diseases or events and/or with or at-risk of renal diseases) as described herein.
The present invention further relates to therapies or therapeutic methods described herein, such as e.g. a method for treating and/or preventing metabolic diseases, especially type 2 diabetes mellitus and/or conditions related thereto (e.g. diabetic complications), comprising administering a therapeutically effective amount of linagliptin (Bl 1356) and metformin to the patient (particularly human patient) in need thereof, such as e.g. a patient as described herein, including at-risk patient (particularly such a patient with or at-risk of cardio- or cerebrovascular diseases or events) as described herein.
The present invention further relates to therapies or therapeutic methods described herein, such as e.g. a method for treating and/or preventing metabolic diseases, especially type 2 diabetes mellitus and/or conditions related thereto (e.g. diabetic complications), comprising administering a therapeutically effective amount of linagliptin (Bl 1356) and telmisartan to the patient (particularly human patient) in need thereof, such as e.g. a patient as described herein, including at-risk patient (particularly such a patient with or at-risk of cardio- or cerebrovascular diseases or events and/or at-risk of renal diseases) as described herein.
Examples of such metabolic disorders or diseases amenable by the therapy of this invention, particularly in the patients having or being at risk of cardiovascular and/or renal disease, may include, without being limited to, type 1 diabetes, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting blood glucose (IFG), hyperglycemia, postprandial hyperglycemia, postabsorptive hyperglycemia, latent autoimmune diabetes in adults (LADA), overweight, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperNEFA-emia, postprandial lipemia, hypertension, atherosclerosis, endothelial dysfunction, osteoporosis, chronic systemic inflammation, non alcoholic fatty liver disease (NAFLD), retinopathy, neuropathy, nephropathy, polycystic ovarian syndrome, and/or metabolic syndrome.
The present invention further relates to at least one of the following methods:
Other aspects of the present invention become apparent to the skilled person from the foregoing and following remarks (including the examples and claims).
The aspects of the present invention, in particular the pharmaceutical compounds, compositions, combinations, methods and uses, refer to DPP-4 inhibitors as defined hereinbefore and hereinafter.
A DPP-4 inhibitor within the meaning of the present invention includes, without being limited to, any of those DPP-4 inhibitors mentioned hereinabove and hereinbelow, preferably orally active DPP-4 inhibitors.
An embodiment of this invention refers to a DPP-4 inhibitor for use in the treatment and/or prevention of metabolic diseases (particularly type 2 diabetes mellitus) in type 2 diabetes patients, wherein said patients further suffering from renal disease, renal dysfunction or renal impairment, particularly characterized in that said DPP-4 inhibitor is administered to said patients in the same dose levels as to patients with normal renal function, thus e.g. said DPP-4 inhibitor does not require downward dosing adjustment for impaired renal function.
For example, a DPP-4 inhibitor according to this invention (especially one which may be suited for patients with impaired renal function) may be such an oral DPP-4 inhibitor, which and whose active metabolites have preferably a relatively wide (e.g. about >100 fold) therapeutic window and/or, especially, that are primarily eliminated via hepatic metabolism or biliary excretion (preferably without adding additional burden to the kidney).
In more detailed example, a DPP-4 inhibitor according to this invention (especially one which may be suited for patients with impaired renal function) may be such an orally administered DPP-4 inhibitor, which has a relatively wide (e.g. >100 fold) therapeutic window (preferably a safety profile comparable to placebo) and/or which fulfils one or more of the following pharmacokinetic properties (preferably at its therapeutic oral dose levels):
In one embodiment, the (main) metabolite in plasma (which may be pharmacologically inactive) of a DPP-4 inhibitor having a 3-amino-piperidin-1-yl substituent is such a derivative where the amino group of the 3-amino-piperidin-1-yl moiety is replaced by a hydroxyl group to form the 3-hydroxy-piperidin-1-yl moiety (e.g. the 3-(S)-hydroxy-piperidin-1-yl moiety, which is formed by inversion of the configuration of the chiral center).
Further properties of a DPP-4 inhibitor according to this invention may be one or more of the following: Rapid attainment of steady state (e.g. reaching steady state plasma levels (>90% of the steady state plasma concentration) between second and fifth day of treatment with therapeutic oral dose levels), little accumulation (e.g. with a mean accumulation ratio RA,AUC≤1.4 with therapeutic oral dose levels), and/or preserving a long-lasting effect on DPP-4 inhibition, preferably when used once-daily (e.g. with almost complete (>90%) DPP-4 inhibition at therapeutic oral dose levels, >80% inhibition over a 24 h interval after once-daily intake of therapeutic oral drug dose), significant decrease in 2 h postprandial blood glucose excursions by ≥80% (already on first day of therapy) at therapeutic dose levels, and cumulative amount of unchanged parent compound excreted in urine on first day being below 1% of the administered dose and increasing to not more than about 3-6% in steady state.
Thus, for example, a DPP-4 inhibitor according to this invention may be characterized in that said DPP-4 inhibitor has a primarily non-renal route of excretion, i.e. said DPP-4 inhibitor is excreted to a non-substantial or only to a minor extent (e.g. <10%, preferably <7%, e.g. about 5%, of administered oral dose, preferably of oral therapeutic dose) via the kidney (measured, for example, by following elimination of a radiolabelled carbon (14C) substance oral dose).
Further, a DPP-4 inhibitor according to this invention may be characterized in that said DPP-4 inhibitor is excreted substantially or mainly via the liver or faeces (measured, for example, by following elimination of a radiolabelled carbon (14C) substance oral dose).
Further, a DPP-4 inhibitor according to this invention may be characterized in that said DPP-4 inhibitor is excreted mainly unchanged as parent drug (e.g. with a mean of >70%, or >80%, or, preferably, 90% of excreted radioactivity in urine and faeces after oral dosing of radiolabelled carbon (14C) substance),
said DPP-4 inhibitor is eliminated to a non-substantial or only to a minor extent via metabolism, and/or
the main metabolite of said DPP-4 inhibitor is pharmacologically inactive or has a relatively wide therapeutic window.
Further, a DPP-4 inhibitor according to this invention may be characterized in that said DPP-4 inhibitor does not significantly impair glomerular and/or tubular function of a type 2 diabetes patient with chronic renal insufficiency (e.g. mild, moderate or severe renal impairment or end stage renal disease), and/or
said DPP-4 inhibitor trough levels in the blood plasma of type 2 diabetes patients with mild or moderate renal impairment are comparable to the levels in patients with normal renal function,
and/or
said DPP-4 inhibitor does not require to be dose-adjusted in a type 2 diabetes patient with impaired renal function (e.g. mild, moderate or severe renal impairment or end stage renal disease, preferably regardless of the stage of renal impairment).
Further, a DPP-4 inhibitor according to this invention may be characterized in that said DPP-4 inhibitor provides its minimally effective dose at that dose that results in >50% inhibition of DPP-4 activity at trough (24 h after last dose) in >80% of patients, and/or said DPP-4 inhibitor provides its fully therapeutic dose at that dose that results in >80% inhibition of DPP-4 activity at trough (24 h after last dose) in >80% of patients.
Further, a DPP-4 inhibitor according to this invention may be characterized in that being suitable for use in type 2 diabetes patients who are with diagnosed renal impairment and/or who are at risk of developing renal complications, e.g. patients with or at risk of diabetic nephropathy (including chronic and progressive renal insufficiency, albuminuria, proteinuria, fluid retention in the body (edema) and/or hypertension).
In a first embodiment (embodiment A), a DPP-4 inhibitor in the context of the present invention is any DPP-4 inhibitor of
formula (I)
wherein R1 denotes ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl, (quinoxalin-6-yl)methyl, (4-methyl-quinazolin-2-yl)methyl, 2-cyano-benzyl, (3-cyano-quinolin-2-yl)methyl, (3-cyano-pyridin-2-yl)methyl, (4-methyl-pyrimidin-2-yl)methyl, or (4,6-dimethyl-pyrimidin-2-yl)methyl and R2 denotes 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino or (2-(S)-amino-propyl)-methylamino,
or its pharmaceutically acceptable salt.
Regarding the first embodiment (embodiment A), preferred DPP-4 inhibitors are any or all of the following compounds and their pharmaceutically acceptable salts:
These DPP-4 inhibitors are distinguished from structurally comparable DPP-4 inhibitors, as they combine exceptional potency and a long-lasting effect with favourable pharmacological properties, receptor selectivity and a favourable side-effect profile or bring about unexpected therapeutic advantages or improvements when combined with other pharmaceutical active substances. Their preparation is disclosed in the publications mentioned.
A more preferred DPP-4 inhibitor among the abovementioned DPP-4 inhibitors of embodiment A of this invention is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, particularly the free base thereof (which is also known as linagliptin or Bl 1356).
A particularly preferred DPP-4 inhibitor within the present invention is linagliptin. The term “linagliptin” as employed herein refers to linagliptin or a pharmaceutically acceptable salt thereof, including hydrates and solvates thereof, and crystalline forms thereof, preferably linagliptin refers to 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine. Crystalline forms are described in WO 2007/128721. Methods for the manufacture of linagliptin are described in the patent applications WO 2004/018468 and WO 2006/048427 for example. Linagliptin is distinguished from structurally comparable DPP-4 inhibitors, as it combines exceptional potency and a long-lasting effect with favourable pharmacological properties, receptor selectivity and a favourable side-effect profile or bring about unexpected therapeutic advantages or improvements in mono- or dual or triple combination therapy.
For avoidance of any doubt, the disclosure of each of the foregoing and following documents cited above in connection with the specified DPP-4 inhibitors is specifically incorporated herein by reference in its entirety.
Within this invention it is to be understood that the combinations, compositions or combined uses according to this invention may envisage the simultaneous, sequential or separate administration of the active components or ingredients.
In this context, “combination” or “combined” within the meaning of this invention may include, without being limited, fixed and non-fixed (e.g. free) forms (including kits) and uses, such as e.g. the simultaneous, sequential or separate use of the components or ingredients.
The combined administration of this invention may take place by administering the active components or ingredients together, such as e.g. by administering them simultaneously in one single or in two separate formulations or dosage forms. Alternatively, the administration may take place by administering the active components or ingredients sequentially, such as e.g. successively in two separate formulations or dosage forms.
For the combination therapy of this invention the active components or ingredients may be administered separately (which implies that they are formulated separately) or formulated altogether (which implies that they are formulated in the same preparation or in the same dosage form). Hence, the administration of one element of the combination of the present invention may be prior to, concurrent to, or subsequent to the administration of the other element of the combination.
Unless otherwise noted, combination therapy may refer to first line, second line or third line therapy, or initial or add-on combination therapy or replacement therapy.
With respect to embodiment A, the methods of synthesis for the DPP-4 inhibitors according to embodiment A of this invention are known to the skilled person. Advantageously, the DPP-4 inhibitors according to embodiment A of this invention can be prepared using synthetic methods as described in the literature. Thus, for example, purine derivatives of formula (I) can be obtained as described in WO 2002/068420, WO 2004/018468, WO 2005/085246, WO 2006/029769 or WO 2006/048427, the disclosures of which are incorporated herein. Purine derivatives of formula (II) can be obtained as described, for example, in WO 2004/050658 or WO 2005/110999, the disclosures of which are incorporated herein. Purine derivatives of formula (III) and (IV) can be obtained as described, for example, in WO 2006/068163, WO 2007/071738 or WO 2008/017670, the disclosures of which are incorporated herein. The preparation of those DPP-4 inhibitors, which are specifically mentioned hereinabove, is disclosed in the publications mentioned in connection therewith. Polymorphous crystal modifications and formulations of particular DPP-4 inhibitors are disclosed in WO 2007/128721 and WO 2007/128724, respectively, the disclosures of which are incorporated herein in their entireties. Formulations of particular DPP-4 inhibitors with metformin or other combination partners are described in WO 2009/121945, the disclosure of which is incorporated herein in its entirety.
Typical dosage strengths of the dual fixed combination (tablet) of linagliptin/metformin IR (immediate release) are 2.5/500 mg, 2.5/850 mg and 2.5/1000 mg, which may be administered 1-3 times a day, particularly twice a day.
Typical dosage strengths of the dual fixed combination (tablet) of linagliptin/metformin XR (extended release) are 5/500 mg, 5/1000 mg and 5/1500 mg (each one tablet), or 2.5/500 mg, 2.5/750 mg and 2.5/1000 mg (each two tablets), which may be administered 1-2 times a day, particularly once a day, preferably to be taken in the evening with meal.
The present invention further provides a DPP-4 inhibitor as defined herein for use in (add-on or initial) combination therapy with metformin (e.g. in a total daily amount from 500 to 2000 mg metformin hydrochloride, such as e.g. 500 mg, 850 mg or 1000 mg once or twice daily).
For pharmaceutical application in warm-blooded vertebrates, particularly humans, the compounds of this invention are usually used in dosages from 0.001 to 100 mg/kg body weight, preferably at 0.01-15 mg/kg or 0.1-15 mg/kg, in each case 1 to 4 times a day. For this purpose, the compounds, optionally combined with other active substances, may be incorporated together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof into conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The pharmaceutical compositions according to this invention comprising the DPP-4 inhibitors as defined herein are thus prepared by the skilled person using pharmaceutically acceptable formulation excipients as described in the art and appropriate for the desired route of administration. Examples of such excipients include, without being restricted to diluents, binders, carriers, fillers, lubricants, flow promoters, crystallisation retardants, disintegrants, solubilizers, colorants, pH regulators, surfactants and emulsifiers.
Oral preparations or dosage forms of the DPP-4 inhibitor of this invention may be prepared according to known techniques.
Examples of suitable diluents for compounds according to embodiment A include cellulose powder, calcium hydrogen phosphate, erythritol, low substituted hydroxypropyl cellulose, mannitol, pregelatinized starch or xylitol.
Examples of suitable lubricants for compounds according to embodiment A include talc, polyethyleneglycol, calcium behenate, calcium stearate, hydrogenated castor oil or magnesium stearate.
Examples of suitable binders for compounds according to embodiment A include copovidone (copolymerisates of vinylpyrrolidon with other vinylderivates), hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyvinylpyrrolidon (povidone), pregelatinized starch, or low-substituted hydroxypropylcellulose (L-HPC).
Examples of suitable disintegrants for compounds according to embodiment A include corn starch or crospovidone.
Suitable methods of preparing pharmaceutical formulations of the DPP-4 inhibitors according to embodiment A of the invention are
Suitable granulation methods are
An exemplary composition (e.g. tablet core) of a DPP-4 inhibitor according to embodiment A of the invention comprises the first diluent mannitol, pregelatinized starch as a second diluent with additional binder properties, the binder copovidone, the disintegrant corn starch, and magnesium stearate as lubricant; wherein copovidone and/or corn starch may be optional.
A tablet of a DPP-4 inhibitor according to embodiment A of the invention may be film coated, preferably the film coat comprises hydroxypropylmethylcellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and iron oxide (e.g. red and/or yellow).
The pharmaceutical compositions (or formulations) may be packaged in a variety of ways. Generally, an article for distribution includes one or more containers that contain the one or more pharmaceutical compositions in an appropriate form. Tablets are typically packed in an appropriate primary package for easy handling, distribution and storage and for assurance of proper stability of the composition at prolonged contact with the environment during storage. Primary containers for tablets may be bottles or blister packs.
A suitable bottle, e.g. for a pharmaceutical composition or combination (tablet) comprising a DPP-4 inhibitor according to embodiment A of the invention, may be made from glass or polymer (preferably polypropylene (PP) or high density polyethylene (HD-PE)) and sealed with a screw cap. The screw cap may be provided with a child resistant safety closure (e.g. press-and-twist closure) for preventing or hampering access to the contents by children. If required (e.g. in regions with high humidity), by the additional use of a desiccant (such as e.g. bentonite clay, molecular sieves, or, preferably, silica gel) the shelf life of the packaged composition can be prolonged.
A suitable blister pack, e.g. for a pharmaceutical composition or combination (tablet) comprising a DPP-4 inhibitor according to embodiment A of the invention, comprises or is formed of a top foil (which is breachable by the tablets) and a bottom part (which contains pockets for the tablets). The top foil may contain a metalic foil, particularly an aluminium or aluminium alloy foil (e.g. having a thickness of 20 μm to 45 μm, preferably 20 μm to 25 μm) that is coated with a heat-sealing polymer layer on its inner side (sealing side). The bottom part may contain a multi-layer polymer foil (such as e.g. poly(vinyl choride) (PVC) coated with poly(vinylidene choride) (PVDC); or a PVC foil laminated with poly(chlorotriflouroethylene) (PCTFE)) or a multi-layer polymer-metal-polymer foil (such as e.g. a cold-formable laminated PVC/aluminium/polyamide composition).
To ensure a long storage period especially under hot and wet climate conditions an additional overwrap or pouch made of a multi-layer polymer-metal-polymer foil (e.g. a laminated polyethylen/aluminium/polyester composition) may be used for the blister packs. Supplementary desiccant (such as e.g. bentonite clay, molecular sieves, or, preferably, silica gel) in this pouch package may prolong the shelf life even more under such harsh conditions.
The article may further comprise a label or package insert, which refer to instructions customarily included in commercial packages of therapeutic products, that may contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. In one embodiment, the label or package inserts indicates that the composition can be used for any of the purposes described herein.
With respect to the first embodiment (embodiment A), the dosage typically required of the DPP-4 inhibitors mentioned herein in embodiment A when administered intravenously is 0.1 mg to 10 mg, preferably 0.25 mg to 5 mg, and when administered orally is 0.5 mg to 100 mg, preferably 2.5 mg to 50 mg or 0.5 mg to 10 mg, more preferably 2.5 mg to 10 mg or 1 mg to 5 mg, in each case 1 to 4 times a day. Thus, e.g. the dosage of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine when administered orally is 0.5 mg to 10 mg per patient per day, preferably 2.5 mg to 10 mg or 1 mg to 5 mg per patient per day.
A dosage form prepared with a pharmaceutical composition comprising a DPP-4 inhibitor mentioned herein in embodiment A contain the active ingredient in a dosage range of 0.1-100 mg. Thus, e.g. particular oral dosage strengths of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine are 0.5 mg, 1 mg, 2.5 mg, 5 mg and 10 mg.
A special embodiment of the DPP-4 inhibitors of this invention refers to those orally administered DPP-4 inhibitors which are therapeutically efficacious at low dose levels, e.g. at oral dose levels<100 mg or <70 mg per patient per day, preferably <50 mg, more preferably <30 mg or <20 mg, even more preferably from 1 mg to 10 mg, particularly from 1 mg to 5 mg (more particularly 5 mg), per patient per day (if required, divided into 1 to 4 single doses, particularly 1 or 2 single doses, which may be of the same size, preferentially, administered orally once- or twice daily (more preferentially once-daily), advantageously, administered at any time of day, with or without food. Thus, for example, the daily oral amount 5 mg Bl 1356 can be given in an once daily dosing regimen (i.e. 5 mg Bl 1356 once daily) or in a twice daily dosing regimen (i.e. 2.5 mg Bl 1356 twice daily), at any time of day, with or without food.
The dosage of the active ingredients in the combinations and compositions in accordance with the present invention may be varied, although the amount of the active ingredients shall be such that a suitable dosage form is obtained. Hence, the selected dosage and the selected dosage form shall depend on the desired therapeutic effect, the route of administration and the duration of the treatment. Suitable dosage ranges for the combination are from the maximal tolerated dose for the single agent to lower doses, e.g. to one tenth of the maximal tolerated dose.
A particularly preferred DPP-4 inhibitor to be emphasized within the meaning of this invention is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine (also known as Bl 1356 or linagliptin). Bl 1356 exhibits high potency, 24 h duration of action, and a wide therapeutic window. In patients with type 2 diabetes receiving multiple oral doses of 1, 2.5, 5 or 10 mg of Bl 1356 once daily for 12 days, Bl 1356 shows favourable pharmacodynamic and pharmacokinetic profile (see e.g. Table 1 below) with rapid attainment of steady state (e.g. reaching steady state plasma levels (>90% of the pre-dose plasma concentration on Day 13) between second and fifth day of treatment in all dose groups), little accumulation (e.g. with a mean accumulation ratio RA,AUC≤1.4 with doses above 1 mg) and preserving a long-lasting effect on DPP-4 inhibition (e.g. with almost complete (>90%) DPP-4 inhibition at the 5 mg and 10 mg dose levels, i.e. 92.3 and 97.3% inhibition at steady state, respectively, and >80% inhibition over a 24 h interval after drug intake), as well as significant decrease in 2 h postprandial blood glucose excursions by 80% (already on Day 1) in doses≥2.5 mg, and with the cumulative amount of unchanged parent compound excreted in urine on Day 1 being below 1% of the administered dose and increasing to not more than about 3-6% on Day 12 (renal clearance CLR,ss is from about 14 to about 70 mL/min for the administered oral doses, e.g. for the 5 mg dose renal clearance is about 70 ml/min). In people with type 2 diabetes Bl 1356 shows a placebo-like safety and tolerability. With low doses of about ≥5 mg, Bl 1356 acts as a true once-daily oral drug with a full 24 h duration of DPP-4 inhibition. At therapeutic oral dose levels, Bl 1356 is mainly excreted via the liver and only to a minor extent (about <7% of the administered oral dose) via the kidney. Bl 1356 is primarily excreted unchanged via the bile. The fraction of Bl 1356 eliminated via the kidneys increases only very slightly over time and with increasing dose, so that there will likely be no need to modify the dose of Bl 1356 based on the patients' renal function. The non-renal elimination of Bl 1356 in combination with its low accumulation potential and broad safety margin may be of significant benefit in a patient population that has a high prevalence of renal insufficiency and diabetic nephropathy.
As different metabolic functional disorders often occur simultaneously, it is quite often indicated to combine a number of different active principles with one another. Thus, depending on the functional disorders diagnosed, improved treatment outcomes may be obtained if a DPP-4 inhibitor is combined with active substances customary for the respective disorders, such as e.g. one or more active substances selected from among the other antidiabetic substances, especially active substances that lower the blood sugar level or the lipid level in the blood, raise the HDL level in the blood, lower blood pressure or are indicated in the treatment of atherosclerosis or obesity.
The DPP-4 inhibitors mentioned above—besides their use in mono-therapy—may also be used in conjunction with other active substances, by means of which improved treatment results can be obtained. Such a combined treatment may be given as a free combination of the substances or in the form of a fixed combination, for example in a tablet or capsule. Pharmaceutical formulations of the combination partner needed for this may either be obtained commercially as pharmaceutical compositions or may be formulated by the skilled man using conventional methods. The active substances which may be obtained commercially as pharmaceutical compositions are described in numerous places in the prior art, for example in the list of drugs that appears annually, the “Rote Liste®” of the federal association of the pharmaceutical industry, or in the annually updated compilation of manufacturers' information on prescription drugs known as the “Physicians' Desk Reference”.
Examples of antidiabetic combination partners are metformin; sulphonylureas such as glibenclamide, tolbutamide, glimepiride, glipizide, gliquidon, glibornuride and gliclazide; nateglinide; repaglinide; mitiglinide; thiazolidinediones such as rosiglitazone and pioglitazone; PPAR gamma modulators such as metaglidases; PPAR-gamma agonists such as e.g. rivoglitazone, mitoglitazone, INT-131 and balaglitazone; PPAR-gamma antagonists; PPAR-gamma/alpha modulators such as tesaglitazar, muraglitazar, aleglitazar, indeglitazar and KRP297; PPAR-gamma/alpha/delta modulators such as e.g. lobeglitazone; AMPK-activators such as AICAR; acetyl-CoA carboxylase (ACC1 and ACC2) inhibitors; diacylglycerol-acetyltransferase (DGAT) inhibitors; pancreatic beta cell GCRP agonists such as SMT3-receptor-agonists and GPR119, such as the GPR119 agonists 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine or 5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-4-ylmethoxy]-2-(4-methanesulfonyl-phenyl)-pyridine; 1113-HSD-inhibitors; FGF19 agonists or analogues; alpha-glucosidase blockers such as acarbose, voglibose and miglitol; alpha2-antagonists; insulin and insulin analogues such as human insulin, insulin lispro, insulin glusilin, r-DNA-insulinaspart, NPH insulin, insulin detemir, insulin degludec, insulin tregopil, insulin zinc suspension and insulin glargin; Gastric inhibitory Peptide (GIP); amylin and amylin analogues (e.g. pramlintide or davalintide); GLP-1 and GLP-1 analogues such as Exendin-4, e.g. exenatide, exenatide LAR, liraglutide, taspoglutide, lixisenatide (AVE-0010), LY-2428757 (a PEGylated version of GLP-1), dulaglutide (LY-2189265), semaglutide or albiglutide; SGLT2-inhibitors such as e.g. dapagliflozin, sergliflozin (KGT-1251), atigliflozin, canagliflozin, ipragliflozin or tofogliflozin; inhibitors of protein tyrosine-phosphatase (e.g. trodusquemine); inhibitors of glucose-6-phosphatase; fructose-1,6-bisphosphatase modulators; glycogen phosphorylase modulators; glucagon receptor antagonists; phosphoenolpyruvatecarboxykinase (PEPCK) inhibitors; pyruvate dehydrogenasekinase (PDK) inhibitors; inhibitors of tyrosine-kinases (50 mg to 600 mg) such as PDGF-receptor-kinase (cf. EP-A-564409, WO 98/35958, U.S. Pat. No. 5,093,330, WO 2004/005281, and WO 2006/041976) or of serine/threonine kinases; glucokinase/regulatory protein modulators incl. glucokinase activators; glycogen synthase kinase inhibitors; inhibitors of the SH2-domain-containing inositol 5-phosphatase type 2 (SHIP2); IKK inhibitors such as high-dose salicylate; JNK1 inhibitors; protein kinase C-theta inhibitors; beta 3 agonists such as ritobegron, YM 178, solabegron, talibegron, N-5984, GRC-1087, rafabegron, FMP825; aldosereductase inhibitors such as AS 3201, zenarestat, fidarestat, epalrestat, ranirestat, NZ-314, CP-744809, and CT-112; SGLT-1 or SGLT-2 inhibitors; KV 1.3 channel inhibitors; GPR40 modulators such as e.g. [(3S)-6-({2′,6′-dimethyl-4′-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid; SCD-1 inhibitors; CCR-2 antagonists; dopamine receptor agonists (bromocriptine mesylate [Cycloset]); 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-oxobutanoic acid; sirtuin stimulants; and other DPP IV inhibitors.
Metformin is usually given in doses varying from about 500 mg to 2000 mg up to 2500 mg per day using various dosing regimens from about 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a day), or about 300 mg to 1000 mg once or twice a day, or delayed-release metformin in doses of about 100 mg to 1000 mg or preferably 500 mg to 1000 mg once or twice a day or about 500 mg to 2000 mg once a day. Particular dosage strengths may be 250, 500, 625, 750, 850 and 1000 mg of metformin hydrochloride.
For children 10 to 16 years of age, the recommended starting dose of metformin is 500 mg given once daily. If this dose fails to produce adequate results, the dose may be increased to 500 mg twice daily. Further increases may be made in increments of 500 mg weekly to a maximum daily dose of 2000 mg, given in divided doses (e.g. 2 or 3 divided doses). Metformin may be administered with food to decrease nausea.
A dosage of pioglitazone is usually of about 1-10 mg, 15 mg, 30 mg, or 45 mg once a day.
Rosiglitazone is usually given in doses from 4 to 8 mg once (or divided twice) a day (typical dosage strengths are 2, 4 and 8 mg).
Glibenclamide (glyburide) is usually given in doses from 2.5-5 to 20 mg once (or divided twice) a day (typical dosage strengths are 1.25, 2.5 and 5 mg), or micronized glibenclamide in doses from 0.75-3 to 12 mg once (or divided twice) a day (typical dosage strengths are 1.5, 3, 4.5 and 6 mg).
Glipizide is usually given in doses from 2.5 to 10-20 mg once (or up to 40 mg divided twice) a day (typical dosage strengths are 5 and 10 mg), or extended-release glibenclamide in doses from 5 to 10 mg (up to 20 mg) once a day (typical dosage strengths are 2.5, 5 and 10 mg).
Glimepiride is usually given in doses from 1-2 to 4 mg (up to 8 mg) once a day (typical dosage strengths are 1, 2 and 4 mg).
A dual combination of glibenclamide/metformin is usually given in doses from 1.25/250 once daily to 10/1000 mg twice daily. (typical dosage strengths are 1.25/250, 2.5/500 and 5/500 mg).
A dual combination of glipizide/metformin is usually given in doses from 2.5/250 to 10/1000 mg twice daily (typical dosage strengths are 2.5/250, 2.5/500 and 5/500 mg).
A dual combination of glimepiride/metformin is usually given in doses from 1/250 to 4/1000 mg twice daily.
A dual combination of rosiglitazone/glimepiride is usually given in doses from 4/1 once or twice daily to 4/2 mg twice daily (typical dosage strengths are 4/1, 4/2, 4/4, 8/2 and 8/4 mg).
A dual combination of pioglitazone/glimepiride is usually given in doses from 30/2 to 30/4 mg once daily (typical dosage strengths are 30/4 and 45/4 mg).
A dual combination of rosiglitazone/metformin is usually given in doses from 1/500 to 4/1000 mg twice daily (typical dosage strengths are 1/500, 2/500, 4/500, 2/1000 and 4/1000 mg).
A dual combination of pioglitazone/metformin is usually given in doses from 15/500 once or twice daily to 15/850 mg thrice daily (typical dosage strengths are 15/500 and 15/850 mg).
The non-sulphonylurea insulin secretagogue nateglinide is usually given in doses from 60 to 120 mg with meals (up to 360 mg/day, typical dosage strengths are 60 and 120 mg); repaglinide is usually given in doses from 0.5 to 4 mg with meals (up to 16 mg/day, typical dosage strengths are 0.5, 1 and 2 mg). A dual combination of repaglinide/metformin is available in dosage strengths of 1/500 and 2/850 mg.
Acarbose is usually given in doses from 25 to 100 mg with meals. Miglitol is usually given in doses from 25 to 100 mg with meals.
Examples of combination partners that lower the lipid level in the blood are HMG-CoA-reductase inhibitors such as simvastatin, atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin and rosuvastatin; fibrates such as bezafibrate, fenofibrate, clofibrate, gemfibrozil, etofibrate and etofyllinclofibrate; nicotinic acid and the derivatives thereof such as acipimox;
PPAR-alpha agonists; PPAR-delta agonists such as e.g. {4-[(R)-2-ethoxy-3-(4-trifluoromethyl-phenoxy)-propylsulfanyl]-2-methyl-phenoxy}-acetic acid; inhibitors of acyl-coenzyme A:cholesterolacyltransferase (ACAT; EC 2.3.1.26) such as avasimibe; cholesterol resorption inhibitors such as ezetimib; substances that bind to bile acid, such as cholestyramine, colestipol and colesevelam; inhibitors of bile acid transport; HDL modulating active substances such as D4F, reverse D4F, LXR modulating active substances and FXR modulating active substances; CETP inhibitors such as torcetrapib, JTT-705 (dalcetrapib) or compound 12 from WO 2007/005572 (anacetrapib) or evacetrapib; LDL receptor modulators; MTP inhibitors (e.g. lomitapide); and ApoB100 antisense RNA.
A dosage of atorvastatin is usually from 1 mg to 40 mg or 10 mg to 80 mg once a day.
Examples of combination partners that lower blood pressure are beta-blockers such as atenolol, bisoprolol, celiprolol, metoprolol, nebivolol and carvedilol; diuretics such as hydrochlorothiazide, chlortalidon, xipamide, furosemide, piretanide, torasemide, spironolactone, eplerenone, amiloride and triamterene; calcium channel blockers such as amlodipine, nifedipine, nitrendipine, nisoldipine, nicardipine, felodipine, lacidipine, lercanipidine, manidipine, isradipine, nilvadipine, verapamil, gallopamil and diltiazem; ACE inhibitors such as ramipril, lisinopril, cilazapril, quinapril, captopril, enalapril, benazepril, perindopril, fosinopril and trandolapril; as well as angiotensin II receptor blockers (ARBs) such as telmisartan, candesartan, valsartan, losartan, irbesartan, olmesartan, azilsartan and eprosartan.
A dosage of telmisartan is usually from 20 mg to 320 mg or 40 mg to 160 mg per day.
Examples of combination partners which increase the HDL level in the blood are Cholesteryl Ester Transfer Protein (CETP) inhibitors; inhibitors of endothelial lipase; regulators of ABC1; LXRalpha antagonists; LXRbeta agonists; PPAR-delta agonists; LXRalpha/beta regulators, and substances that increase the expression and/or plasma concentration of apolipoprotein A-I.
Examples of combination partners for the treatment of obesity are sibutramine; tetrahydrolipstatin (orlistat); alizyme (cetilistat); dexfenfluramine; axokine; cannabinoid receptor 1 antagonists such as the CB1 antagonist rimonobant; MCH-1 receptor antagonists; MC4 receptor agonists; NPY5 as well as NPY2 antagonists (e.g. velneperit); beta3-AR agonists such as SB-418790 and AD-9677; 5HT2c receptor agonists such as APD 356 (lorcaserin); myostatin inhibitors; Acrp30 and adiponectin; steroyl CoA desaturase (SCD1) inhibitors; fatty acid synthase (FAS) inhibitors; CCK receptor agonists; Ghrelin receptor modulators; Pyy 3-36; orexin receptor antagonists; and tesofensine; as well as the dual combinations bupropion/naltrexone, bupropion/zonisamide, topiramate/phentermine and pramlintide/metreleptin.
Examples of combination partners for the treatment of atherosclerosis are phospholipase A2 inhibitors; inhibitors of tyrosine-kinases (50 mg to 600 mg) such as PDGF-receptor-kinase (cf. EP-A-564409, WO 98/35958, U.S. Pat. No. 5,093,330, WO 2004/005281, and WO 2006/041976); oxLDL antibodies and oxLDL vaccines; apoA-1 Milano; ASA; and VCAM-1 inhibitors.
Further, within the meaning of this invention, optionally in addition, the DPP-4 inhibitor may be combined with one or more other antioxidants, anti-inflammatories and/or vascular endothelial protective agents.
Examples of antioxidant combination partners are selenium, betaine, vitamin C, vitamin E and beta carotene.
An example of an anti-inflammatory combination partner is pentoxifylline; another example of an anti-inflammatory combination partner is a PDE-4 inhibitor, such as e.g. tetomilast, roflumilast, or 3-[7-ethyl-2-(methoxymethyl)-4-(5-methyl-3-pyridinyl)pyrrolo[1,2-b]pyridazin-3-yl]propanoic acid (or other species disclosed in U.S. Pat. No. 7,153,854, WO 2004/063197, U.S. Pat. No. 7,459,451 and/or WO 2006/004188).
A further example of an anti-inflammatory partner drug is a caspase inhibitor, such as e.g. (3S)-5-fluoro-3-({[(5R)-5-isopropyl-3-(1-isoquinolinyl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino-4-oxopentanoic acid (or other species disclosed in WO 2005/021516 and/or WO 2006/090997).
An example of a vascular endothelial protective agent is a PDE-5 inhibitor, such as e.g. sildenafil, vardenafil or tadalafil; another example of a vascular endothelial protective agent is a nitric oxide donor or stimulator (such as e.g. L-arginine or tetrahydrobiopterin).
Further, within the meaning of this invention, optionally in addition, the DPP-4 inhibitor may be combined with one or more antiplatelet agents, such as e.g. (low-dose) aspirin (acetylsalicylic acid), a selective COX-2 or nonselective COX-1/COX-2 inhibitor, or a ADP receptor inhibitor, such as a thienopyridine (e.g. clopidogrel or prasugrel), elinogrel or ticagrelor, or a thrombin receptor antagonist such as vorapaxar.
Yet further, within the meaning of this invention, optionally in addition, the DPP-4 inhibitor may be combined with one or more anticoagulant agents, such as e.g. heparin, warfarin, or a direct thrombin inhibitor (such as e.g. dabigatran), or a Faktor Xa inhibitor (such as e.g. rivaroxaban or apixaban or edoxaban or otamixaban).
Still yet further, within the meaning of this invention, optionally in addition, the DPP-4 inhibitor may be combined with one or more agents for the treatment of heart failure.
Examples of combination partners for the treatment of heart failure are beta-blockers such as atenolol, bisoprolol, celiprolol, metoprolol and nebivolol; diuretics such as hydrochlorothiazide, chlortalidone, xipamide, furosemide, piretanide, torasemide, spironolactone, eplerenone, amiloride and triamterene; ACE inhibitors such as ramipril, lisinopril, cilazapril, quinapril, captopril, enalapril, benazepril, perindopril, fosinopril and trandolapril; angiotensin II receptor blockers (ARBs) such as telmisartan, candesartan, valsartan, losartan, irbesartan, olmesartan and eprosartan; heart glycosides such as digoxin and digitoxin; combined alpha/beta-blockers such as carvedilol; vasodilators; antiarrhythmic drugs; or B-type natriuretic peptide (BNP) and BNP-derived peptides and BNP-fusion products.
Moreover, within the meaning of this invention, optionally in addition, a DPP-4 inhibitor may be combined with one or more CCK-2 or gastrin agonists, such as e.g. proton pump inhibitors (including reversible as well as irreversible inhibitors of the gastric H+/K+-ATPase), for example omeprazole, esomeprazole, pantoprazole, rabeprazole or lansoprazole.
The present invention is not to be limited in scope by the specific embodiments described herein. Various modifications of the invention in addition to those described herein may become apparent to those skilled in the art from the present disclosure. Such modifications are intended to fall within the scope of the appended claims.
All patent applications cited herein are hereby incorporated by reference in their entireties.
Further embodiments, features and advantages of the present invention may become apparent from the following examples. The following examples serve to illustrate, by way of example, the principles of the invention without restricting it.
Antioxidant Effects:
Anti-Inflammatory and Vasodilatory Potential of Linagliptin
Direct antioxidant effects of gliptins (linagliptin, alogliptin, vildagliptin, saxagliptin, sitagliptin) are assessed by interfering with superoxide formation from xanthine oxidase, peroxynitrite (authentic and Sin-1 derived) or hydrogen peroxide/peroxidase mediated 1-electron-oxidation. These oxidations are detected by fluorescence, chemiluminescence and nitration of phenols (traced by HPLC). Indirect antioxidant effects of gliptins are measured in isolated human leukocytes (PMN) by interfering with oxidative burst (NADPH oxidase activation) induced by the phorbol ester PDBu, the endotoxines LPS and zymosan A and the chemotactic peptide fMLP.
Direct vasodilatory effects of gliptins are measured by the isometric tension technique in isolated aortic ring segments. Indirect antioxidant effects of linagliptin are also tested in a rat model of nitroglycerin-induced nitrate tolerance and linagliptin treatment (3-10 mg/kg/d by special diet for 7 d) by determination of endothelial function (acetylcholine-dependent relaxation of phenylephrine preconstricted aortic vessel segments), smooth muscle function (nitroglycerin-dependent relaxation) by isometric tension recordings. In addition reactive oxygen and nitrogen species (RONS) formation is determined in isolated cardiac mitochondria and LPS or PDBu-triggered oxidative burst in whole blood. Also, the anti-inflammatory potential of linagliptin is tested in an experimental model of LPS (10 mg/kg i.p. for 24 h)-induced septic shock in Wistar rats. The effects of sepsis and linagliptin cotherapy (3-10 mg/kg/d by special diet for 7 d) are assessed by isometric tension recordings, vascular, cardiac, and blood RONS formation and protein expression by Western blotting.
Results:
(See
Direct Antioxidant Properties:
All gliptins only show marginal direct antioxidant capacity. Minor (but significant) suppression of superoxide formation is observed for vildagliptin and for linagliptin in response to peroxynitrite formation/-mediated nitration. All gliptins except saxagliptin show significant interference with 1-electron-oxidations by the hydrogen peroxide/peroxidase system with linagliptin being the most potent compound.
Indirect antioxidant properties in isolated human neutrophils:
Linagliptin shows the best inhibition of oxidative burst in isolated human leukocytes in response to NADPH oxidase activation by LPS and zymosan A. Using L-012 enhanced chemiluminescence, LPS (0.5, 5 and 50 μg/ml) increases the PMN derived RONS signal in a concentration-dependent fashion and linagliptin suppresses the signal concentration-dependently.
In experiments with luminol/peroxidase enhances chemiluminescence, linagliptin is much more efficient in suppressing LPS or zymosan A-triggered oxidative burst in isolated PMN than other gliptins. In this assay, linagliptin is as efficient as nebivolol. The efficiency to inhibit LPS-dependent RONS formation is somewhat more pronounced than the suppressing effect on zymosan A-triggered RONS. All of these measurements support a superior antioxidant effect of linagliptin in isolated neutrophils as compared to other gliptins.
Inhibition of adhesion of activated neutrophils to endothelial cells:
By studying the adhesion of LPS-stimulated human neutrophils to cultured endothelial cells (the number of adherent PMN correlates with the PDBu-triggered oxidative burst which can be measured amplex red/peroxidase fluorescence), linagliptin suppresses leukocyte adhesion to endothelial cells in the presence of LPS.
Treatment of Vascular Dysfunction and/or Oxidative Stress:
Effects of oral linagliptin treatment on vascular dysfunction and oxidative stress in nitrate tolerant rats:
Isometric tension studies in organ baths reveal that nitroglycerin and LPS treatment induces remarkable endothelial dysfunction and nitrate tolerance. Endothelial dysfunction caused by both factors is significantly improved by linagliptin therapy (
Summarized, linagliptin in vivo treatment ameliorates nitroglycerin-induced endothelial dysfunction and shows minor improvement of ROS formation in isolated cardiac mitochondria and oxidative burst in whole blood from nitrate-tolerant rats.
Effects of linagliptin treatment on vascular dysfunction and oxidative stress in septic rats:
Very similar protective effects for linagliptin are observed in an experimental model of septic shock. Vascular function (Ach-, GTN-, and diethylamine NONOate-dependent relaxation) are largely impaired by LPS and almost normalized by linagliptin therapy. Mitochondrial and whole blood (LPS, PDBu-stimulated) RONS production is dramatically increased by LPS and improved by linagliptin treatment. Vascular oxidative stress (measured by DHE-dependent fluorescent microtopography) and markers of vascular inflammation (VCAM-1, Cox-2, and NOS-2) are dramatically increased by LPS treatment and significantly improved by linagliptin therapy. Similar effects are observed for aortic protein tyrosine nitration and malondialdehyde content (both markers for oxidative stress) as well as aortic NADPH oxidase subunit expression (Nox1 and Nox2). As proof of concept DPP-4 activity and GLP-1 levels are detected from the respective animals and demonstrate potent inhibition of DPP-4 and an approximate 10-fold increase of plasma GLP-1 levels.
Direct Vasodilatory Effects of Gliptins:
Isometric tension recording reveals that several gliptins display direct vasodilatory effects in the concentration range of 10-100 μM. Linagliptin is the most potent compound directly followed by alogliptin and vildagliptin, whereas sitagliptin and saxagliptin are not more efficient in the induction of vasodilation than the solvent alone control (DMSO) (see
These observations support pleiotropic antioxidant and anti-inflammatory properties of linagliptin, which are not (or to a minor extent) shared by other gliptins. Furthermore, linagliptin reduces leukocyte adhesion to endothelial cells due to the presence of LPS and improves nitroglycerin- and inflammation-induced endothelial dysfunction and oxidative stress. This may contribute to improved endothelial function and support of cardioprotective action of linagliptin. Thus, there is evidence that linagliptin confers antioxidant effects that beneficially influence cardiovascular diseases, which are secondary to diabetic complications with high levels of morbidity and mortality.
Treatment of Diabetic Nephropathy and Albuminuria:
Endothelial damage is characteristic for type 2 diabetes and contributes to the development of end stage kidney disease. Further, vascular endothelial NO synthase (eNOS) activity is altered in T2D and genetic abnormalities in the respected gene (NOS3) are associated with the development of advanced diabetic nephropathy (DN) in patients with type 1 and type 2 diabetes. The use of low dose STZ to induce T2D in this genetic phenotype (eNOS−/−) has been recently reported (Brosius et al, JASN 2009) to be a valid experimental model for DN. Eight week old eNOS −/− mice are rendered diabetic with intraperitoneal injections of streptozotocin (100 mg/kg per day for two consecutive days). Development of diabetes (defined by blood glucose>250 mg/dl) is verified one week after streptozotocin injection. No insulin is given because that could prevent the development of diabetic nephropathy. Mice are treated for 4 weeks with:
1) Non-diabetic eNOS ko control mice, placebo (natrosol) (n=14)
2) sham treated diabetic eNOS ko mice, placebo (natrosol) (n=17)
3) Telmisartan (p.o. 1 mg/kg) treated diabetic eNOS ko mice (n=17)
4) Linagliptin inhibitor (p.o. 3 mg/kg) treated diabetic eNOS ko mice (n=14)
5) Telmisartan (1 mg/kg)+Linagliptin (3 mg/kg) treated diabetic eNOS ko mice (n=12)
Renal function (s-creatinine, albuminuria) and blood glucose level are detected. No significant differences on blood sugar are detected after treatment with linagliptin, telmisartan or the combination versus placebo in STZ treated animals (see
Despite no effect on the blood glucose is detected, the albumin/creatinin ratio is significantly reduced in the group receiving linagliptin+telmisartan (mid bar, No. 5 in
Treatment of Congestive Heart Failure and Cardiac Hypertrophy:
We hypothesize that glucose/energy supply is particularly important in the failing heart that is characterized by cardiac hypertrophy. Inadequate energy supply is considered as one of the most important steps from compensated to decompensated left ventricular hypertrophy resulting in heart failure. A classical model of hypertension induced left ventricular hypertrophy that results on the long run in left ventricular failure and pathological remodeling is the two-kidney-one clip reno-vascular hypertension (Goldblatt) model (2K1C model).
Animals are treated 3 months with the following regimen:
Non-invasive, systolic blood pressure is measured in all groups to the time points (1. before treatment; 2. after 1 weeks 3. after 4 weeks; 4. after 6 weeks 5. after 12 weeks; and 6. after 6 weeks of treatment with the respective compounds.
Before treatment only the sham treated animals are significant different to all other groups. From week 1 of treatment until the end of the study telmisartan and the combination of telmisartan with linagliptin are always significant versus vehicle treated animals. The combination of telmisartan with linagliptin reaches the level of placebo treated sham animals and shows additional effects to the mono treatment of temisartan (see
Treatment of Uremic Cardiomyopathy:
Uremic cardiomyopathy contributes substantially to morbidity and mortality of patients with chronic kidney disease, which is in turn also a frequent complication of type 2 diabetes. Glucagon-like peptide-1 (GLP-1) may improve cardiac function and GLP-1 is mainly degraded by dipeptidyl peptidase-4 (DPP-4). Linagliptin is the only DPP-4 inhibitor that can be used clinically (e.g. in patients with type 2 diabetes and diabetic nephropathy) at all stages of renal insufficiency without dose adjustment.
It is investigated linagliptin in a rat model of chronic renal insufficiency (5/6 nephrectomy [5/6N]):
Eight weeks after 5/6N or sham surgery, rats are treated orally with 3.3 mg/kg linagliptin or vehicle for 4 days, and, subsequently, plasma is sampled for 72 h for quantification of DPP-4 activity and GLP-1 levels. At the end of the study, heart tissue is harvested for mRNA analyses.
5/6N causes a significant (p<0.001) decrease in GFR measured by creatinine clearance (sham: 2510±210 mU24 h; 5/6N: 1665±104.3 mU24 h) and increased cystatin C levels (sham: 700±35.7 ng/mL; 5/6N: 1434±77.6 ng/mL). DPP-4 activity is significantly reduced at all time points with no difference between sham or 5/6N animals. In contrast, active GLP-1 levels are significantly increased in 5/6N animals, as measured by the maximum plasma concentration (Cmax; 5/6N: 6.36±2.58 pg/mL vs sham: 3.91±1.86 pg/mL; p<0.001) and AUC(0-72 h) (5/6N: 201 pg·h/mL vs sham: 114 pg·h/mL; p<0.001). The mRNA levels of cardiac fibrosis markers (pro-fibrotic factors) such as TGF-β, tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) and collagens 1α1 and 3α1 as well as markers of left ventricular dysfunction such as brain natriuretic peptide (BNP) are all significantly increased in 5/6N versus sham animals and consequently are reduced or even normalized by linagliptin treatment (all p<0.05, see
Linagliptin increases the AUC of GLP-1 approximately twofold in a rat model of renal failure, and decreases gene expression of BNP, a marker of left ventricular dysfunction, as well as markers of cardiac fibrosis (TGF-β, TIMP-1, Col 1α1 and Col 3α1) in hearts of uremic rats. These effects support the use of linagliptin in treating and/or preventing uremic cardiomyopathy. Linagliptin offers a new therapeutic approach for patients with uremic cardiomyopathy.
Effect on Infarction Size and Cardiac Function after Myocardial Ischemia/Reperfusion:
The objective of this study is to evaluate the cardiac effects (particularly on myocardial ischemia/reperfusion, cardiac function or infarcation size) of a xanthine based DPP-4 inhibitor of this invention, such as e.g. in conditions involving stromal cell-derived factor-1 alpha (SDF-1α).
Male Wistar rats are divided into 3 groups: sham, ischemia/reperfusion (I/R), and I/R+DPP-4 inhibitor of this invention; n=10-12 per group. The DPP-4 inhibitor is given once daily starting 2 days before I/R. The left anterior descending coronary artery is ligated for 30 min. Echocardiography is performed after 5 days and cardiac catheterization after 7 days. The DPP-4 inhibitor significantly reduces the absolute infarction size (−27.8%; p<0.05), the proportion of infarcted tissue relative to the total area at risk (−18.5%; p<0.05) and the extent of myocardial fibrosis (−31.6%; p<0.05). The DPP-4 inhibitor significantly increases the accumulation of stem/progenitor cells as characterized by CD34−, CXCR4−, and C-kit-expression and the cardiac immunoreactivity for active SDF-1α in the infarcted myocardium. Left ventricular ejection fraction is similar in all MI groups after 7 days, however, the DPP-4 inhibition reduces infarct size, reduces fibrotic remodelling and increases the density of stem cells in infarcted areas by blocking the degradation of SDF-1α.
A xanthine based DPP-4 inhibitor of this invention is able to reduce infarct size after myocardial infarct. Mechanisms of action may include reduced degradation of SDF-1α with subsequent increased recruitment of circulating CXCR-4+ stem cells and/or incretin receptor dependent pathways.
These data strengthen the usability of a xanthine based DPP-4 inhibitor of this invention for increasing recruitment of stem cells, improving tissue repair, activating myocardial regeneration, reducing infarct size, reducing fibrotic remodelling and/or increasing density of stem cells in infarcted cardiac areas in the treatment or prevention of myocardial ischemia/reperfusion and/or in cardio-protecting.
Based on that infarct size is a predictor of future events (including mortality), it is postulated that a xanthine based DPP-4 inhibitor of this invention may be further useful for improving cardiac (systolic) function, cardiac contractility and/or mortality after myocardial ischemia/reperfusion.
Effect of Linagliptin on Infarction Size and Cardiac Function after Myocardial Ischemia/Reperfusion:
Materials and methods: Male Wistar rats are divided into three groups: sham, I/R and I/R plus linagliptin (n=16-18 per group). Linagliptin is given once daily (3 mg/kg) starting 30 days before I/R. I/R is induced by ligation of the left anterior descending coronary artery for 30 min, Echocardiography is performed after 58 days and cardiac catheterization after 60 days.
Linagliptin significantly reduces the proportion of infarcted tissue relative to the total area at risk (−21%; p<0.001) as well as the absolute infarction size (−18%; p<0.05) in this ischemia reperfusion injury (I/R) model. In addition, glucagon-like peptide-1 (GLP-1) levels are increased 18-fold (p<0.0001) and DPP-4 activity is reduced by 78% (p<0.0001). Left ventricular left end diastolic and systolic pressure as well all echocardiography parameters are similar between groups, with a significant improvement of isovolumetric contractility indices (dP/dTmin) from −4771±79 mmHg/s to −4957±73 mmHg/s or improved maximum rate of left ventricular pressure decline. These data further support a cardioprotective function of linagliptin in the setting of acute myocardial infarction.
Treating ARB-Resistant Diabetic Nephropathy:
The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin receptor blockers (ARBs). This study investigates the effect of linagliptin, alone and in combination with the ARB telmisartan, on the progression of diabetic nephropathy in diabetic eNOS knockout mice, a new model closely resembling human pathology.
Sixty-five male eNOS knockout C57BL/6J mice are divided into 4 groups after receiving intraperitoneal high-dose streptozotocin: telmisartan (1 mg/kg), linagliptin (3 mg/kg), linagliptin+telmisartan (3+1 mg/kg), and vehicle. Fourteen mice are used as non-diabetic controls. After 12 weeks, urine and blood are obtained and blood pressure measured. Glucose concentrations are increased and similar in all diabetic groups. Telmisartan alone reduces blood pressure modestly by 5.9 mmHg vs diabetic controls (111.2±2.3 mmHg vs 117.1±2.2 mmHg; mean±SEM; n=14 each; p=0.071) and none of the other treatments reaches significance. Combined treatment significantly reduces albuminuria (e.g. urinary albumin excretion per 24 h and/or the albumin/creatinine ration) compared with diabetic controls (71.7±15.3 μg/24 h vs 170.8±34.2 μg/24 h; n=12-13; p=0.017), whereas the effects of single treatment with either telmisartan (97.8±26.4 μg/24 h; n=14) or linagliptin (120.8±37.7 μg/24 h; n=11) are not statistically significant (see
Further, linagliptin, alone and in combination with telmisartan, leads to a significantly reduced glomerulosclerosis in the kidney measured by histological score compared with diabetic controls (2.1+/−0.0 vs 2.4+/−0.0; p<0.05), whereas the reduction achieved by telmisartan alone is not significantly different. In conclusion, linagliptin significantly reduces urinary albumin excretion in diabetic eNOS knockout mice that are refractory to ARB (e.g. in a blood pressure-independent manner). These effects may support the use of linagliptin in renoprotection and in treating and/or preventing ARB-resistant diabetic nephropathy. Linagliptin may offer a new therapeutic approach for patients resistant to ARB treatment.
Delaying Onset of Diabetes and Preserving Beta-Cell Function in Non-Obese Type-1 Diabetes:
Though reduced pancreatic T-cell migration and altered cytokine production is considered important players for the onset of insulinitis the exact mechanism and effects on the pancreatic cell pool is still incompletely understood. In an attempt to evaluate the effect of linagliptin on pancreatic inflammation and beta-cell mass it is examined the progression of diabetes in the non-obese-diabetic (NOD) mice over a 60 day experimental period coupled with terminal stereological assessment of cellular pancreatic changes.
Sixty female NOD mice (10 weeks of age) sre included in the study and fed a normal chow diet or a diet containing linagliptin (0.083 g linagliptin/kg chow; corresponding to 3-10 mg/kg, p.o) throughout the study period. Bi-weekly plasma samples are obtained to determine onset of diabetes (BG>11 mmol/l). At termination, the pancreata are removed and a terminal blood sample is obtained for assessment of active GLP-1 levels.
At the end of the study period the incidence of diabetes is significantly decreased in linagliptin-treated mice (9 out of 30 mice) compared with the control group (18 of 30 mice, p=0.021). The subsequent stereological assessment of beta-cell mass (identified by insulin immunoreactivity) demonstrates a significantly larger beta cell mass (veh 0.18±0.03 mg; lina 0.48±0.09 mg, p<0.01) and total islet mass (veh 0.40±0.04 mg; lina 0.70±0.09 mg, p<0.01) in linagliptin treated mice. There is a tendency for linagliptin to reduce peri-islet infiltrating lymphocytes (1.06±0.15; lina 0.79±0.12 mg, p=0.17). As expected active plasma GLP-1 are higher at termination in linagliptin treated mice.
In summary, the data demonstrate that linagliptin is able to delay the onset of diabetes in a type-1 diabetic model (NOD mouse). The pronounced beta-cell sparing effects which can be observed in this animal model indicate that such DPP-4 inhibition not only protects beta-cells by increasing active GLP-1 levels, but may also exerts direct or indirect anti-inflammatory actions. These effects may support the use of linagliptin in treating and/or preventing type 1 diabetes or latent autoimmune diabetes in adults (LADA). Linagliptin may offer a new therapeutic approach for patients with or at-risk of type 1 diabetes or LADA.
Effect of linagliptin on body weight total body fat, liver fat and intramyocellular fat
In a further study the efficacy of chronic treatment with linagliptin on body weight, total body fat, intra-myocellular fat, and hepatic fat in a non-diabetic model of diet induced obesity (D10) in comparison to the appetite suppressant subutramine is investigated:
Rats are fed a high-fat diet for 3 months and received either vehicle, linagliptin (10 mg/kg), or sibutramine (5 mg/kg) for 6 additional weeks, while continuing the high-fat diet. Magnetic resonance spectroscopy (MRS) analysis of total body fat, muscle fat, and liver fat is performed before treatment and at the end of the study.
Sibutramine causes a significant reduction of body weight (−12%) versus control, whereas linagliptin has no significant effect (−3%). Total body fat is also significantly reduced by sibutramine (−12%), whereas linagliptin-treated animals show no significant reduction (−5%). However, linagliptin and sibutramine result both in a potent reduction of intramyocellular fat (−24% and −34%, respectively). In addition, treatment with linagliptin results in a profound decrease of hepatic fat (−39%), whereas the effect of sibutramine (−30%) does not reach significance (see Table below). Thus, linagliptin is weight neutral but improves intra-myocellular and hepatic lipid accumulation. A reduction of steatosis, inflammation and fibrosis in the liver measured by histological scoring is also observed for linagliptin treatment.
In conclusion, linagliptin treatment provokes a potent reduction of intramyocellular lipids and hepatic fat, which are both independent of weight loss. The treatment with linagliptin provides additional benefit to patients with diabetes who are additionally affected by liver steatosis (e.g. NAFLD). The effects of sibutramine on muscular and hepatic fat are attributed mainly to the known weight reduction induced by this compound.
Linagliptin has Similar Efficacy to Glimepiride but Improves Cardiovascular Safety Over 2 Years in Patients with Type 2 Diabetes Inadequately Controlled on Metformin:
In a 2-year double-blind trial the long-term efficacy and safety of adding linagliptin or glimepiride to ongoing metformin to treat type 2 diabetes (T2DM) is investigated. T2DM patients on stable metformin (≥1500 mg/d) for ≥10 weeks are randomized to linagliptin 5 mg/day (N=764) or glimepiride 1-4 mg/day (N=755) over 2 years. Efficacy analyses are based on HbA1c change from baseline in the full analysis set (FAS) and per-protocol (PP) population. Safety evaluations includ pre-specified, prospective, and adjudicated capture of cardiovascular (CV) events (CV death, non-fatal myocardial infarction or stroke, unstable angina with hospitalization). Baseline characteristics are well balanced in the 2 groups (HbA1c 7.7% for both). In the PP population, adjusted mean (±SE) HbA1c changes from baseline are −0.4% (±0.04%) for linagliptin 5 mg/day vs −0.5% (±0.04%) for glimepiride (mean dose 3 mg/day). Mean between-group difference is 0.17% (95% Cl, 0.08-0.27%; p=0.0001 for noninferiority). Similar results are observed in the FAS population. Far fewer patients experience investigator-defined, drug-related hypoglycemia with linagliptin than glimepiride (7.5% vs 36.1%; p<0.0001). Body weight is decreased with linagliptin and increased with glimepiride (−1.4 kg vs+1.3 kg; adjusted mean difference, −2.7 kg; p<0.0001). CV events occur in 13 (1.7%) linagliptin patients vs 26 (3.4%) glimepiride patients revealing a significant 50% reduction in relative risk for the combined CV endpoint (RR, 0.50; 95% Cl, 0.26-0.96; p=0.04). In conclusion, when added to metformin monotherapy, linagliptin provides similar HbA1c reductions to glimepiride but with less hypoglycemia, relative weight loss, and significantly fewer adjudicated CV events.
Cardiovascular Risk with Linagliptin in Patients with Type 2 Diabetes: A Pre-Specified, Prospective, and Adjudicated Meta-Analysis from a Large Phase III Program:
The cardiovascular (CV) benefit of glucose lowering, particularly if too intensive, in type 2 diabetes mellitus (T2DM) is currently debated. Some modalities have even been reported, unexpectedly, to be associated with worse CV outcomes.
Linagliptin is the first once-daily DPP-4 inhibitor available as one dose without the need for dose adjustment for declining renal function. Linagliptin achieves glycemic control without weight gain or increased hypoglycemic risk that may translate into CV benefits.
To investigate the CV profile of the DPP-4 inhibitor linagliptin, a pre-specified meta-analysis of all CV events from 8 phase III randomized, double blind, controlled trials (≥12 weeks) is conducted. CV events are prospectively adjudicated by a blinded independent expert committee. The primary endpoint of this analysis is a composite of CV death, non-fatal stroke, non-fatal myocardial infarction (MI), and hospitalization for unstable angina pectoris (UAP). Other secondary and tertiary CV endpoints are also assessed, including FDA-custom major adverse CV events (MACE).
Of 5239 patients included (mean baseline HbA1c 8.0%) 3319 receive linagliptin once daily (5 mg: 3159, 10 mg: 160) and 1920 comparator (placebo: 977, glimepiride: 781, voglibose: 162). Cumulative exposure (person yrs) is 2060 for linagliptin and 1372 for comparators. Overall, adjudicated primary CV events occurre in 11 (0.3%) patients receiving linagliptin and 23 (1.2%) receiving comparator. The hazard ratio for the primary endpoint is significantly lower for linagliptin vs comparator and hazard ratios are similar or significantly lower with linagliptin vs comparator for all other CV endpoints (TABLE).
This is the first pre-specified, prospective, and independently adjudicated CV meta-analysis of a DPP-4 inhibitor in a large Phase III program. Although a meta-analysis, with distinct limitations, the data support a potential reduction of CV events with linagliptin.
Treatment of Patients with Type 2 Diabetes Mellitus at High Cardiovascular Risk
The longterm impact on cardiovascular morbidity and mortality and relevant efficacy parameters (e.g. HbA1c, fasting plasma glucose, treatment sustainability) of treatment with linagliptin in a relevant population of patients with type 2 diabetes mellitus is investigated as follows:
Type 2 diabetes patient with insufficient glycemic control (naïve or currently treated (mono or dual therapy) with e.g. metformin and/or an alpha-glucosidase inhibitor (e.g. having HbA1c 6.5-8.5%), or currently treated (mono or dual therapy) with e.g. a sulphonylurea or glinide, with or without metformin or an alpha-glucosidase inhibitor (e.g. having HbA1c 7.5-8.5%)) and high risk of cardiovascular events, e.g. defined as one or more of risk factors A), B), C) and D) indicated below, are treated over a lengthy period (e.g. for >/=2 years, 4-5 years or 1-6 years) with linagliptin (optionally in combination with one or more other active substances, e.g. such as those described herein) and compared with patients who have been treated with other antidiabetic medicaments (e.g. a sulphonylurea, such as glimepiride) or with placebo. Evidence of the therapeutic success compared with patients who have been treated with other antidiabetic medicaments or with placebo can be found in the smaller number of single or multiple complications (e.g. cardio- or cerebrovascular events such as cardiovascular death, myocardial infarction, stroke, or hospitalisation (e.g. for acute coronary syndrome, leg amputation, urgent revascularization procedures or for unstable angina pectoris), or, preferably, in the longer time taken to first occurrence of such complications, e.g. time to first occurrence of any of the following components of the primary composite endpoint: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalisation for unstable angina pectoris.
Additional therapeutic success can be found in greater proportion of patients on study treatment at study end maintain glycemic control (e.g. HbA1c</=7%) without need of rescue medication and without weight gain (e.g. >/=2%). Further additional therapeutic success can be found in greater proportion of patients on study treatment at study end maintain glycemic control (e.g. HbA1c</=7%) without need of rescue medication and without moderate/severe hypoglycemic episodes and without weight gain (e.g. >/=2%).
Further therapeutic success can be found e.g. in CV superiority of treatment with linagliptin versus treatment with glimepiride (each optionally as monotherapy or as add-on therapy to metformin or an alpha-glucosidase inhibitor) with a risk reduction of preferably about 20%, for example.
Risk factors A), B), C) and D) for cardiovascular events:
Beneficial effects (e.g. improvement) on cognitive function (e.g. cognitive decline, changes in psychomotor speed, psychological well-being), β-cell function (e.g. insulin secretion rate derived from a 3 h meal tolerance test, long term β-cell function), renal function parameters, diurnal glucose pattern (e.g. ambulatory glucose profile, glycemic variability, biomarkers of oxidation, inflammation and endothelial function, cognition and CV morbidity/mortality), silent MI (e.g. ECG parameters, CV prophylactic properties), LADA (e.g. use of rescue therapy or disease progression in LADA) and/or durability of glucose control according to β-cell autoantibody status (e.g., GAD) of treatment with linagliptin is investigated in substudies.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10191261 | Nov 2010 | EP | regional |
| 11168317 | May 2011 | EP | regional |
| 11170992 | Jun 2011 | EP | regional |
| Number | Name | Date | Kind |
|---|---|---|---|
| 2056046 | Fourneau | Sep 1936 | A |
| 2375138 | Salvin | May 1945 | A |
| 2629736 | Krimmel | Feb 1953 | A |
| 2730544 | Sahyun | Jan 1956 | A |
| 2750387 | Krimmel | Jun 1956 | A |
| 2928833 | Leake et al. | Mar 1960 | A |
| 3174901 | Sterne | Mar 1965 | A |
| 3236891 | Seemuller | Feb 1966 | A |
| 3454635 | Muth | Jul 1969 | A |
| 3673241 | Marxer | Jun 1972 | A |
| 3925357 | Okada et al. | Dec 1975 | A |
| 4005208 | Bender et al. | Jan 1977 | A |
| 4061753 | Bodor et al. | Dec 1977 | A |
| 4159345 | Takeo et al. | Jun 1979 | A |
| 4382091 | Benjamin et al. | May 1983 | A |
| 4599338 | Regnier et al. | Jul 1986 | A |
| 4639436 | Junge et al. | Jan 1987 | A |
| 4687777 | Meguro et al. | Aug 1987 | A |
| 4743450 | Harris et al. | May 1988 | A |
| 4764466 | Suyama et al. | Aug 1988 | A |
| 4816455 | Schickaneder et al. | Mar 1989 | A |
| 4873330 | Lindholm | Oct 1989 | A |
| 4968672 | Jacobson et al. | Nov 1990 | A |
| 5034225 | Bennett et al. | Jul 1991 | A |
| 5041448 | Janssens et al. | Aug 1991 | A |
| 5051509 | Nagano et al. | Sep 1991 | A |
| 5051517 | Findeisen et al. | Sep 1991 | A |
| 5084460 | Munson, Jr. et al. | Jan 1992 | A |
| 5120712 | Habener | Jun 1992 | A |
| 5130244 | Nishimaki et al. | Jul 1992 | A |
| 5164526 | Macher | Nov 1992 | A |
| 5219870 | Kim | Jun 1993 | A |
| 5223499 | Greenlee et al. | Jun 1993 | A |
| 5234897 | Findeisen et al. | Aug 1993 | A |
| 5258380 | Janssens et al. | Nov 1993 | A |
| 5266555 | Findeisen et al. | Nov 1993 | A |
| 5273995 | Roth | Dec 1993 | A |
| 5284967 | Macher | Feb 1994 | A |
| 5300298 | LaNoue | Apr 1994 | A |
| 5329025 | Wong et al. | Jul 1994 | A |
| 5332744 | Chakravarty et al. | Jul 1994 | A |
| 5389642 | Dorsch et al. | Feb 1995 | A |
| 5399578 | Buhlmayer et al. | Mar 1995 | A |
| 5407929 | Takahashi et al. | Apr 1995 | A |
| 5461066 | Gericke et al. | Oct 1995 | A |
| 5470579 | Bonte et al. | Nov 1995 | A |
| 5591762 | Hauel et al. | Jan 1997 | A |
| 5594003 | Hauel et al. | Jan 1997 | A |
| 5602127 | Hauel et al. | Feb 1997 | A |
| 5614519 | Hauel et al. | Mar 1997 | A |
| 5719279 | Kufner-Muhl et al. | Feb 1998 | A |
| 5728849 | Bouchard et al. | Mar 1998 | A |
| 5753635 | Buckman et al. | May 1998 | A |
| 5777115 | Leigh et al. | Jul 1998 | A |
| 5830908 | Grunenberg et al. | Nov 1998 | A |
| 5879708 | Makino et al. | Mar 1999 | A |
| 5958951 | Ahmdt et al. | Sep 1999 | A |
| 5965555 | Gebert et al. | Oct 1999 | A |
| 5965592 | Buhlmayer et al. | Oct 1999 | A |
| 6011049 | Whitcomb | Jan 2000 | A |
| 6107302 | Carter et al. | Aug 2000 | A |
| 6166063 | Villhauer | Dec 2000 | A |
| 6200958 | Odaka et al. | Mar 2001 | B1 |
| 6248758 | Klokkers et al. | Jun 2001 | B1 |
| 6303661 | Demuth et al. | Oct 2001 | B1 |
| 6342601 | Bantick et al. | Jan 2002 | B1 |
| 6372940 | Cavazza | Apr 2002 | B1 |
| 6399101 | Frontanes et al. | Jun 2002 | B1 |
| 6448323 | Jordan et al. | Sep 2002 | B1 |
| 6548481 | Demuth et al. | Apr 2003 | B1 |
| 6579868 | Asano et al. | Jun 2003 | B1 |
| 6689353 | Wang et al. | Feb 2004 | B1 |
| 6699845 | Asahi | Mar 2004 | B2 |
| 6727261 | Gobbi et al. | Apr 2004 | B2 |
| 6784195 | Hale et al. | Aug 2004 | B2 |
| 6821978 | Chackalamannil et al. | Nov 2004 | B2 |
| 6869947 | Kanstrup et al. | Mar 2005 | B2 |
| 6890898 | Bachovchin et al. | May 2005 | B2 |
| 6995183 | Hamann et al. | Feb 2006 | B2 |
| 7034039 | Oi et al. | Apr 2006 | B2 |
| 7060722 | Kitajima et al. | Jun 2006 | B2 |
| 7074794 | Kitajima et al. | Jul 2006 | B2 |
| 7074798 | Yoshikawa et al. | Jul 2006 | B2 |
| 7074923 | Dahanukar et al. | Jul 2006 | B2 |
| 7109192 | Hauel et al. | Sep 2006 | B2 |
| 7179809 | Eckhardt et al. | Feb 2007 | B2 |
| 7183280 | Himmelsbach et al. | Feb 2007 | B2 |
| 7192952 | Kanstrup et al. | Mar 2007 | B2 |
| 7217711 | Eckhardt et al. | May 2007 | B2 |
| 7220750 | Himmelsbach et al. | May 2007 | B2 |
| 7235538 | Kanstrup et al. | Jun 2007 | B2 |
| 7247478 | Eberhardt et al. | Jul 2007 | B2 |
| 7282219 | Nomura et al. | Oct 2007 | B2 |
| 7291642 | Kauffmann-Hefner et al. | Nov 2007 | B2 |
| 7361687 | Barth et al. | Apr 2008 | B2 |
| 7393847 | Eckhardt et al. | Jul 2008 | B2 |
| 7407955 | Himmelsbach et al. | Aug 2008 | B2 |
| 7432262 | Eckhardt et al. | Oct 2008 | B2 |
| 7439370 | Eckhardt | Oct 2008 | B2 |
| 7470716 | Eckhardt et al. | Dec 2008 | B2 |
| 7476671 | Eckhardt et al. | Jan 2009 | B2 |
| 7482337 | Himmelsbach et al. | Jan 2009 | B2 |
| 7495002 | Langkopf et al. | Feb 2009 | B2 |
| 7495003 | Eckhardt et al. | Feb 2009 | B2 |
| 7495005 | Himmelsbach et al. | Feb 2009 | B2 |
| 7501426 | Himmelsbach et al. | Mar 2009 | B2 |
| 7550455 | Himmelsbach et al. | Jun 2009 | B2 |
| 7560450 | Eckhardt et al. | Jul 2009 | B2 |
| 7566707 | Eckhardt et al. | Jul 2009 | B2 |
| 7569574 | Maier et al. | Aug 2009 | B2 |
| 7579449 | Eckhardt et al. | Aug 2009 | B2 |
| 7610153 | Carter, Jr. et al. | Oct 2009 | B2 |
| 7645763 | Himmelsbach et al. | Jan 2010 | B2 |
| 7718666 | Boehringer et al. | May 2010 | B2 |
| 7754481 | Eberhardt et al. | Jul 2010 | B2 |
| 7799782 | Munson et al. | Sep 2010 | B2 |
| 7820815 | Pfrengle et al. | Oct 2010 | B2 |
| 7838529 | Himmelsbach et al. | Nov 2010 | B2 |
| 7919572 | Angot et al. | Apr 2011 | B2 |
| 8039477 | Hendrix et al. | Oct 2011 | B2 |
| 8071583 | Himmelsbach | Dec 2011 | B2 |
| 8106060 | Pfrengle et al. | Jan 2012 | B2 |
| 8119648 | Himmelsbach et al. | Feb 2012 | B2 |
| 8158633 | Hendrix et al. | Apr 2012 | B2 |
| 8178541 | Himmelsbach et al. | May 2012 | B2 |
| 8232281 | Dugi et al. | Jul 2012 | B2 |
| 8338450 | Arora et al. | Dec 2012 | B2 |
| 8399414 | Harada et al. | Mar 2013 | B2 |
| 8455435 | Franz et al. | Jun 2013 | B2 |
| 8513264 | Mark et al. | Aug 2013 | B2 |
| 8541450 | Pfrengle et al. | Sep 2013 | B2 |
| 8637530 | Pfrengle et al. | Jan 2014 | B2 |
| 8664232 | Himmelsbach et al. | Mar 2014 | B2 |
| 8673927 | Dugi et al. | Mar 2014 | B2 |
| 8679520 | Horres et al. | Mar 2014 | B2 |
| 8697868 | Himmelsbach et al. | Apr 2014 | B2 |
| 8785455 | Hotter et al. | Jul 2014 | B2 |
| 8846695 | Dugi | Sep 2014 | B2 |
| 8853156 | Dugi et al. | Oct 2014 | B2 |
| 8865729 | Sieger et al. | Oct 2014 | B2 |
| 8883800 | Pfrengle et al. | Nov 2014 | B2 |
| 8883805 | Pfrengle et al. | Nov 2014 | B2 |
| 8962636 | Pfrengle et al. | Feb 2015 | B2 |
| 9034883 | Klein et al. | May 2015 | B2 |
| 9108964 | Himmelsbach et al. | Aug 2015 | B2 |
| 9149478 | Klein et al. | Oct 2015 | B2 |
| 9155705 | Friedl et al. | Oct 2015 | B2 |
| 9173859 | Dugi et al. | Nov 2015 | B2 |
| 9186392 | Klein et al. | Nov 2015 | B2 |
| 9199998 | Pfrengle et al. | Dec 2015 | B2 |
| 9212183 | Sieger et al. | Dec 2015 | B2 |
| 9266888 | Sieger et al. | Feb 2016 | B2 |
| 9321791 | Himmelsbach et al. | Apr 2016 | B2 |
| 9415016 | Friedl et al. | Aug 2016 | B2 |
| 9486426 | Eller | Aug 2016 | B2 |
| 9457029 | Dugi et al. | Oct 2016 | B2 |
| 9486526 | Dugi | Nov 2016 | B2 |
| 9493462 | Sieger | Nov 2016 | B2 |
| 9815837 | Sieger | Nov 2017 | B2 |
| 10023574 | Himmelsbach | Jul 2018 | B2 |
| 10034877 | Dugi | Jul 2018 | B2 |
| 10092571 | Dugi et al. | Oct 2018 | B2 |
| 10155000 | Meinicke et al. | Dec 2018 | B2 |
| 10301313 | Sieger et al. | May 2019 | B2 |
| 10973827 | Friedl et al. | Apr 2021 | B2 |
| 11033552 | Kohlrausch et al. | Jun 2021 | B2 |
| 20010020006 | Demuth et al. | Sep 2001 | A1 |
| 20010051646 | Demuth et al. | Dec 2001 | A1 |
| 20020019411 | Robl et al. | Feb 2002 | A1 |
| 20020042393 | Oobae et al. | Apr 2002 | A1 |
| 20020049164 | Demuth et al. | Apr 2002 | A1 |
| 20020115718 | Chen et al. | Aug 2002 | A1 |
| 20020137903 | Ellsworth et al. | Sep 2002 | A1 |
| 20020160047 | Hussain et al. | Oct 2002 | A1 |
| 20020161001 | Kanstrup et al. | Oct 2002 | A1 |
| 20020169174 | Chackalamannil et al. | Nov 2002 | A1 |
| 20020198205 | Himmelsbach et al. | Dec 2002 | A1 |
| 20030040490 | Sugiyama et al. | Feb 2003 | A1 |
| 20030078269 | Pearson et al. | Apr 2003 | A1 |
| 20030100563 | Edmondson et al. | May 2003 | A1 |
| 20030104053 | Gusler et al. | Jun 2003 | A1 |
| 20030104983 | DeFelippis et al. | Jun 2003 | A1 |
| 20030105077 | Kanstrup et al. | Jun 2003 | A1 |
| 20030114390 | Washbum et al. | Jun 2003 | A1 |
| 20030130313 | Fujino et al. | Jul 2003 | A1 |
| 20030149071 | Gobbi et al. | Aug 2003 | A1 |
| 20030153509 | Bachovchin et al. | Aug 2003 | A1 |
| 20030166578 | Arch et al. | Sep 2003 | A1 |
| 20030199528 | Kanstrup et al. | Oct 2003 | A1 |
| 20030224043 | Appel et al. | Dec 2003 | A1 |
| 20030232987 | Dahanukar et al. | Dec 2003 | A1 |
| 20030236272 | Carr | Dec 2003 | A1 |
| 20040018468 | Gorokhovsky | Jan 2004 | A1 |
| 20040023981 | Ren et al. | Feb 2004 | A1 |
| 20040034014 | Kanstrup et al. | Feb 2004 | A1 |
| 20040037883 | Zhou et al. | Feb 2004 | A1 |
| 20040063725 | Barth et al. | Apr 2004 | A1 |
| 20040077645 | Himmelsbach et al. | Apr 2004 | A1 |
| 20040082570 | Yoshikawa et al. | Apr 2004 | A1 |
| 20040087587 | Himmelsbach et al. | May 2004 | A1 |
| 20040097410 | Zheng et al. | May 2004 | A1 |
| 20040097510 | Himmelsbach et al. | May 2004 | A1 |
| 20040116328 | Yoshikawa et al. | Jun 2004 | A1 |
| 20040122048 | Benjamin et al. | Jun 2004 | A1 |
| 20040122228 | Maier et al. | Jun 2004 | A1 |
| 20040126358 | Warne et al. | Jul 2004 | A1 |
| 20040138214 | Himmelsbach et al. | Jul 2004 | A1 |
| 20040138215 | Eckhardt et al. | Jul 2004 | A1 |
| 20040152659 | Matsuoka et al. | Aug 2004 | A1 |
| 20040152720 | Hartig et al. | Aug 2004 | A1 |
| 20040166125 | Himmelsbach et al. | Aug 2004 | A1 |
| 20040171836 | Fujino et al. | Sep 2004 | A1 |
| 20040180925 | Matsuno et al. | Sep 2004 | A1 |
| 20040259843 | Madar et al. | Dec 2004 | A1 |
| 20040259903 | Boehringer et al. | Dec 2004 | A1 |
| 20040266806 | Sanghvi et al. | Dec 2004 | A1 |
| 20050004107 | Kohlrausch | Jan 2005 | A1 |
| 20050020484 | Harada et al. | Jan 2005 | A1 |
| 20050020574 | Hauel et al. | Jan 2005 | A1 |
| 20050026921 | Eckhardt et al. | Feb 2005 | A1 |
| 20050027012 | Kohlrausch | Feb 2005 | A1 |
| 20050031682 | Cucala Escoi et al. | Feb 2005 | A1 |
| 20050032804 | Cypes et al. | Feb 2005 | A1 |
| 20050065145 | Cao et al. | Mar 2005 | A1 |
| 20050070562 | Jones et al. | Mar 2005 | A1 |
| 20050070594 | Kauschke et al. | Mar 2005 | A1 |
| 20050070694 | Gelfanova et al. | Mar 2005 | A1 |
| 20050097798 | Evans et al. | May 2005 | A1 |
| 20050107730 | Doty et al. | May 2005 | A1 |
| 20050119162 | Harada et al. | Jun 2005 | A1 |
| 20050130985 | Himmelsbach et al. | Jun 2005 | A1 |
| 20050143377 | Himmelsbach et al. | Jun 2005 | A1 |
| 20050171093 | Eckhardt et al. | Aug 2005 | A1 |
| 20050187227 | Himmelsbach et al. | Aug 2005 | A1 |
| 20050203095 | Eckhardt et al. | Sep 2005 | A1 |
| 20050234108 | Himmelsbach et al. | Oct 2005 | A1 |
| 20050234235 | Eckhardt et al. | Oct 2005 | A1 |
| 20050239778 | Konetzki et al. | Oct 2005 | A1 |
| 20050244502 | Mathias et al. | Nov 2005 | A1 |
| 20050256310 | Hulin et al. | Nov 2005 | A1 |
| 20050261271 | Feng et al. | Nov 2005 | A1 |
| 20050261352 | Eckhardt | Nov 2005 | A1 |
| 20050266080 | Desai et al. | Dec 2005 | A1 |
| 20050276794 | Papas et al. | Dec 2005 | A1 |
| 20060004074 | Eckhardt et al. | Jan 2006 | A1 |
| 20060008829 | Hess | Jan 2006 | A1 |
| 20060034922 | Cheng et al. | Feb 2006 | A1 |
| 20060039968 | Manikandan et al. | Feb 2006 | A1 |
| 20060039974 | Akiyama et al. | Feb 2006 | A1 |
| 20060047125 | Leonardi et al. | Mar 2006 | A1 |
| 20060058323 | Eckhardt et al. | Mar 2006 | A1 |
| 20060063787 | Yoshikawa et al. | Mar 2006 | A1 |
| 20060074058 | Holmes et al. | Apr 2006 | A1 |
| 20060079541 | Langkopf et al. | Apr 2006 | A1 |
| 20060094722 | Yasuda et al. | May 2006 | A1 |
| 20060100199 | Yoshikawa et al. | May 2006 | A1 |
| 20060106035 | Hendrix et al. | May 2006 | A1 |
| 20060111372 | Hendrix et al. | May 2006 | A1 |
| 20060111379 | Guillemont et al. | May 2006 | A1 |
| 20060134206 | Iyer et al. | Jun 2006 | A1 |
| 20060142310 | Pfrengle et al. | Jun 2006 | A1 |
| 20060154866 | Chu et al. | Jul 2006 | A1 |
| 20060159746 | Troup et al. | Jul 2006 | A1 |
| 20060173056 | Kitajima et al. | Aug 2006 | A1 |
| 20060205711 | Himmelsbach et al. | Sep 2006 | A1 |
| 20060205943 | Dahanukar et al. | Sep 2006 | A1 |
| 20060247226 | Himmelsbach et al. | Nov 2006 | A1 |
| 20060270668 | Chew et al. | Nov 2006 | A1 |
| 20060270701 | Kroth et al. | Nov 2006 | A1 |
| 20070027168 | Pfrengle et al. | Feb 2007 | A1 |
| 20070059797 | Low et al. | Mar 2007 | A1 |
| 20070060530 | Christopher et al. | Mar 2007 | A1 |
| 20070072803 | Chu et al. | Mar 2007 | A1 |
| 20070072810 | Asakawa | Mar 2007 | A1 |
| 20070088038 | Eckhardt et al. | Apr 2007 | A1 |
| 20070093659 | Bonfanti et al. | Apr 2007 | A1 |
| 20070142383 | Eckhardt et al. | Jun 2007 | A1 |
| 20070173452 | DiMarchi et al. | Jul 2007 | A1 |
| 20070185091 | Himmelsbach et al. | Aug 2007 | A1 |
| 20070196472 | Kiel et al. | Aug 2007 | A1 |
| 20070197522 | Edwards et al. | Aug 2007 | A1 |
| 20070197552 | Carr | Aug 2007 | A1 |
| 20070219178 | Muramoto | Sep 2007 | A1 |
| 20070254944 | Hughes | Nov 2007 | A1 |
| 20070259880 | Sakashita et al. | Nov 2007 | A1 |
| 20070259900 | Sieger et al. | Nov 2007 | A1 |
| 20070259925 | Boehringer et al. | Nov 2007 | A1 |
| 20070259927 | Suzuki et al. | Nov 2007 | A1 |
| 20070265349 | Rapin et al. | Nov 2007 | A1 |
| 20070281940 | Dugi et al. | Dec 2007 | A1 |
| 20070299076 | Piotrowski et al. | Dec 2007 | A1 |
| 20080014270 | Harada | Jan 2008 | A1 |
| 20080039427 | Ray et al. | Feb 2008 | A1 |
| 20080107731 | Kohlrausch et al. | May 2008 | A1 |
| 20080108816 | Zutter | May 2008 | A1 |
| 20080221200 | Allison et al. | Sep 2008 | A1 |
| 20080234291 | Francois et al. | Sep 2008 | A1 |
| 20080249089 | Himmelsbach et al. | Oct 2008 | A1 |
| 20080255159 | Himmelsbach et al. | Oct 2008 | A1 |
| 20080312243 | Eckhardt et al. | Dec 2008 | A1 |
| 20080318922 | Nakahira et al. | Dec 2008 | A1 |
| 20090023920 | Eckhardt | Jan 2009 | A1 |
| 20090054303 | Gougoutas et al. | Feb 2009 | A1 |
| 20090082256 | Abe et al. | Mar 2009 | A1 |
| 20090088408 | Meade et al. | Apr 2009 | A1 |
| 20090088569 | Eckhardt et al. | Apr 2009 | A1 |
| 20090093457 | Himmelsbach et al. | Apr 2009 | A1 |
| 20090131432 | Himmelsbach et al. | May 2009 | A1 |
| 20090136596 | Munson et al. | May 2009 | A1 |
| 20090137801 | Himmelsbach et al. | May 2009 | A1 |
| 20090149483 | Nakahira et al. | Jun 2009 | A1 |
| 20090186086 | Shankar et al. | Jul 2009 | A1 |
| 20090192314 | Pfrengle et al. | Jul 2009 | A1 |
| 20090253752 | Burkey et al. | Oct 2009 | A1 |
| 20090297470 | Franz | Dec 2009 | A1 |
| 20090301105 | Loerting | Dec 2009 | A1 |
| 20090325926 | Himmelsbach | Dec 2009 | A1 |
| 20100074950 | Sesha | Mar 2010 | A1 |
| 20100092551 | Nakamura et al. | Apr 2010 | A1 |
| 20100173916 | Himmelsbach et al. | Jul 2010 | A1 |
| 20100179191 | Himmelsbach et al. | Jul 2010 | A1 |
| 20100183531 | Johncock et al. | Jul 2010 | A1 |
| 20100204250 | Himmelsbach et al. | Aug 2010 | A1 |
| 20100209506 | Eisenreich | Aug 2010 | A1 |
| 20100310664 | Watson et al. | Dec 2010 | A1 |
| 20100317575 | Pinnetti et al. | Dec 2010 | A1 |
| 20100330177 | Pourkavoos | Dec 2010 | A1 |
| 20110009391 | Braun et al. | Jan 2011 | A1 |
| 20110028391 | Holst et al. | Feb 2011 | A1 |
| 20110046076 | Eickelmann et al. | Feb 2011 | A1 |
| 20110065731 | Dugi et al. | Mar 2011 | A1 |
| 20110092510 | Klein et al. | Apr 2011 | A1 |
| 20110098240 | Dugi et al. | Apr 2011 | A1 |
| 20110112069 | Himmelsbach et al. | May 2011 | A1 |
| 20110144083 | Himmelsbach et al. | Jun 2011 | A1 |
| 20110144095 | Himmelsbach et al. | Jun 2011 | A1 |
| 20110190322 | Klein et al. | Aug 2011 | A1 |
| 20110195917 | Dugi et al. | Aug 2011 | A1 |
| 20110206766 | Friedl et al. | Aug 2011 | A1 |
| 20110212982 | Christopher et al. | Sep 2011 | A1 |
| 20110263493 | Dugi et al. | Oct 2011 | A1 |
| 20110263617 | Mark et al. | Oct 2011 | A1 |
| 20110275561 | Graefe-Mody et al. | Nov 2011 | A1 |
| 20110301182 | Dugi | Dec 2011 | A1 |
| 20120003313 | Kohlrausch et al. | Jan 2012 | A1 |
| 20120035158 | Himmelsbach et al. | Feb 2012 | A1 |
| 20120040982 | Himmelsbach et al. | Feb 2012 | A1 |
| 20120053173 | Banno et al. | Mar 2012 | A1 |
| 20120094894 | Graefe-Mody et al. | Apr 2012 | A1 |
| 20120107398 | Schneider et al. | May 2012 | A1 |
| 20120121530 | Klein et al. | May 2012 | A1 |
| 20120122776 | Graefe-Mody et al. | May 2012 | A1 |
| 20120129874 | Sieger et al. | May 2012 | A1 |
| 20120142712 | Pfrengle et al. | Jun 2012 | A1 |
| 20120165251 | Klein et al. | Jun 2012 | A1 |
| 20120208831 | Himmelsbach et al. | Aug 2012 | A1 |
| 20120219622 | Kohlrausch et al. | Aug 2012 | A1 |
| 20120219623 | Meinicke | Aug 2012 | A1 |
| 20120232004 | Bachovchin et al. | Sep 2012 | A1 |
| 20120252782 | Himmelsbach et al. | Oct 2012 | A1 |
| 20120252783 | Himmelsbach et al. | Oct 2012 | A1 |
| 20120296091 | Sieger et al. | Nov 2012 | A1 |
| 20130064887 | Ito et al. | Mar 2013 | A1 |
| 20130122089 | Kohlrausch et al. | May 2013 | A1 |
| 20130172244 | Klein et al. | Jul 2013 | A1 |
| 20130184204 | Pfrengle et al. | Jul 2013 | A1 |
| 20130196898 | Dugi et al. | Aug 2013 | A1 |
| 20130236543 | Ito et al. | Sep 2013 | A1 |
| 20130303462 | Klein | Nov 2013 | A1 |
| 20130303554 | Klein et al. | Nov 2013 | A1 |
| 20130310398 | Mark et al. | Nov 2013 | A1 |
| 20130315975 | Klein et al. | Nov 2013 | A1 |
| 20130317046 | Johansen | Nov 2013 | A1 |
| 20130324463 | Klein et al. | Dec 2013 | A1 |
| 20140100236 | Busl et al. | Apr 2014 | A1 |
| 20140274889 | Johansen et al. | Sep 2014 | A1 |
| 20140315832 | Broedl et al. | Oct 2014 | A1 |
| 20140343014 | Klein et al. | Nov 2014 | A1 |
| 20140371243 | Klein et al. | Dec 2014 | A1 |
| 20150196565 | Klein et al. | Jul 2015 | A1 |
| 20150246045 | Klein et al. | Sep 2015 | A1 |
| 20150265538 | Balthes et al. | Sep 2015 | A1 |
| 20160058769 | Graefe-Mody et al. | Mar 2016 | A1 |
| 20160082011 | Klein et al. | Mar 2016 | A1 |
| 20160089373 | Johansen et al. | Mar 2016 | A1 |
| 20160106677 | Boeck et al. | Apr 2016 | A1 |
| 20160310435 | Friedl et al. | Oct 2016 | A1 |
| 20170020868 | Dugi et al. | Jan 2017 | A1 |
| 20170354660 | Meinicke et al. | Dec 2017 | A1 |
| 20210299120 | Gupta | Sep 2021 | A1 |
| 20220378797 | Friedl et al. | Dec 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 2003280680 | Jun 2004 | AU |
| 2009224546 | Sep 2009 | AU |
| 1123437 | May 1982 | CA |
| 2136288 | May 1995 | CA |
| 2375779 | May 2000 | CA |
| 2418656 | Feb 2002 | CA |
| 2435730 | Sep 2002 | CA |
| 2496249 | Mar 2004 | CA |
| 2496325 | Mar 2004 | CA |
| 2498423 | Apr 2004 | CA |
| 2505389 | May 2004 | CA |
| 2508233 | Jun 2004 | CA |
| 2529729 | Dec 2004 | CA |
| 2543074 | Jun 2005 | CA |
| 2555050 | Sep 2005 | CA |
| 2556064 | Sep 2005 | CA |
| 2558067 | Oct 2005 | CA |
| 2558446 | Oct 2005 | CA |
| 2561210 | Oct 2005 | CA |
| 2562859 | Nov 2005 | CA |
| 2576294 | Mar 2006 | CA |
| 2590912 | Jun 2006 | CA |
| 2599419 | Nov 2006 | CA |
| 2651019 | Nov 2007 | CA |
| 2651089 | Nov 2007 | CA |
| 2720450 | Oct 2009 | CA |
| 101035522 | Sep 2007 | CN |
| 101234105 | Aug 2008 | CN |
| 101309689 | Nov 2008 | CN |
| 101590007 | Dec 2009 | CN |
| 104130258 | Nov 2014 | CN |
| 104418857 | Mar 2015 | CN |
| 105272982 | Jan 2016 | CN |
| 2205815 | Aug 1973 | DE |
| 2758025 | Jul 1979 | DE |
| 19705233 | Aug 1998 | DE |
| 10109021 | Sep 2002 | DE |
| 10117803 | Oct 2002 | DE |
| 10238243 | Mar 2004 | DE |
| 102004019540 | Nov 2005 | DE |
| 102004024454 | Dec 2005 | DE |
| 102004044221 | Mar 2006 | DE |
| 102004054054 | May 2006 | DE |
| 201300121 | Oct 2009 | EA |
| 0023032 | Jan 1981 | EP |
| 0149578 | Jul 1985 | EP |
| 0189941 | Aug 1986 | EP |
| 0223403 | May 1987 | EP |
| 0237608 | Sep 1987 | EP |
| 0248634 | Dec 1987 | EP |
| 0289282 | Nov 1988 | EP |
| 0342675 | Nov 1989 | EP |
| 0389282 | Sep 1990 | EP |
| 0399285 | Nov 1990 | EP |
| 0400974 | Dec 1990 | EP |
| 409281 | Jan 1991 | EP |
| 0412358 | Feb 1991 | EP |
| 443983 | Aug 1991 | EP |
| 0475482 | Mar 1992 | EP |
| 0524482 | Jan 1993 | EP |
| 0638567 | Feb 1995 | EP |
| 0657454 | Jun 1995 | EP |
| 0775704 | May 1997 | EP |
| 0950658 | Oct 1999 | EP |
| 1054012 | Nov 2000 | EP |
| 1066265 | Jan 2001 | EP |
| 1310245 | May 2003 | EP |
| 1333033 | Aug 2003 | EP |
| 1338595 | Aug 2003 | EP |
| 1406873 | Apr 2004 | EP |
| 1500403 | Jan 2005 | EP |
| 1514552 | Mar 2005 | EP |
| 1523994 | Apr 2005 | EP |
| 1535906 | Jun 2005 | EP |
| 1537880 | Jun 2005 | EP |
| 1557165 | Jul 2005 | EP |
| 1586571 | Oct 2005 | EP |
| 1604989 | Dec 2005 | EP |
| 1743655 | Jan 2007 | EP |
| 1760076 | Mar 2007 | EP |
| 1829877 | Sep 2007 | EP |
| 1852108 | Nov 2007 | EP |
| 1897892 | Mar 2008 | EP |
| 2143443 | Jan 2010 | EP |
| 2166007 | Mar 2010 | EP |
| 2308878 | Apr 2011 | EP |
| 3646859 | May 2020 | EP |
| 385302 | Apr 1973 | ES |
| 2256797 | Jul 2006 | ES |
| 2263057 | Dec 2006 | ES |
| 2707641 | Jan 1995 | FR |
| 2084580 | Apr 1982 | GB |
| 9003243 | May 1990 | HU |
| 9902308 | Jul 2000 | HU |
| S374895 | Jun 1962 | JP |
| 61030567 | Feb 1986 | JP |
| 770120 | Mar 1995 | JP |
| 8333339 | Dec 1996 | JP |
| 11193270 | Jul 1999 | JP |
| 2000502684 | Mar 2000 | JP |
| 2001213770 | Aug 2001 | JP |
| 2001278812 | Oct 2001 | JP |
| 2001292388 | Oct 2001 | JP |
| 2002348279 | Dec 2002 | JP |
| 2003286287 | Oct 2003 | JP |
| 2003300977 | Oct 2003 | JP |
| 2004161749 | Jun 2004 | JP |
| 2004196824 | Jul 2004 | JP |
| 2004250336 | Sep 2004 | JP |
| 2005511636 | Apr 2005 | JP |
| 2005519059 | Jun 2005 | JP |
| 2006503013 | Jan 2006 | JP |
| 2006045156 | Feb 2006 | JP |
| 2006137678 | Jun 2006 | JP |
| 2007501231 | Jan 2007 | JP |
| 2007510059 | Apr 2007 | JP |
| 2007522251 | Aug 2007 | JP |
| 2007531780 | Nov 2007 | JP |
| 2008513390 | May 2008 | JP |
| 2008536881 | Sep 2008 | JP |
| 2010500326 | Jan 2010 | JP |
| 2010053576 | Mar 2010 | JP |
| 2010070576 | Apr 2010 | JP |
| 2010524580 | Jul 2010 | JP |
| 2010535850 | Nov 2010 | JP |
| 2010536734 | Dec 2010 | JP |
| 2011088838 | May 2011 | JP |
| 2011529945 | Dec 2011 | JP |
| 2012502081 | Jan 2012 | JP |
| 2012505859 | Mar 2012 | JP |
| 20070111099 | Nov 2007 | KR |
| 8706941 | Nov 1987 | WO |
| 199107945 | Jun 1991 | WO |
| 199205175 | Apr 1992 | WO |
| 199219227 | Nov 1992 | WO |
| 199308259 | Apr 1993 | WO |
| 199402150 | Feb 1994 | WO |
| 199403456 | Feb 1994 | WO |
| 1994012200 | Jun 1994 | WO |
| 9532178 | Nov 1995 | WO |
| 199609045 | Mar 1996 | WO |
| 199611917 | Apr 1996 | WO |
| 199636638 | Nov 1996 | WO |
| 199718814 | May 1997 | WO |
| 199723447 | Jul 1997 | WO |
| 199723473 | Jul 1997 | WO |
| 199728808 | Aug 1997 | WO |
| 199746526 | Dec 1997 | WO |
| 1998007725 | Feb 1998 | WO |
| 199811893 | Mar 1998 | WO |
| 9818770 | May 1998 | WO |
| 199822464 | May 1998 | WO |
| 199828007 | Jul 1998 | WO |
| 199840069 | Sep 1998 | WO |
| 1998046082 | Oct 1998 | WO |
| 199856406 | Dec 1998 | WO |
| 9903854 | Jan 1999 | WO |
| 199929695 | Jun 1999 | WO |
| 1999038501 | Aug 1999 | WO |
| 199950248 | Oct 1999 | WO |
| 1999049857 | Oct 1999 | WO |
| 199956561 | Nov 1999 | WO |
| 199967279 | Dec 1999 | WO |
| 2000003735 | Jan 2000 | WO |
| 200012064 | Mar 2000 | WO |
| 200072873 | May 2000 | WO |
| 200034241 | Jun 2000 | WO |
| 0069464 | Nov 2000 | WO |
| 200066101 | Nov 2000 | WO |
| 0072799 | Dec 2000 | WO |
| 0078735 | Dec 2000 | WO |
| 200072973 | Dec 2000 | WO |
| 200073307 | Dec 2000 | WO |
| 200107441 | Feb 2001 | WO |
| 2001032158 | May 2001 | WO |
| 2001040180 | Jun 2001 | WO |
| 200152825 | Jul 2001 | WO |
| 200152852 | Jul 2001 | WO |
| 2001047514 | Jul 2001 | WO |
| 2001051919 | Jul 2001 | WO |
| 2001066548 | Sep 2001 | WO |
| 2001068603 | Sep 2001 | WO |
| 2001068646 | Sep 2001 | WO |
| 200177110 | Oct 2001 | WO |
| 2001072290 | Oct 2001 | WO |
| 200196301 | Dec 2001 | WO |
| 200197808 | Dec 2001 | WO |
| 200202560 | Jan 2002 | WO |
| 200214271 | Feb 2002 | WO |
| 200224698 | Mar 2002 | WO |
| 2002053516 | Jul 2002 | WO |
| 2002068420 | Sep 2002 | WO |
| 2003000241 | Jan 2003 | WO |
| 2003000250 | Jan 2003 | WO |
| 2003002531 | Jan 2003 | WO |
| 2003002553 | Jan 2003 | WO |
| 2003004496 | Jan 2003 | WO |
| 2003006425 | Jan 2003 | WO |
| 2003024965 | Mar 2003 | WO |
| 2003033686 | Apr 2003 | WO |
| 03038123 | May 2003 | WO |
| 2003034944 | May 2003 | WO |
| 2003035177 | May 2003 | WO |
| 2003037327 | May 2003 | WO |
| 2003053929 | Jul 2003 | WO |
| 2003055881 | Jul 2003 | WO |
| 2003057200 | Jul 2003 | WO |
| 2003057245 | Jul 2003 | WO |
| 2003059327 | Jul 2003 | WO |
| 2003061688 | Jul 2003 | WO |
| 2003064454 | Aug 2003 | WO |
| 2003074500 | Sep 2003 | WO |
| 2003088900 | Oct 2003 | WO |
| 2003094909 | Nov 2003 | WO |
| 2003099279 | Dec 2003 | WO |
| 2003099836 | Dec 2003 | WO |
| 2003104229 | Dec 2003 | WO |
| 2003106428 | Dec 2003 | WO |
| 2004002924 | Jan 2004 | WO |
| 2004011416 | Feb 2004 | WO |
| 2004016587 | Feb 2004 | WO |
| 2000003735 | Mar 2004 | WO |
| 2004018467 | Mar 2004 | WO |
| 2004018468 | Mar 2004 | WO |
| 2004018469 | Mar 2004 | WO |
| 2004028524 | Apr 2004 | WO |
| 2004033455 | Apr 2004 | WO |
| 2004035575 | Apr 2004 | WO |
| 2004037169 | May 2004 | WO |
| 2004041820 | May 2004 | WO |
| 2004043940 | May 2004 | WO |
| 2004046148 | Jun 2004 | WO |
| 2004048379 | Jun 2004 | WO |
| 2004050658 | Jun 2004 | WO |
| 2004052362 | Jun 2004 | WO |
| 2004058233 | Jul 2004 | WO |
| 2004062689 | Jul 2004 | WO |
| 2004065380 | Aug 2004 | WO |
| 2004074246 | Sep 2004 | WO |
| 2004081006 | Sep 2004 | WO |
| 2004082402 | Sep 2004 | WO |
| 2004096806 | Nov 2004 | WO |
| 2004096811 | Nov 2004 | WO |
| 2004018468 | Dec 2004 | WO |
| 2004106279 | Dec 2004 | WO |
| 2004108730 | Dec 2004 | WO |
| 2004111051 | Dec 2004 | WO |
| 2005000846 | Jan 2005 | WO |
| 2005000848 | Jan 2005 | WO |
| 2005007137 | Jan 2005 | WO |
| 2005007647 | Jan 2005 | WO |
| 2005007658 | Jan 2005 | WO |
| 2005012288 | Feb 2005 | WO |
| 2005016365 | Feb 2005 | WO |
| 2005023179 | Mar 2005 | WO |
| 2005049022 | Jun 2005 | WO |
| 2005051950 | Jun 2005 | WO |
| 2005058901 | Jun 2005 | WO |
| 2005061489 | Jul 2005 | WO |
| 2005063750 | Jul 2005 | WO |
| 2005075410 | Aug 2005 | WO |
| 2005082906 | Sep 2005 | WO |
| 2005085246 | Sep 2005 | WO |
| 2005092870 | Oct 2005 | WO |
| 2005092877 | Oct 2005 | WO |
| 2005095343 | Oct 2005 | WO |
| 2005095381 | Oct 2005 | WO |
| 2005097798 | Oct 2005 | WO |
| 2005107730 | Nov 2005 | WO |
| 2005116000 | Dec 2005 | WO |
| 2005116014 | Dec 2005 | WO |
| 2005117861 | Dec 2005 | WO |
| 2005117948 | Dec 2005 | WO |
| 2005119526 | Dec 2005 | WO |
| 2006005613 | Jan 2006 | WO |
| 2006027204 | Mar 2006 | WO |
| 2006029577 | Mar 2006 | WO |
| 2006029769 | Mar 2006 | WO |
| 2006036664 | Apr 2006 | WO |
| 2006040625 | Apr 2006 | WO |
| 2006041976 | Apr 2006 | WO |
| 2006047248 | May 2006 | WO |
| 2006048209 | May 2006 | WO |
| 2006048427 | May 2006 | WO |
| 2006068163 | Jun 2006 | WO |
| 2006071078 | Jul 2006 | WO |
| 2006076231 | Jul 2006 | WO |
| 2006078593 | Jul 2006 | WO |
| 2006083491 | Aug 2006 | WO |
| 2006116157 | Nov 2006 | WO |
| 2006129785 | Dec 2006 | WO |
| 2006135693 | Dec 2006 | WO |
| 2006137085 | Dec 2006 | WO |
| 2007007173 | Jan 2007 | WO |
| 2007014886 | Feb 2007 | WO |
| 2007014895 | Feb 2007 | WO |
| 2007017423 | Feb 2007 | WO |
| 07035665 | Mar 2007 | WO |
| 2007033350 | Mar 2007 | WO |
| 2007035355 | Mar 2007 | WO |
| 2007035665 | Mar 2007 | WO |
| 2007038979 | Apr 2007 | WO |
| 2007041053 | Apr 2007 | WO |
| 2007050485 | May 2007 | WO |
| 2007071738 | Jun 2007 | WO |
| 2007072083 | Jun 2007 | WO |
| 2007078726 | Jul 2007 | WO |
| 2007093610 | Aug 2007 | WO |
| 2007099345 | Sep 2007 | WO |
| 2007120702 | Oct 2007 | WO |
| 2007120936 | Oct 2007 | WO |
| 2007128721 | Nov 2007 | WO |
| 2007128724 | Nov 2007 | WO |
| 2007128761 | Nov 2007 | WO |
| 2007135196 | Nov 2007 | WO |
| 2007136151 | Nov 2007 | WO |
| 2007137107 | Nov 2007 | WO |
| 2007147185 | Dec 2007 | WO |
| 2007148185 | Dec 2007 | WO |
| 2007149797 | Dec 2007 | WO |
| 2003057245 | Jan 2008 | WO |
| 2008005569 | Jan 2008 | WO |
| 2008005576 | Jan 2008 | WO |
| 2008017670 | Feb 2008 | WO |
| 2008017670 | Feb 2008 | WO |
| 2008022267 | Feb 2008 | WO |
| 2008055870 | May 2008 | WO |
| 2008055940 | May 2008 | WO |
| 2008070692 | Jun 2008 | WO |
| 2008077639 | Jul 2008 | WO |
| 2008081205 | Jul 2008 | WO |
| 2008083238 | Jul 2008 | WO |
| 2008087198 | Jul 2008 | WO |
| 2008093878 | Aug 2008 | WO |
| 2008093882 | Aug 2008 | WO |
| 2008097180 | Aug 2008 | WO |
| 2008113000 | Sep 2008 | WO |
| 2008130998 | Oct 2008 | WO |
| 2008131149 | Oct 2008 | WO |
| 2008137435 | Nov 2008 | WO |
| 2009011451 | Jan 2009 | WO |
| 2009022007 | Feb 2009 | WO |
| 2009022007 | Feb 2009 | WO |
| 2009022008 | Feb 2009 | WO |
| 2009022009 | Feb 2009 | WO |
| 2009022010 | Feb 2009 | WO |
| 2009024542 | Feb 2009 | WO |
| 2009063072 | May 2009 | WO |
| 2009091082 | Jul 2009 | WO |
| 2009099734 | Aug 2009 | WO |
| 2009111200 | Sep 2009 | WO |
| 2009112691 | Sep 2009 | WO |
| 2009121945 | Oct 2009 | WO |
| 2009123992 | Oct 2009 | WO |
| 199967278 | Dec 2009 | WO |
| 2009147125 | Dec 2009 | WO |
| 201092124 | Feb 2010 | WO |
| 2010015664 | Feb 2010 | WO |
| 2010018217 | Feb 2010 | WO |
| 2010029089 | Mar 2010 | WO |
| 2010043688 | Apr 2010 | WO |
| 2010045656 | Apr 2010 | WO |
| 2010072776 | Jul 2010 | WO |
| 2010079197 | Jul 2010 | WO |
| 2010086411 | Aug 2010 | WO |
| 2010092125 | Aug 2010 | WO |
| 2010092163 | Aug 2010 | WO |
| 2010096384 | Aug 2010 | WO |
| 2010106457 | Sep 2010 | WO |
| 2010126908 | Nov 2010 | WO |
| 2010140111 | Dec 2010 | WO |
| 2010147768 | Dec 2010 | WO |
| 2011011541 | Jan 2011 | WO |
| 2011039337 | Apr 2011 | WO |
| 2011039367 | Apr 2011 | WO |
| 2011064352 | Jun 2011 | WO |
| 2011109333 | Sep 2011 | WO |
| 2011113947 | Sep 2011 | WO |
| 2011138380 | Nov 2011 | WO |
| 2011138421 | Nov 2011 | WO |
| 2011154496 | Dec 2011 | WO |
| 2011161161 | Dec 2011 | WO |
| 2011163206 | Dec 2011 | WO |
| 2012031124 | Mar 2012 | WO |
| 2012039420 | Mar 2012 | WO |
| 2012065993 | May 2012 | WO |
| 2012088682 | Jul 2012 | WO |
| 2012089127 | Jul 2012 | WO |
| 2012106303 | Aug 2012 | WO |
| 2012120040 | Sep 2012 | WO |
| 2003061688 | Apr 2013 | WO |
| 2013098372 | Jul 2013 | WO |
| 2013103629 | Jul 2013 | WO |
| 2013131967 | Sep 2013 | WO |
| 2013171167 | Nov 2013 | WO |
| 2013174768 | Nov 2013 | WO |
| 2013179307 | Dec 2013 | WO |
| 2014029848 | Feb 2014 | WO |
| 2014140284 | Sep 2014 | WO |
| 2014170383 | Oct 2014 | WO |
| 2017047970 | Mar 2017 | WO |
| 2020016232 | Jan 2020 | WO |
| 2020016232 | Jan 2020 | WO |
| Entry |
|---|
| Rungby, Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes, 2009, Expert Opin. Investig. Drugs, vol. 18 iss. 6, pp. 835-838. (Year: 2009). |
| Lee et al., Radical approach to diabetic nephropathy, 2007, Kidney International, vol. 72. p. S67-S70. (Year: 2007). |
| Gennaro, Alfonso R., Remington Farmacia, 19th Edition, Spanish copy, 1995, p. 2470. |
| Gennaro, Alfonso, R; Remington: The Science and Practice of Pharmacy: Oral Solid Dosage Forms; Mack Publishing Company, Philadelphia, PA (1995) vol. II, 19th Edition, Ch. 92 pp. 1615-1649. |
| Gennaro, Alfonso; Remington: The Science and Practice of Pharmacy, Twentieth Edition, 2000, Chapter 45, pp. 860-869. |
| Giron, D.; Thermal Analysis and Calorimetric Methods in the Characterisation of Polymorphs and Solvates; Thermochimica Acta (1995) vol. 248 pp. 1-59. |
| GLUCOPHAGE® Prescribing Information, 2001. |
| Glucotrol XL (glipizide), package insert, Pfizer, Apr. 1, 2002. |
| Goldstein, L.A., et al., “Molecular cloning of seprase: a serine integral membrane protease from human melanoma.” Biochimica et Biophysica Acta, vol. 1361, 1997, No. 1, pp. 11-19. |
| Gomez-Perez, et al, “Insulin Therapy:current alternatives”, Arch. Med.Res. 36: p. 258-272 (2005). |
| Goodarzi, M.O. et al., “Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.” Diabetes, Obesity and Metabolism, 2005, vol. 7, pp. 654-665. |
| Graefe-Mody et al., “The novel DPP-4 inhibitor BI 1356 (proposed tradename ONDERO) and Metformin can be Safely Co-administered Without Dose Adjustment.” Poster No. 553-P ADA Jun. 6-10, 2008, San Francisco http://professional.diabetes.org/content/posters/2008/p553-p.pdf. |
| Graefe-Mody, et al; Evaluation of the Potential for Steady-State Pharmacokinetic and Phamacodynamic Interactions Between the DPP-4 Inhibitor Linagliptin and Metformin in Healthy Subjects; Currents Medical Research and Opinion (2009) vol. 25, No. 8 pp. 1963-1972. |
| Graefe-Mody, U. et al., “Effect of Renal Impairment on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin.” Diabetes, Obseity and Metabolism, 2011, pp. 939-946. |
| Greene, T.W, et al., “Protection for the Amino Group”. Protective Groups in Organic Synthesis, 3rd edition, 1999, p. 494-653. |
| Greischel, et al., Drug Metabolism and Deposition, “The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Exhibits Time- and Dpse-Dependent Localization in Kidney, Liver, and Intestine after Intravenous Dosing: Results from High Resolution Autoradiography in Rats”, 2010, vol. 38, No. 9, p. 1443-1448. |
| Groop, P.-H et al., “Effects of the DPP-4 Inhibitor Linagliptin on Albuminuria in Patients with Type 2 Diabetes and Diabetic Nephropathy.” 48th EASD Annual Meeting, Berlin, Abstract 36, Oct. 2012. |
| Guglielmi, C. et al., “Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy.” Diabetes/Metabolism Research and Reviews, 2012, vol. 28, Supplement 2, pp. 40-46. |
| Gupta, V. et al., “Choosing a Gliptin.” Indian Journal of Endocrinology and Metabolism, 2011, vol. 15, No. 4, pp. 298-308. |
| Gwaltney, S. “Medicinal Chemistry Approaches to the Inhibition of Dipeptidyl Peptidase IV”, Current Topics in Medicinal Chemistry, 2008, 8, p. 1545-1552. |
| Gwaltney, S.L. II et al., “Inhibitors of Dipeptidyl Peptidase 4.” Annual Reports In Medicinal Chemistry, 2005, vol. 40, pp. 149-165. |
| Hainer, Vojtech MD, PhD “Comparative Efficiency and Safety of Pharmacological Approaches to the Management of Obesity.” Diabetes Care, 2011, vol. 34, Suppl. 2, pp. S349-S354. |
| Halimi, “Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet”, Vascular Health and Risk Management, 2008 481-92. |
| Halimi, S. et al., “Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.” Vascular Health and Risk Management, 2008, vol. 4, No. 3, pp. 481-492. |
| Haluzik, M. et al., “Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria.” International Journal of Endocrinology, 2013, vol. 35, No. 6, pp. 1-7. |
| Hammouda, Y. et al., “Lactose-induced Discoloration of Amino Drugs in Solid Dosage Form.” Die Pharmazie, 1971, vol. 26, p. 181. |
| Hansen, H. et al., “Co-Administration of the DPP-4 Inhibitor Linagliptin and Native GLP-1 Induce Body Weight Loss and Appetite Suppression.” 73rd Annual Meeting Science Session, ADA, Chicago, Jun. 21, 2013. |
| Hashida, Mitsuru, “Strategies for designing and developing oral administration formulations.” Yakuji-Jiho, Inc., 1995, pp. 50-51 and 89. |
| Hayashi, Michio., “Recipe for Oral Hypoglycemic Agents to Pathological Condition” Pharmacy (2006) vol. 57, No. 9 pp. 2735-2739. |
| He, Y. L. et al., “Bioequivalence of Vildagliptin/Metformin Combination Tablets and Coadministration of Vildagliptin and Metformin as Free Combination in Healthy Subjects”. J. Clinical Pharmacology, 2007, vol. 47, No. 9, Abstracts of the 36th Annual Meeting of the American College of Clinical Pharmacology, San Francisco, CA, Abstract 116, p. 1210. |
| He, Y.L. et al., “The influence of hepatic impariment on the pharmacokinetics f the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin” European Journal of Clinical Pharmacology, vol. 63, No. 7, May 8, 2007, p. 677-686. |
| He, Y.L. et al., “The Influence of Renal Impairment on the Pharmacokinetics of Vildagliptin.” Clinical Pharmacology & Therapeutics, 2007, vol. 81, Suppl. 1, Abstract No. PIII-86. |
| Headland, K. et al., “The Effect of Combination Linagliptin and Voglibose on Glucose Control and Body Weight.” 73rd Annual Meeting Science Session, ADA, Chicago, Jun. 21, 2013. |
| Heihachiro, A. et al., “Synthesis of Prolyl Endopeptidase Inhibitors and Evaluation of Their Structure-Activity Relationships: In Vitro Inhibition of Prolyl Endopeptidase from Canine Brain.” 1993, Chemical and Pharmaceutical Bulletin, vol. 41, pp. 1583-1588. |
| Heise, et al., Diabetes, Obesity and Metabolism, “Pharmacokinetics, pharmacokinetics and tolerability of mutilple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients”, 2009, vol. 11, No. 8, p. 786-794. |
| Heise, T. et al., “Treatment with BI 1356, a Novel and Potent DPP-IV Inhibitor, Significantly Reduces Glucose Excursions after an oGTT in Patients with Type 2 Diabetes.” A Journal of the American Diabetes Association, Jun. 2007, vol. 56, Supplement 1, Poster No. 0588P. |
| Herman, G. A. et al., “Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus on Sitagliptin.” Clinical Pharmacology and Therapeutics, 2007, vol. 81, No. 5, pp. 761-767. |
| Herman, Gary et al. “Co-Administration of MK-0431 and Metformin in Patients with Type 2 Diabetes Does Not Alter the Pharmacokinetics of MK-0431 or Metformin” (2005) Journal of American Diabetes Association vol. 54, Supplement 1, 3 pgs. |
| Hermann, Robert, et al; Lack of Association of PAX4 Gene with Type 1 Diabetes in the Hungarian Populations; Diabetes (2005) vol. 54 pp. 2816-2819. |
| Hermansen, K., “Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Glimepiride Alone or on Glimepiride and Metformin”. Diabetes, Obesity and Metabolism (2007) vol. 9, No. 5 pp. 733-745. |
| Hilfiker, R. et al., “Relevance of Solid-state Properties for Pharmaceutical Products.” Polymorphism in the Pharmaceutical Industry, 2006, Chapter 1, pp. 1-19. |
| Hinke, S.A. et al., “Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1.” Biochemical and Biophysical Research Communications, 2002, vol. 291, No. 5, pp. 1302-1308. |
| Hinke, S.A. et al., “On Combination Therapy of Diabetes With Metformin and Dipeptidyl Peptidase IV Inhibitors.” Diabetes Care, 2002, vol. 25, No. 8, pp. 1490-1492. |
| Hinnen, D. et al., “Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes.” Journal Of The American Board Of Family Medicine, 2006, vol. 19, No. 6, pp. 612-620. |
| Hocher, B. et al., “Renal and Cardiac Effects of DPP-4 Inhibitors—from Preclinical Development to Clinical Research.” Kidney & Blood Pressue Research, 2012, vol. 36, No. 1, pp. 65-84. |
| Hocher, B. et al., “The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/ reperfusion in rats.” International Journal of Cardiology, 2013, vol. 167, pp. 87-93. |
| Holman, et al., “Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes”, N. England Journal Medicine, p. 1716-1730, 2007. |
| Horsford, E. N. “On the source of free hydrochloric acid in the gastric juice.” Proceedings of the Royal Society of London, Published in 1868-1869, vol. 17, pp. 391-395. |
| Hu, Y. et al., “Synthesis and Structure-activity Relationship of N-alkyl Gly-boro-Pro Inhibitors of DPP4, FAP, and DPP7.” Bioorganic & Medicinal Chemistry Letters 15, 2005, pp. 4239-4242. |
| Huettner Silks et al: “BI 1356, a novel and selective xanthine based DPP-IV inhibitor, demonstrates good safety and tolerability with a wide therapeutic window” Diabetes< American Diabetes Association, US, vol. 56, No. Suppl 1, Jun. 1, 2007, p. A156. |
| Hull, R. et al., “Nephrotic syndrome in adults.” British Medical Journal, 2008, vol. 336, pp. 1185-1190. |
| Hunziker, D. et al, “Inhibitors of DPP IV-recent advances and structural views”, Current Topics in Medicinal Chemistry, 2005, vol. 5 issue 16, pp. 1623-1637. |
| Cygankiewicz, Andrzej et al., Investigations into the Piperazine Derivatives of Dimethylxanthine:, Acta Polon. Pharm. [Papers of Polish Pharmacology], XXXOV, No. 5, pp. 607-612, 1977. |
| Dave, K.G. et al., “Reaction of Nitriles under Acidic Conditions, Part I. A General Method of Synthesis of Condensed Pyrimidines”, J. Heterocyclic Chemistry, BD, 17, 1, ISSN 0022-152X,Nov. 1980, p. 1497-1500. |
| Dave, Rutesh H. “Overview of pharmaceutical excipients used in tablets and capsules.” Drug Topics, Oct. 24, 2008. |
| Deacon, Carolyn F. et al., “Linaglipitn, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes” Expert Opin. Investig. Drugs (2010) 19(1) p. 133-140. |
| Deacon, C.F. et al; “Dipeptidyl peptidase IV inhabitation as an approach to the treatment and prevention of type 2 diabetes: a historical perspective;” Biochemical and Biophysical Research Communications (BBRC) 294 (2002) 1-4. |
| Deacon, C.F., et al. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opinion on Investigational Drugs, Sep. 2004, vol. 13, No. 9, p. 1091-1102. |
| Deacon, Carolyn F., “Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes.” Expert Opinion on Investigational Drugs, 2007, vol. 16, No. 4, pp. 533-545. |
| Definition of “prevent”, e-dictionary, Aug. 15, 2013, http://dictionary.reference.com/browse/prevent. |
| DeMeester, I. et al.; “CD26, let it cut or cut it down”, Review: Immunology Today; Aug. 1999, vol. 20, No. 8 pp.367-375. |
| Demuth, H-U. et al., “Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors”. Biochimica et Biophysica Acta, vol. 1751(1), 2005, p. 33-44. |
| Diabetes Frontier, 2007, vol. 18, No. 2, p. 145-148. |
| Diabetes Health Center, “Diabetic Retinopathy—Prevention.” Retrieved online Mar. 22, 2011. www.diabetes.webmd.com/tc/diabetic-retinopathy-prevention <http://www.diabetes.webmd.com/tc/diabetic-retinopathy-prevention? print=true>. |
| Diabetesincontrol.com “EASD: Eucreas, a Combination of Galvus and Metformin, Recommended for Approval.” Diabetes In Control.com, Sep. 25, 2007, Retrieved from internet on Nov. 30, 2012, http:/ /www.diabetesincontrol.com/articles/53-diabetes-news/5145. |
| Diabetic Neuropathy, Retrieved online Mar. 6, 2012. www.mayoclinic.com/health/diabetic-neuropathy/DS01045/METHOD=print&DSE <http://www.mayoclinic.com/health/diabetic-neuropathy/DS01045/METHOD=print&DSE>. |
| Dittberner, S. et al., “Determination of the absolute bioavailability of BI 1356, a substance with non-linear pharmacokinetics, using a population pharmacokinetic modeling approach.” Abstracts of the Annual Meeting of the Population Approach Group in Europe, 2007. |
| Drucker, Daniel J., “Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes.” Diabetes Care, 2007, vol. 30, No. 6, pp. 1335-1343. |
| Drucker, et al.., The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368: 1696-705. |
| Dugi, K. et al., “Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356, a novel DPP-IV inhibitor with a wide therapeutic window.” Diabetic Medicine, 2006, vol. 23, Suppl. 4, p. 300. |
| Dugi, K.A. et al., “BI 1356, a novel xanthine-based DPP-IV inhibitor, exhibits high potency with a wide therapeutic window and significantly reduces postprandial glucose excursions after an oGTT”. Diabetologia, vol. 50, No. Suppl 1, Sep. 2007, pS367, and 43rd Annual Meeting of the European Association for the Study of Diabetes; Amsterdam, Netherlands, Sep. 18-21, 2007. |
| Dunitz, J. et al., “Disappearing Polymorphs.” Acc. Chem. Res. 1995, vol. 28, No. 4, pp. 193-200. |
| Eckhardt Matthias et al: 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-yny 1-3-methyl-1-(4-methyl-quina zolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes: Journal of Medicinal Chemistry, American Chemical Society. Washington.; US, vol. 50, No. 26, Dec. 1, 2007, p. 6450-6453. |
| Eckhardt, M. et al., “3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors” Bioorganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science, GB, vol. 18, No. 11, Jun. 1, 2008, pp. 3158-3162, XP022711188. |
| Edosada, C. Y. et al. “Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity.” The Journal of Biological Chemistry, 2006, vol. 281, No. 11, pp. 7437-7444. |
| Elrishi M A et al: “The dipeptidyl-peptidase-4 (D::- 4) inhibitors: A new class of oral therapy for patients with type 2 diabetes mellitus” Practical Diabetes International Chichester, vol. 24, No. 9, Nov. 1, 2007 pp. 474-482. |
| EMEA: European Medicines Agency, “Galvus (vildagliptin)” Retrieved online on Jan. 21, 2016. |
| EMEA: European Medicines Agency, ICH Topic E4, “Dose Response Information to Support Drug Registration.” 1994, pp. 1-10. |
| Eucreas Scientific Discussion, 2007, p. 1-27, www.emea.europa.eu/humandocs/PD/Fs/EPAR/eucreas/H-807-en6.pdf, Anonymous. |
| European Search Report for EP 08 15 9141 dated Apr. 6, 2009 (European counterpart of U.S. Appl. No. 12/143,128). |
| Eyjolfsson, Reynir “Lisinopril-Lactose Incompatibility.” Drug Development and Industrial Pharmacy, 1998, vol. 24, No. 8, pp. 797-798. |
| Feng, J. et al., “Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV.” Journal of Medicinal Chemistry, 2007, vol. 50, No. 10, pp. 2297-2300. |
| Ferreira, L. et al., “Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat).” Mediators of Inflammation, 2010, vol. 2010, pp. 1-11. |
| Ferry, Robert Jr., “Diabetes Causes.” eMedicine Health, MedicineNet.com, 2013, Retrieved from internet on Aug. 22, 2013, <http://www.onhealth.com/diabetes_health/page3.htm#diabetes_causes>. |
| Flatt, P.R. et al., “Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.” Frontiers in Bioscience, 2008, vol. 13, pp. 3648-3660. |
| Florez, J. et al. “TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program.” The New England Journal of Medicine, 2006, vol. 355, No. 3, pp. 241-250. |
| Forst, T. et al., “The Novel, Potent, and Selective DPP-4 Inhibitor BI 1356 Significantly Lowers HbA1c after only 4 weeks of Treatment in Patients with Type 2 Diabetes.” Diabetes, Jun. 2007, Poster No. 0594P. |
| Forst, T. et al., “The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.” Diabetes, Obesity and Metabolism, 2011, vol. 13, pp. 542-550. |
| Fukushima et al., Drug for Treating Type II Diabetes (6), “action-mechanism of DPP-IV inhibitor and the availability thereof” Mebio, 2009, vol. 26, No. 8, p. 50-58. |
| Gall, “Prevalence of micro-and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin dependent) diabetic patients”, Diabetologia (1991) 655-661. |
| Gallwitz, B. “Sitagliptin with Metformin: Profile of a Combination for the Treatment of Type 2 Diabetes”. Drugs of Today, Oct. 2007, 43(10), p. 681-689. |
| Gallwitz, B. et al., “2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.” Lancet, 2012, vol. 380, pp. 475-483. |
| Gallwitz, B. et al., “Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes”. IDRUGS, vol. 11, No. 12, Dec. 2008, p. 906-917. |
| Gallwitz, B. et al., DPP IV inhibitors for the Treatment of Type 2 Diabetes; Diabetes Frontier (2007) vol. 18, No. 6 pp. 636-642. |
| Gallwitz, B., “Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.” Therapeutic Advances in Endocrinology and Metabolism, 2013, vol. 4, No. 3, pp. 95-105. |
| Galvus (Vildagliptin) Scientific Discussion, EMEA, 2007, pp. 1-34. |
| Garber, A.J. et al., “Effects of Vildagliptin on Glucose Control in Patients with Type 2 Diabetes Inadequately Controlled with a Sulphonylurea”. Diabetes, Obesity and Metabolism (2008) vol. 10 pp. 1047-1055. |
| Garber, A.J. et al., “Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.” Diabetes, Obesity and Metabolism, 2002, vol. 4, pp. 201-208. |
| Garber, A.J. et al., “Update: Vildaglitin for the treatment of Type 2 diabetes” Expert Opinion on Investigational Drugs, 200801GB, vol. 17, No. 1, Jan. 2008, p. 105-113. |
| Garcia-Soria, et al., “The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patents with type 2 diabetes mellitus”. Diabetes, Obesity and Metabolism, Apr. 2008, vol. 10, No. 4, p. 293-300. |
| Geka, 2001, vol. 67, No. 11, p. 1295-1299. |
| Gennaro, Alfonso R. Remington Farmacia, 2003, Spanish copy: p. 828, English copy: pp. 711-712, Preformulation, Chapter 38. |
| Nursten, The Mailard Reaction, Chemistry, Biochemistry, and Implications, Chapter 10, p. 1-8., 2018. |
| DiFeo, Drug Product Development, A Technical Review of Chemistry, Drug Development and Industrial Pharmacy, vol. 29, 2003, p. 939-958. |
| Federal register, Department of Health and Human Services, vol. 62, 1997. |
| Van Veen, Compaction of Powder blends, University Medical Center, 2003. |
| MacDonald, No Fraud, No conspiracy, No error, France and Merck say reformulated Euthyrox is safe, Pharmatechnolgist, 2017. |
| Nachaegari, Coprocessed Excipients for Solid Dosage Forms, Pharmaceutical technology, 2004. |
| Gohel, A. review of coprocessed Directly compressible excipients, J. Pharm Pharmaceutical Sci, 2005. |
| Cotton, The Selection of an appropriate salt form and preparation of a stable oral formulation, International Journal of Pharmaceutics, 1994, p. 237-249. |
| Ahmed, Materials Formulation of Low Dose Medicines, Americal Pharma review, vol. 3, 2000. |
| Wikipedia, Polyvinylpyrrolidone, https:en.wikipedia.org/wiki/access date May 15, 2018. |
| Westerhuis, Optimisation of the composition and production of mannitol cellulose tablets International Journal of Pharmaceutics, 1996, p. 143, 151-162. |
| Portincasa, Current Pharmacological Treatment of Nonalcoholic Fatty Liver, Current Medicinal Chem, 2006, p. 2889-2900. |
| Del Prato, Diabetes, Obesity and Metabolism, Effect of linagliptin monotherapy on glycemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial, 2011, p. 258-267. |
| Gallwitz, linagliptin-A novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy, Clinical Medicine Indights: Endocrinology and Diabetes, 2012, vol. 5, p. 1-11. |
| Lakey, Technical Aspects of islet preparation and transplantation, Burridge Medical Researach Institute, 2003. |
| Mikhail, Investigating Drugs, Incretin Mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of Type 2 diabetes, vol. 17, 2008, p. 845-853. |
| Cefalu, Animal Models of Type 2 Diabetes: Clinical Presentation and Pathophysiological Relevance to the Human Condition, ILAR Journal, vol. 47, No. 3, 2006. |
| Crowe, Early Guidelines and Identification Management of Chronic Kidney Disease, 2008, summary of NICE guidance, vol. 337, p. 812-815. |
| Zaman, Comparison Between Effect of Vildagliptin and Linagliptin on Glycaemic control, renal function, liver function and lipid profile in patients of T2DM Inadequately controlled with combo of Metformin and Glimepiride, Journal of Dental and Medical Sciences, vol. 16, Issue 9, 2017. p. 27-31. |
| Connelly, Dipeptyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease, Clinical and Investigative Medicine, vol. 37, p. 172-185, 2014. |
| Scheen, Clinical Pharmacokinetics of metformin, Clinical Pharmacokinetics, vol. 30, No. 5, 1996, p. 359-371. |
| Zhang, Classification and Treatment Prinicples of Diabetes, Beijing Medical Univ and China Union Medical Univ. Joint Publishing House. 1st ed., 1998, p. 939. |
| Diabetes and Foot ulcers, www.diabetes.co.uk/diabetes-complications/diabetic-foot-ulcers.html, 2018. |
| Aronow, Congestive Heart Failure, Treatment of Heart Failure in Older Persons with Coexisting Conditions, vol. 9, No. 3, 2003, p. 142-147. |
| Tiwari, Linagliptin, A dipeptyl peptidase-4 inhibitor for the treatment of type 2 diabetes, Current Opinion in Ivestigational Drugs, vol. 10, 2009, p. 1091-1104. |
| Somaa, Chronic Comlications in patients with slowly progressing atutoimmune type 1 diabetes, Diabetes Care, vol. 22, 1999, p. 1347-1353. |
| Seijin-Byou, The Journal of Adult Diseases, 2008, vol. 38, p. 438-444., abstract attached. |
| Fuguchi, Therapeutic Effects and Adverse Reactions to Oral Hypoglycemic Agents, Journal of the Nippon Hospital Pharmacists Assoc, 1976, vol. 1, p. 226-229, abstract only. |
| Colorcon (retrieved from website http://www.colorcon.com/products-formulation/all-products/film-coatings/immediate-release/opadry, published2015). |
| Bergmann, Decrease of serum dipeptidylpeptidase activity in severs sepsis patients, Clinica Chimica Acta 2002., p. 123-126. |
| Gallwitz, Safety and Efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors, vol. 4,2013. |
| Groop, Effects of The DPP-4inhibitor linagliptin on albuminuria in patients with type 2 diabetes, www.abstractsonline.com, 2013. |
| Cooper, Kidney Disease End Points in a Pooled Analysis of individual Patient-Level Data from a large Clinical Trials Program of the Dipeptyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes, vol. 66, American Journal of Kidney Diseases, 2015. |
| Hocher, Renal and Cardiac Effects of DPP4 in inhibitors from preclinical development to clinical research, Kidney and Blood Pressure Research, vol. 36, 2012, p. 65-84. |
| Von Eynatten, Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease, vol. 12, 2013. |
| Seijin-Byou, abstract, The Journal of Adult Diseases, 2008. , vol. 38. |
| Clinical Journal of Chinese Medicine, vol. 3, 2008, p. 360-364. |
| Clinical Trials.gov, Efficacy and Safety of Lingliptin in Elderly Patients with Type 2 Diabetes, Mar. 10, 2010, NCT01084005. |
| Barrara, Granulation, Handbook of Powder Technology, vol. 11, 2015. |
| Piatti, Long term Oral L- Arginine-Administration Improves Peripheral and Hepatic Insulin Sensitivity, Emerging Treatments and Technology, Diabestes Care, vol. 24, 2011. |
| Clinical Trials.gov, NCT00622284, Efficacy and Safety of BI 1356 in Combination with Metformin in Patients with Type 2 Diabetes, 2013. |
| Kleeman, Pharmaceutical Substances, Synthesesm Patents, Applications, p. 1196-1997, 1999. |
| Rowe, Handbook of Pharmaceutical Excipients, Fifth Ed., Calcium Bicarbonate, 2006. |
| Clinical Trials.gov, Efficacy and Safety of BI 1356 in Combination with Metformin in Patients with Type 2 Diabetes, NCT00309608, 2006. |
| Clinical Trials.gov, 52-week add-on to metformin comparison of saxagliptin and sulphonurea, NCT00575588, 2007. |
| Walsh, Pharmaceutical Biotechnology,Ovewview of Protein structure, 2007. |
| Katdare, Excipient Development for Pharmaceutical Biotechnology and Drug Delivery Systems, Ten of the most common Neutralizers Used, 2006. |
| Remington , The Science of Pharmacy, 22nd Ed., Pharmacuetical Dosage Forms, 2013. |
| Lide, CRC Handbook of Chem and Physics, Disassociation Constants of Organic Acids and Bases, 2002, 82nd Ed. |
| Stahl, Handbook of Pharmaceutical Salts, Properties, Selection and Use, 2002. |
| Nippon Boehringer Ingelheim Co., Ltd., Press Release, Linagliptin Showing improvement in Albuminuria, Jun. 18, 2012. |
| Japanese Society Of Nephrology, Clinical Practice Guidebook, 2012, 145 pages. |
| Lee, Common foot diseases that primary care physicians should know about, Korean Journal of Family Medicine, vol. 26, 2005, p. 127-137. |
| Bundgaard, H. “Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities”. Royal Danish School of Pharmacy, 1985, p. 1-92. |
| Busso et al., “Circulating CD26 is Negatively Associated with Inflammation in Human and Experimental Arthritis,” Am. J. Path., vol. 166, No. 2, Feb. 2005, pp. 433-442. |
| Byrn, Stephen R. “Solid-State Chemistry of Drugs.” Academic Press, 1982, pp. 1-27. |
| Caira, M.R., “Crystalline polymorphism of organic compounds” Topics in Current Chemistry, Springer, Berlin, vol. 198, 1998, p. 163-208. |
| Campbell, R. Keith “Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus.” The Annals of Pharmacotherapy, Jan. 2007, vol. 41, pp. 51-60. |
| Canadian Diabetes Association, “Pharmacologic Management of Type 2 Diabetes.” Canadian Journal of Diabetes, 2003, vol. 27, Suppl. 2, pp. S37-S42. |
| Canadian Pharmacists Association, Compendium of Pharmaceuticals and Specialties, “Zestril” 2004, pp. 2289-2293. |
| Cao, C. et al., “The clinical application of linagliptin in Asians.” Therapeutics and Clinical Risk Management, 2015, vol. 11, pp. 1409-1419. |
| Castello, R. et al., “Discoloration of Tablets Containing Amines and Lactose.” Journal of Pharmaceutical Sciences, 1962, vol. 51, No. 2, pp. 106-108. |
| Chan, J.C. et al., “Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.” 2008, Diabetes, Obesity and Metabolism, vol. 10, pp. 545-555. |
| Charbonnel, B. et al., “Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone.” Diabetes Care, 2006, vol. 29, No. 12, pp. 2638-2643. |
| Chaykovska, L. et al., “Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy.” www.plosone.org, 2011, vol. 6, No. 11, p. e27861. |
| ChemGaroo, “Leaving Group.” 1999, Retrieved online: http://www.chemgapedia.de/vsengine/vlu/vsc/en/ch/12/oc/vlu organik/substitution/sn _ 2/sn 2. vlu/Page/vsc/en/ch/12/oc/substitution/sn _ 2/abgangsgrupen/abgangsgruppe. vscml.html. |
| Chemical Abstract. EP412358, 1991:185517, Findeisen. |
| Chemical Abstract: FR2707641, 1995:543545, Dodey. |
| Chemical Abstract: No. 211513-37-0—Dalcetrapib. “Propanethioic acid, 2-methyl-, S-(2-[[[1-(2-ethylbutyl)cyclohexyl} carbonyl}amino}pheyl}ester”. Formula: C23 H35 N O2 S. American Chemical Society. Sep. 20, 1998. |
| Chemical Abstract: No. 875446-37-0—Anacetrapib. “2-Oxazolidinone, 5-[3,5-bis(trifluoromethyl)phenyl]-3[[4′fluoro-2′-methoxy-5′-(1-methylethyl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl]-4-methyl-,(4S,5R)-” Formula: C30 H25 F10 N O3. American Chemical Society, Feb. 28, 2006. |
| Chemical Abstracts Accession No. 106:95577 Romanenko et al., “Synthesis and Biological Activity of 3-Methyl, 7- or 8-alkyl-7,8dialkyl, heterocyclic, and cyclohexylaminoxanthines,” Zaporozh. Med. Institute (1986). |
| Chemical Abstracts Accession No. 1987:95577: Abstract of Romanenko et al., “Synthesis and biological activity of 3-methyl, 7- or 8-alkyl, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines,” Zapoeozh, USSR, Farmatsevtichnii Zhurnal, 1986, (Kiev), vol. 5, 1986, pp. 41-44. |
| Chemical Abstracts Service, Database Accession number No. RN 668270-12-01, 2004, “1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]”. |
| Chemistry Review: Tradjenta, “NDA 201280, CMC Director Review Tradjenta (Linagliptin) Tablets.” Center for Drug Evaluation and Research, Aug. 9, 2010, Retrieved from the internet on Nov. 1, 2013, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000ChemR.pdf. |
| Cheon, et al., Biochemical Pharmacology, “Inhibition of dipeptidyl IV by novel inhibitors with pyrazolidine scaffold”, 2005, vol. 70, p. 22-29. |
| Chiasson, J.-L et al., “The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes.” Diabetes Care, 2001, vol. 24, No. 6, pp. 989-994. |
| Chisari, A. et al. “Sulphinyl, Sulphonyl, and Sulphonium Groups as Leaving Groups in Aromatic Nucleophilic Substitutions.” Journal of the Chemical Society, Perkin Transactions II, 1982, pp. 957-959. |
| Chowhan, Z.T. et al., Drug-Excipient Interaction Resulting from Powder Mixing IV: Role of Lubricants and Their Effect on In Vitro Dissolution, Journal of Pharmaceutical Sciences, 1986, vol. 75, No. 6, pp. 542-545. |
| Clinical Trial NCT00622284 (published online at clinicaltrials.gov on Feb. 22, 2008). |
| Clinical Trial Protocol, “A Randomised, Double-blind, Placebo-controlled, Five Parallel Groups Study Investigating the Efficacy and Safety of BI 1356 BS.” Boehringer Ingelheim Pharmaceuticals, last updated on Jun. 24, 2014. |
| Clinical Trial, NCT00622284, clinicaltrials.gov, updated Feb. 22, 2008. |
| Clinical Trials NCT00601250, clinicaltrials.gov, Jan. 25, 2008. |
| Clinical Trials, No. NCT00309608, “Efficacy and Safety of BI 1356 BS in Combination with Metformin in Patients With type2 Diabetes” 2009, pp. 1-3. |
| Clinical Trials, No. NCT00622284, “Efficacy and Safety of BI 1356 in combination with metformin in patients with type 2 diabetes” 2012, pp. 1-5. |
| Clinical Trials. “View of NCT00601250 on Jan. 25, 2008: Efficacy and Safety of BI 1356 vs Placebo added to Metformin Background Therapy in Patients with Type 2 Diabetes” Clinical Trials. Gov Archive, [Online] Jan. 25, 2008 URL:http://clinicaltrials.gov/archive/NCTO0601250/2008_01_25 [retrieved on Feb. 27, 2009]. |
| Clinical Trials. NCTO0622284. “Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes” ClinicalTrials.gov (Online) No. NCT00622284, Feb. 13, 2008, p. 1-5, URL:http://clinicaltrial.gov/ct2/show/. |
| Clinical Trials. View of NCT00730275 updated on Aug. 7, 2008. “A study to assess the pharmacokinetics, safety and tolerability of Sitagliptin in adolescents”. http://clinicaltrials.gov/archive/NCT00730275/2008_08_07. |
| Clinical Trials: NCT00954447, View on Jun. 14, 2010. “Efficacy and Safety of Linagliptin in Combination with Insulin in Patients with Type 2 Diabetes”. <http://clinicaltrials.gov/archive/NCT00954447/2010_06_14>. |
| Clinical Trials: NCT00103857, “A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control” last updated on Apr. 27, 2015. |
| Clinical Trials: NCT00309608, “Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes” Boehringer Ingelheim Pharmaceuticals, last updated on Jun. 24, 2014. |
| Clinical Trials: NCT00309608, “Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes” Boehringer Ingelheim Pharmaceuticals, last updated: Dec. 11, 2013. |
| Clinical Trials: NCT00309608. Efficacy and safety of BI 1356 in combination with metformin in patients with type2 diabetes. Boehringer Ingelheim Pharmaceuticals, Jan. 27, 2009. Clinical Trials.gov . http://clinicaltrials.gov/ archive/NCT00309608/2009_01_27. |
| Clinical Trials: NCT00602472. “Bi 1356 in combination withe metformin and a sulphonylurea in Type 2 Diabetes”. DrugLib.com, Nov. 3, 2008. http://www.druglib.com/trial/08/NCT00309608.html. |
| Clinical Trials: NCT00622284. Efficacy and Safety of BI 1356 in Combination with Metformin in Patients with Type 2 Diabetes. Boehringer Ingelheim Pharmaceuticals, Aug. 2008. http://clinicaltrials.gov/archive/ NCT00622284/2010_01_13. |
| Clinical Trials: NCT00798161. “Safety and efficacy of Bi 1356 Plus Metformin in Type 2 Diabetes, Factorial Design”. Clinical Trials.gov archive. A Service of the U.S> National Institutes of Health. Nov. 24, 2008, p1-3. http://clinicaltrials.gov/archive/NCT00798161/2008_11_24. |
| Colorcon, “Lactose Replacement with Starch 1500 in a Direct Compression Formula.” 2005, pp. 1-4. |
| Colorcon, “Reducing Coated Tablet Defects from Laboratory through Production Scale: Performance of Hypromellose or Polyvinyl Alcohol-Based Aqueous Film Coating Systems.” Opadry II, 2009, pp. 1-7. |
| Combs, D. W. et al., “Phosphoryl Chloride Induced Ring Contraction of 11,4-Benzodiazepinones to Chloromethylquinazolines”. J. Heterocyclic Chemistry, BD. 23, 1986, p. 1263-1264. |
| Conarello, S.L. et al., “Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance”. PNAS, May 27, 2003, vol. 100, No. 11, p. 6825-6830. |
| Conarello, S.L. et al; “Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance,” PNAS 2003; 100:6825-6830; originally published online May 14, 2003; information current as of Dec. 2006. www.pnas.org/cgi/content/full/100/11/6825. |
| Cotton, M.L. et al., “L-649,923—The selection of an appropriate salt form and preparation of a stable oral formulation.” International Journal of Pharmaceutics, 1994, vol. 109, Issue 3, pp. 237-249. |
| Craddy, P. et al., “Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison.” Diabetes Therapy, 2014, vol. 5, No. 1, pp. 1-41. |
| Crowe, E. et al., “Early identification and management of chronic kidney disease: summary of NICE guidance.” British Medical Journal, 2008, vol. 337, pp. 812-815. |
| Kosugi, eNOS KNockout Mice with advanced diabetic neuropathy have less benefir from Renin-Angiostatin Blockade than from Aldosterone Receptor Antagonists, Amer. J. of Pathology, vol. 176, 2010. |
| Schmeider, Telmisartan in incipient and overt renal disease, J. Nephrol, vol. 24, 2011. |
| Stedman's Medical Doctionary, 27th edition, Def. of nephropathy, 1999. |
| Clarivate Analytics on STN: Confirmation of the public accessibility of Schmeider before May 31, 2011. |
| Anonymous, New England Journal of Medicine, The effect of intensive treatment of diabetes on the development and brogession of long term complicationsin insulin dependent mellitus, vol. 329, 1993. |
| Hanrimwon, Pharmaceutics Subcommitee, 2000, p. 321-322. |
| Eckhardt, 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BO1356), Journal of Medicinal Chem., vol. 50, 2007, p. 6450-5453. |
| Heizmann, Xanthines as a scaffold for molecular diversity, Molecular Diversity, vol. 2, 1996. |
| Rabinovitch, Thyophylline protects against diabetes in BB rats, Diabetologica, vol. 33, 1990. |
| International Search Report for PCT/EP2019/069131 dated Oct. 8, 2019. |
| Gallwitz, Safety and Efficacy of linagliptin type 2 diabetes patients, Therapeutic advances in Endocrinology, vol. 4, 2013. |
| Lehrke, Safety and Efficacy of linagliptin in patients with Type 2 diabetes, Journal of Diabetes, vol. 30, 2016. |
| Clinical Trials.gov, for BI1356 for Patients in Combination wtih Metormin in Patients with Type 2 Diabetes.2014. |
| Gross, Diabetic Neuropathy, Diabetes Care, vol. 28, 2005. |
| Scheen, Lina plus metformin, Expert opinion on Drug metabolism & Toxicology, 2013. |
| McGill, Long term Efficacy and Safety of Linaglip in patients with Type 2 diabetes, Clinical Care, vol. 35, 2013. |
| Bell, Diabetes Care, The frequent, forgotten, and and often fatal complication of diabetes, vol. 26, 2003. |
| International Search Report for PCT/EP2019/EP069131 dated Jan. 28, 2021. |
| Isoda, Certificate of experimental Results, Analytical Research Development, 2021. |
| Luo, Shanghai Scientific and Technical Lit Publishing House, Theory and Practice of Modern Physical Pharmacy, vol. 4, 2005, p. 294. |
| Peticao, Diagnosis and Classification of Diabetes Mellitus, Diabetes Care, vol. 37, 2014. |
| Winzell, Diabetes, The High Fat diet fed Mouse, vol. 53, 2004. |
| Okruhlicova, Cell Research, Ultrastructure and Histchemistry of rat capilary endothelial cells in response to diabetes, vol. 15, 2005. |
| Wufele, Combination of Insulin and Metformin in Treatment, Clinical Care, vol. 25, 2002. |
| Owens, Efficacy and Safety of linagliptin in person with type 2 diabetes, Diabetic Meds, vol. 28, 2021. |
| Haak, Comibination of Linaglptin and metformin, Clinical Med insights, 2015. |
| Forst, ADA, Novel, Potent, Selective, DPP-4 inhibitor BI 1356 Significantly lowers HbA1c after only 4 weeks of treatment, 2007. |
| Park, Stability evalustion test for linagliptin formulation , CKD formuation lab, 2018. |
| Groop, Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction, Diabetes Care, vol. 36, 2013. |
| Rosenstock, Effect of linagliptin v. placebo, JAMA, vol. 321, 2018. |
| The 4th Edition, Experimental Chem., Course 1, Society of Japan, 1990, p. 184-186. |
| The 13th Ed., Manual of Japanese Pharmacopoeia, 1996. |
| Pharma Safety Bureau Eval, Regarding guidelines on residual solvent of pharma drugs, 1998. |
| Stahl, Handbook of Pharmaceutical Salts, Wiley, Introduction, 2002. |
| Eynatten, Efficacy and safety of linagliptin in type 2 diabetessubjects, Cardiovascular diabetology, vol. 12, 2009. |
| Cooper, Kidney Disease End points in a pooled analysis of individual patient level data, Amer. J. of kidney diseases, vol. 66, 2001. |
| Rosenstock, Cardiovascular safety of linagliptin in type 2 diabetes, Cardiovascular Diabetology, vol. 14, 2015. |
| Hocher, Renal and cardiac effects of DPP-4 inhibitors, Kidney and Blood pressureresearch, vol. 36, 2001. |
| Groop, Effects of the DPP-IIV inhibitor linagliptin, Abstracts online, 2013. |
| Snyder, Use of Insulin and Oral hypoglycemic medication in patients with diabetes mellitus and advanced kidney disease, Diabetic Medication in Kidney Disease, Seminars in Dialysis, vol. 17, 2004, p. 365-370. |
| Xie, Hypoglycemic Drugs, New Practical Pharmacy, 2007, p. 832-934. |
| Akiyama, Sulphostin, a potent Inhibitor for dipeptiyl peptidase IV, The Journal of Antibiotics, vol. 54, No. 9, 2001, p. 744-746. |
| Artunc, Expert opinion relating to Euro patent Ep2640371, May 11, 2022, 5 pages. |
| Wong, Endothelial Dysfunction, J. Cardiovasc Pharmacol, vol. 55, 2010, 8 pages. |
| Groop, Linagliptin and its effects on hyperglycemia, Diabetes and obes Metab vol. 10, 2017, 10 pages. |
| Wang, A modest decease in endothelial NOS in mice, PNAS vol. 108, 2011, 7 pages. |
| Pschryrembe, Clinical Dictionary, excerpt of Diabetes Mellitus, 2013. |
| Du, Hyperglycemia inhibits endothelial nitric oxide synthase oxide activity, JCI, vol. 108, 2001, 9 pages. |
| Craven, Impaired nitric oxide release by glomeruli from diabetic rats, Metabolism, vol. 44, 1995, 4 pages. |
| Excerpts of Diabetologie in Klinik and Praxis, 5th Edition, 2003, pp. 384 and 434. |
| Huttner, S. et al., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers.” Journal of Clinical Pharmacology, 2008, vol. 48, No. 10, pp. 1171-1178. |
| International Search Report—European Search Report for PCT/EP2003/09127 datd Mar. 1, 2011. |
| International Search Report and Written Opinion for PCT/EP2006/064657 datd Nov. 2, 2006. |
| International Search Report and Written Opinion for PCT/EP2007/054201 datd Aug. 29, 2007. |
| International Search Report and Written Opinion for PCT/EP2007/054270 datd Aug. 14, 2007. |
| International Search Report and Written Opinion for PCT/EP2008/060740 datd Mar. 30, 2009. |
| International Search Report and Written Opinion for PCT/EP2009/053978 datd Sep. 29, 2009. |
| International Search Report and Written Opinion for PCT/EP2009/056722 datd Aug. 13, 2009. |
| International Search Report and Written Opinion for PCT/EP2009/060521 datd Mar. 9, 2010. |
| International Search Report and Written Opinion for PCT/EP2009/063511 datd Feb. 26, 2010. |
| International Search Report and Written Opinion for PCT/EP2009/067772 datd Apr. 14, 2010. |
| International Search Report and Written Opinion for PCT/EP2010/050103 datd Mar. 22, 2010. |
| International Search Report and Written Opinion for PCT/EP2010/051093 datd Jul. 14, 2010. |
| International Search Report and Written Opinion for PCT/EP2010/051817 dated Jun. 8, 2010. |
| International Search Report and Written Opinion for PCT/EP2010/064691 datd Apr. 6, 2011. |
| International Search Report and Written Opinion for PCT/EP2010068349 datd Feb. 4, 2011. |
| International Search Report and Written Opinion for PCT/EP2011/054169 datd Aug. 4, 2011. |
| International Search Report and Written Opinion for PCT/EP2011/057163 datd Jun. 27, 2011. |
| International Search Report and Written Opinion for PCT/EP2011/057256 datd Jul. 22, 2011. |
| International Search Report and Written Opinion for PCT/EP2011/060449 datd Sep. 27, 2011. |
| International Search Report and Written Opinion for PCT/EP2011/070156 dated Jan. 17, 2012. |
| International Search Report and Written Opinion for PCT/EP2012/053910 datd May 14, 2012. |
| International Search Report and Written Opinion for PCT/EP2012/063852 datd Sep. 6, 2012. |
| International Search Report and Written Opinion for PCT/EP2012/077024 datd Feb. 19, 2013. |
| International Search Report and Written Opinion for PCT/EP2013/054524 datd Apr. 24, 2013. |
| International Search Report and Written Opinion for PCT/EP2013/059828 datd Aug. 6, 2013. |
| International Search Report and Written Opinion for PCT/EP2013/059831 datd Aug. 9, 2013. |
| International Search Report and Written Opinion for PCT/EP2013/060311 datd Aug. 9, 2013. |
| International Search Report and Written Opinion for PCT/EP2013/060312 datd Sep. 4, 2013. |
| International Search Report and Written Opinion for PCT/EP2013/070978 datd Oct. 31, 2013. |
| International Search Report and Written Opinion for PCT/EP2014/055113 datd May 16, 2014. |
| International Search Report and Written Opinion for PCT/EP2014/062398 datd Aug. 20, 2014. |
| International Search Report and Written Opinion for PCT/EP2015/054114 datd May 12, 2015. |
| International Search Report and Written Opinion for PCT/EP2015/074030 datd Feb. 4, 2016. |
| International Search Report and Written Opinon for PCT/EP2007/054204 datd Aug. 3, 2007. |
| International Search Report for PCT/EP03/12821 datd Mar. 30, 2004. |
| International Search Report for PCT/EP03/13648 datd Apr. 5, 2004. |
| International Search Report for PCT/EP2002/01820 datd May 7, 2002. |
| International Search Report for PCT/EP2003/12821 datd Mar. 30, 2004. |
| International Search Report for PCT/EP2003/13648 datd Apr. 5, 2004. |
| International Search Report for PCT/EP2005/001427 datd May 23, 2005. |
| International Search Report for PCT/EP2005/055711 dated Mar. 29, 2006. |
| International Search Report for PCT/EP2007/054204 datd Mar. 8, 2007. |
| International Search Report for PCT/EP2007/058181 datd Nov. 28, 2007. |
| International Search Report for PCT/EP2008/060738 datd Nov. 5, 2008. |
| International Search Report for PCT/EP2009/060170 datd Oct. 28, 2009. |
| International Search Report for PCT/EP2010/064691 datd Jan. 20, 2011. |
| International Search Report for PCT/EP2013/060309 datd Aug. 9, 2013. |
| International Search Report for PCT/EP2013/070979 datd Nov. 26, 2013. |
| International Search Report for PCT/EP2014/060160 datd Nov. 8, 2014. |
| Inukai, T., “Treatment of Diabetes in Patients for Whom Metformin Treatment is Not Appropriate.” Modern Physician, 2008, vol. 28, No. 2, pp. 163-165. |
| Inzucchi, Silvio E., “Oral Antihyperglycemic Therapy for Type 2 Diabetes.” The Journal of the American Medical Association, 2002, vol. 287, No. 3, pp. 360-372. |
| Somaa, B. et al., “Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome.” Diabetes Care, 2001, vol. 24, No. 4, pp. 683-689. |
| Iwamoto, Yasuhiko, “Insulin Glargine.” Nippon Rinsho, 2002, vol. 60, Suppl. 9, pp. 503-515. |
| Janumet Prescribing Information, revised Jan. 2008. |
| Januvia Medication Guide, 2010. |
| Januvia Prescribing Information and Product Label, 2006. |
| Januvia, 25mg, 50mg, 100 mg, Summary of Product Characteristics, 2015, www.medicines.org.uk/EMC <http://www.medicines.org.uk/EMC>. |
| Johansen, O. E. et al., “Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.” Cardiovascular Diabetology, Biomed Central, 2012, vol. 11, No. 3, pp. 1-10. |
| Johansen, O.E. et al., “b-cell Function in Latnet Autoimmune Diabetes in Adults (LADA) Treated with Linagliptin Versus Glimepiride: Exploratory Results from a Two Year Double-Blind, Randomized, Controlled Study.” www.abstractsonline.com, Jun. 10, 2012, XP-002708003. |
| John Hopkins Children's Center, “Liver Disorders and Diseases.” Retrieved online May 26, 2014 <http://www.hopkinschildrens.org/non-alcoholic-fatty-liver-disease.aspx>. |
| Jones, R.M. et al., “GPR119 agonists for the treatment of type 2 diabetes”. Expert Opinion on Therapeutic Patents 2009 Informa Healthcare for GBR LNKSD—DOI: 10.1517/13543770903153878, vol. 19, No. 10, Oct. 2009, p. 1339-1359. |
| Kanada, S. et al., “Safety, tolerability, pharmacokenetics and pharmacodynamics of multiple doses of BI 1356 (proposed tradename ONDERO), a dipeptidyl peptidase 4 inhibitor, in Japanese patients with type 2 diabetes” Diabetes, vol. 57, No. Suppl. 1, Jun. 2008, p. A158-A159 and 68th Annual Meeting of the American Diabetes Association: San Francisco, CA , Jun. 6-10, 2008. |
| Kelly. T., “Fibroblast activation protein-cx and dipeptidyl peptidase IV (CD26)P: Cell-surface proteases that activate cell signaling and are potential targets for cancer therapy”. Drug Resistence Update 8, 2005, vol. 8. No. 1-2, pp. 51-58. |
| Kendall, D. M. et al., “Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: A Review of Emerging Therapies for Type 2 Diabetes.” Diabetes Technology & Therapeutics, 2006, vol. 8, No. 3, pp. 385-398. |
| Kharkevich, D. A., “Educational Literature” Pharmacology (1987) Third Edition, Meditsina Press, Moscow pp. 47-48. |
| Kibbe, A., Editor. Handbook of Pharmaceutical Excipients, Third Edition, Copovidon—pp. 196-197, Date of Revision: Dec. 16, 2008. Mannitol—pp. 424-425, Date of Revision: Feb. 19, 2009, Published in 2009. |
| Kidney Disease (Nephropathy), Retrieved online May 13, 2013. www.diabetes.org/living-with-diabetes/complications/kidney-disease-nephropathy.html <http://www.diabetes.org/living-with-diabetes/complications/kidney-disease-hephropathy.html>. |
| Kim, D. et al., “(2R)-4-Oxo-4-(3-(Trifluoremethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV inhibitor for the Treatment of Type 2 Diabetes.” Journal Med. Chem, 2005, 48, p. 141-151. |
| Kim, Kwang-Rok et al., “KR-62436, 6-{2-{2-(5-cyano4,5-dihydropyrazol-1-yl)-2-oxoethylamino}ethylamino} nicotinonitrile, is a novel dipeptidyl peptidase-IV (DDP-IV inhibitor with anti-hyperglycemic activity” European Journal of Pharmacology 518, 2005, p. 63-70. |
| Kiraly, K. et al., “The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord.” European Journal of Pharmacology, 2011, vol. 650, pp. 195-199. |
| Kirpichnikov, D. et al., “Metformin: An Update.” Annals of Internal Medicine, 2002, vol. 137, No. 1, pp. 25-33. |
| Klein, T. et al., “Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.” Medical Molecular Morphology, 2014, vol. 47, pp. 137-149. |
| Knorr, M. et al., “Comparison of Direct and Indirect Antioxidant Effects of Linagliptin (BI 1356, Ondero) with other Gliptins—Evidence for Anti-Inflammatory Properties of Linagliptin”. Free Radical Biology and medicine, Elsevier Science, U.S. vol. 49, Oct. 23, 2010, p. S197. |
| Knowler, W.C. et al., “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin.” The New England Journal of Medicine, 2002, vol. 346, No. 6, pp. 393-403. |
| Komori, Kiyoshi., “Treatment of Diabetes in Patients for Whom Metforming Treatment is Not Appropriate” Modern Physician (2008) vol. 28, No. 2 pp. 163-165. |
| Konstantinou, D. M et al., “Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction.” Pharmacology & Therapeutics, 2013, vol. 140, No. 2, pp. 156-166. |
| Korom, S. et al.; Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients1,2, Transplantation, May 27, 1997, vol. 63, No. 10, pp. 1495-1500. |
| Kroller-Schön, S. et al., “Glucose-independent Improvement of Vascular Dysfunction in Experimental Sepsis by Dipeptidyl Peptidase-4 Inhibition.” Cardiovascular Research, 2012, vol. 96, No. 1, pp. 140-149. |
| Kumar, V. et al., “Maillard Reaction and Drug Stability.” Maillard Reactions in Chemistry, Food, and Health, 1994, No. 151, pp. 20-27. |
| Kuno, Y. et al., “Effect of the type of lubricant on the characteristics of orally disintegrating tablets manufactured using the phase transition of sugar alcohol.” European Journal of Pharmaceutics and Biopharmaceutics, 2008, vol. 69, pp. 986-992. |
| Lachman, L. et al., “The Theory and Practice of Industrial Pharmacy.” Varghese Publishing House, Third Edition, 1987, pp. 190-194. |
| Lakatos, P. L. et al., “Elevated Serum Dipeptidyl IV (CD26, Ec 3.4.14.5) Activity in Experimental Liver Cirrhosis.” European Journal of Clinical Investigation, 2000, vol. 30, No. 9, pp. 793-797. |
| Lakatos, P. L. et al., “Elevated serum dipeptidyl peptidase IV (CD26, Ec 3.4.14.5) activity in patients with primary biliary cirrhosis.” Journal of Hepatol, 1999, vol. 30, p. 740. |
| Lambier, A.M. et al., Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV. Critical Reviews in Clinical Laboratory Sciences, 2003, 40(3), p. 209-294. |
| Lee Jones, K. et al., “Effect of Metformin in Pediatric Patients With Type 2 Diabetes.” Diabetes Care, 2002, vol. 25, No. 1, pp. 89-94. |
| Leibovitz, E. et al., “Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).” Cardiovascular Diabetology, 2013, vol. 12, No. 1, pp. 1-7. |
| Levien, T.L. et al., “New drugs in development for the treatment of diabetes”, Diabetes Spectrum, American Diabetes Association, US, vol. 22, No. 2, Jan. 1, 2009, pp. 92-106. |
| Lieberman, H. et al., “Pharmaceutical Dosage Forms.” Marcel Dekker, Inc., 1980, vol. 1, p. 38. |
| Lim, S. et al., “Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats.” Plos One, 2012, vol. 7, No. 4, pp. 1-11. |
| Linagliptin Monograph, Published by VACO PBM-SHG US Veteran's Administration, 2011, pp. 1-17. |
| Lindsay, J.R. et al., “Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.” Diabetic Medicine, 2005, vol. 22, pp. 654-657. |
| Lovshin, J.A. et al., “Incretin-based therapies for type 2 diabetes mellitus.” Nature Reviews Endocrinology, 2009, vol. 5, pp. 262-269. |
| Lu, “High prevlaence of albuminuria in population based patients diagnosed with type 2 diabetes in the Shanghai downtown”, Diabestes Research and Clinical Practice (2007) 184-192. |
| Lyssenko, V. et al., “Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.” The Journal of Clinical Investigation, 2007, vol. 117, No. 8, pp. 2155-2163. |
| March, J. “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure”. Fourth Edition, 1992, pp. 652-653. |
| Mathieu, C. et al., “Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential tole of incretin mimetics and DPP-4 inhibitors.” International Journal of Clinical Practice, 2007, vol. 61, Suppl. 154, pp. 29-37. |
| Matsumiya, Teruhiko, et al., “Therapeutic Drugs for Clinicians” Diagnosis and Treatment (2008) vol. 96, No. 2 pp. 389-390. |
| Mayo Clinic Staff: “Nonalchoholic fatty liver disease: Prevention” [retrieved on Nov. 3, 20120]. retrieved from the Internet: ,URL: http://www.mayoclinic.com/health/nonalcoholic-fatty-liver-disease/DS00577DSECTION=prevention>. |
| Mcnay, David E.G et al., “High fat diet causes rebound weight gain.” Molecular Metabolism, 2013, vol. 2, pp. 103-108. |
| The Textbook of Pharmaceutics, Pharmcaeutical Subcommitee Hanrimwon, 2005, p. 1-6. |
| Mettler Toledo “interpreting DSC curves Part 1: Dynamic Measurements” Jan. 2000. Available from www.masointechnology.ie.x/Usercom_11.pdf. |
| Glucophage (metformin hydrochloride tablets) revised label, 2003. |
| Stahl, Selected Procedures for the Preparation of Pharmaceutically Acceptable salts, Handbook of Pharmaceutical Salts Properties, Chapter 11, 2015. |
| Caira, Crystalline Polymorphism of Organic Compounds, Topics in Current Chemistry, vol. 198, 2015. |
| Brittain, Polymorphism on Pharmaceutical Solids, Chapter 5 Generation of Polymorphs, vol. 95, 1999, p. 183-226. |
| Luo, Theory and Practice of Modern Physical Pharmacy, Shangai Scientific And Technical Literature Publishing House, 2005, p. 294. |
| Thomas, (R)-8-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione(BI1236, a Novel Xanthine based Dipeptidyl Peptidase 4 inhibitor, has a Superior Potency and longer duration of action compared with other dipeptyl Peptidase-4 inhibitors, The Journal of Pharmacology and Experimental Therapeutica, vol. 325, 2008, p. 175-182. |
| Medicine Department of Pharmacy, Pharmaceutical Subcommitte, Book Publishing Harwinton, 1996, p. 283. |
| Huang, et al. Elimination of metformin-croscarmellose sodium interaction by competition, International Journal of Pharmaceutics, 2006, p. 33-39. |
| Freeman, Initial Combination therapy for patients with type 2 diabetes mellitus, Drugs in Context, 2013, p. 212256. |
| Scheen, Efficacy and Safety of Jentadueto, Expert Opinion on Drug and Safety, vol. 12, No. 2, 2013, p. 275-289. |
| Haak, Initial Combination of linagliptin and metformin improves glycemic control in type 2 diabetes, Diabetes, Obesity and Metabolism, vol. 14, 2012, p. 565-574. |
| International Search Report and Written Opinion for PCT/EP2017/064007, dated Jun. 8, 2017. |
| Wikipedia, the free encyclopedia, The carbonyl group, 2017. |
| Controlling Temperature (Guidelines for the Storage of Essential Medicines and Other Health Commodities, 2003, http://apps.who.int.medicinedocs/en/d/Js4885e/6.5html). |
| Pharmaceutical Manufacturing and Storage (Concepts and Design, Inc.) 2009. |
| Methocel Cellulose Ethers in Aqueous Systems for tablet coating: retrieved from Internet: http;//msdssearch.dow.com/PublishedLiterature DOWCOM/dh_004a/0901b8038004ab56.pdf?filepath=198-00755.pd?fromPage=GetDoc, published2002. Retrieved Dec. 8, 2017. |
| Wu, Reactive Impurities in Excipients-Profiling, American Association of Pharmaceutical Scientists, 2011, vol. 12, No. 4, p. 1248-1263. |
| Waterman, Accelerating aging-Prediction of Chemical Stability of Pharmaceuticals, International Journal of Pharmaceutics, 2005, vol. 293, p. 101-125. |
| Herman, The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces Glucose following an OGTT in Type 2 Diabetics, American Diabetes Asociation, 2004. |
| Kaur, Development of new incretin drugs: Promising Therapies, Indian Journal Pharmacology, 2006, vol. 38, Issue 2, p. 100-106. |
| Clinical Trial results of Tradjenta Tablet, Center for Drug Evaluation and Research, 2010. |
| Pregelatinized Starch, Drugs.com, derived from https://drugs.com/inactive/pregelatinized-starch-136.html, accessed Nov. 17, 2017. |
| The textbooks of Pharmaceutics, Department of Pharmacy, Pharmaceutical Committee, 1996. |
| The Textbooks of Pharmaceutics, Department of Pharmacy, Pharmaceutical Subcommitee, 2000. |
| Approval material for Tradjenta tablet, Trial 1218.2, Center for Drug Eval. and Research, 2011. |
| Development Guideline for Excellent Drug, 2008, MFDS. |
| Hu, Diabetes Mellitus and Cardiovascular Disease, People's Military Medical Press, 2005, p. 211. |
| Susman, Ada: Linagliptin Works in Diabetic Kidney Disease, Med Page Today, 2011. |
| Announcement of the approval of Novel oral Diabetes Drug JANUVIA, Press Release, 2006. |
| Okano, Renal Clearance, New General Pharmaceutics, Revised 3rd Edition, 1987p. 213-215. |
| Clinical trials, A Randomized, Double Blind, Active Controlled parallel Group Efficacy and Safety Study of BI 1356 Compared to Glimepiride over 2 years in Type 2 Diabetic Patients with insufficient glycemic control despite metformin therapy, https://clinicaltrials.gov/archive/NCT00622284/20120606, 2008. |
| Eckhardt, “-(3-(R)-Aminopiperidin-1-yl)7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes”, J. med. Chem, vol. 50, 2007. |
| Shigai, “How to use medicines in case of kidney injury caused by medicine” Journal of the Japanese Association of Rural Medicine, vol. 51, 2002, p. 63-67. |
| Zeng, “Efficacy and Safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial”, Current Medical Research and Opinion, 2013. |
| Seino, Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double blind, placebo- controlled trial with an open label, long term extension, Current Medical Research and Opinion, 2011, vol. 27, p. 21-29. |
| Kurozumi, Efficacy of a-glucosidase inhibitors combined with dipeptyl-peptidase-4 inhibitor for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring, Journal of Diabetes Investigation, 2013, vol. 4, p. 393-398. |
| Horikawa, Synergistic Efffect of a-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment, Journal of Diabetes Investigation, 2011, vol. 2, p. 200-203. |
| Yamazaki, Comparison of Efficacies of a Dipeptidyl Peptidase IV Inhibitor and a-Glucosodase Inhibitors in Oral Carbohydrate and Meal Tolerance Tests and their Effects of their tolerance in mice, J. Pharmacol Science, 2007, p. 29-38. |
| Kawamori, Linagliptin monotherapy provides superior glycaemic control v. placebo or voglibose with comparable safety In Japanese patients with type 2 diabetes, a randomized , placebo and active comparator—controlled double blind study, 2011, Diabetes, Obesity and Metabolism, p. 348-357. |
| Inagaki, Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes, Diabetes, Obesity and Metabolis, 2013, p. 833-843. |
| Tang, Protection of DPP-4 inhibitors on cardiovascular, Drug Evaluation, vol. 9, 2012, p. 6-9. |
| Han, Basic and Clinical Coronary Heart Disease, Jilin Univ. Press, 2012, p. 114-118. |
| Lakey, Technical Aspects of Islet Preparation, Translp, Int.m 2003, vol. 16, p. 613-632. |
| White, Cardiovascular Events in patients receiving alogliptin, Diabetes Pro, 2010, vol. 59, p. 391. |
| Johansen, Cardiovascular safety with linagliptin on patients with type 2 diabetes mellitus, Cardiovascular Diabetology, 2012, vol. 11, p. 1-10. |
| Pham, New Onset Diabetes Mellitus After Solid Organ Transplantation, Endocrinology and Metabolism Clinics of North America, 2007, p. 873-890. |
| Huettner, Diabetes, Novel and Selective Xanthine, Jun. 2007 Supplement vol. 56,. |
| Heizmann, Xanthines as scaffold for molecular diversity, Molecular doversity, vol. 2, 1996, p. 171-174. |
| Rabinovitch, Theophylline protects against diabetes in BB rats, Diabetologica, 1990. |
| De galan, Theophylline Improves Hypoglycemia Unawareness, Diabetes, vol. 51, 2002. |
| Mark, A novel and Selective Xanthine Based Competitive DPP-IV Inhibitor, Diabetes, vol. 56, 2007. |
| Abdoh, Amlodipine Besylate-Excipients Interaction in Solid Dosage Form, Phamra Dev. and Strategy, 2018. |
| Bruni, Drug Excipient Compatibility Studiesm J. of Thermal Analysis, 2018. |
| Crowley, Drug-Excipient interactions, Pharma Tech Europe, vol. 13, 2001. |
| Macdonald, no fraud, no conspiracy, No. error, Pharmatechnologist, 2017. |
| Hanrinwon, Pharmaceutical Subcommittee, Pharmaceutics, p. 284-288, 1995. |
| Nathan, Managment of Hyperglycemia in Type 2 Diabetes, Diabetes Care, vol. 31, 2008. |
| Eckhardt, 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-yny 1-3-methyl-1-(4-methyl-quina zolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and Orally Bioavailable DPP-4 Inhibitor, J. Med Chem. vol. 50, 2007. |
| Forst, The novel, potent, and selective DPP-4 inhibitor, ADA Poster, 2007. |
| Heise, Pharmacokinetics, pharmacodynamics, and tolerablity of mutiple does of linagliptin, Diabetes, Obesity and Metabolism, vol. 11, 2009. |
| Schafer, Impaired glucagen like peptide 1 induced insulin secretions in carriers of transcription, Diabetologica, vol. 50, 2007. |
| Hu, Research and Application, Biomedical Info in Translational Research, 2008. |
| Pearson, Variation in TCF7L2Influences Therapeutic Response to Sulfonylreas, Diabetes, vol. 56, 2007. |
| Florez, Genetic Susteptibility to Type 2 Diabetes, J. of Diabetes, vol. 3, 2009. |
| Levien, New Drugs in Development for the Treatment of Diabetes, Diabetes Spectrum, vol. 22, 2009. |
| Graefe-Mody, Evaluation of the Potential for steady state phamracokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin, Current Medical Research and Opinion, vol. 25, 2009. |
| Encyclopedia of Pharma Technology, Swarbrick, 3rd Ed., vol. 1, Absorption of Solid Surfaces, 2007. |
| Ahren, Emerging Dipeptyl peptidase-4 inhibitors for the treatment of diabetes, Expert Opinion on Emerging Drugs, vol. 13, 2008. |
| Ohlden, New data from Boehringer INgelheim's Ongoing Linagliptin Trial Programme Shows Promising Safety and Efficacy results, Newswire, 2020. |
| Lovshin, Incretin based therapies for type 2 diabetes mellitus, Nature, vol. 5, 2009. |
| Clinical Trials, NCT006002472, BI 1356 In combination with Metformin submitted Feb. 27, 2014. |
| Boehringer Ingelheim Press Release: Boehringer Ingelheim's diabetes Pipeline continues to advance as the company announces conclusion of robust Phase III pivotal trials programme for linalgiptin, Small Molecules, Published Sep. 28, 2009. |
| Wu, Primacy of the 3b Approach to Control risk factors for Cardiovascular dissease in type 2 diabetes patient,s Diabetes Mellitus and Cardio Disease, People's Military Press, 2005. |
| Diabetes and Foot Ulcers, www.diabetes.co.uk/diabetes-comolications/diabetic-foot-ulcers.html, 2018. |
| Nationale Versorgungs-Leitlinie, Diabetes Mellitus, 2004. |
| Deutsche Evidenzbasierte Diabetes-Leitlinien, Diabetes and Herz, 2002. |
| Menielly, Diabetes in Elderly adults, J. of Gerontolgy, vol. 56A, 2001. |
| Herrington, Metformin, Effective ans safe in renal Disease? Int. Urol. Nephrol. vol. 40, 2008. |
| Bruni, Drug Excipient compatibility, Journal of Thermal Analysis and Calorimetry, vol. 68, 2002. |
| Lee, Drug delivery system and pharmaceutical preparation, 2003. |
| Kibbe, Handbook of Pharmaceutical Excipients, 3rd Edition, 2009, p. 104-107. |
| Abdoh, Amlodipine besylate excipients interaction in solid dosage form, Pharmaceutical Development and Technology, vol. 9, 2004. |
| Sung, Study on the preparation of tablets by direct compression method, Kisti, 2006. |
| Crowley, Drug-Excipients Interactions, Pharmaceutical Technology Europe, vol. 13, 2001. |
| Wade, Organic Chem, 6th Edition, 2006, p. 918, 943-956. |
| News Article, https:/www.in-phamratechnologist.com-Article-France-and-maerck-say-reformulated-Euthyrox-is-safe.)—Sep. 17, 2017. |
| Hu, Diabetes Mellitus and Heart Disease, People's Military Press, 2005. |
| Fadini, The oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients with Type 2 Diabetes, Diabetes Care, vol. 33, 2010. |
| Cade, Diabetes Related Microvascular Diseases in the Physical Therapy Setting, Journal of the American Physical Therapy Assoc., 2008. |
| Makino, Decreased CirculatingCD-34 cells, Diabetic Medicine, 2009. |
| Pink Sheet Daily, Boehringer/Lilly's Linagliptin Approved, 2011. |
| Ahren, Dipeptidyl Peptidase-4 Inhibitors, Diabetes Care, vol. 30, 2007. |
| Deacon, Linagliptin, a xanthing based dipeptidyl peptidase 4 inhibitor, Informa Healthcare, vol. 19, 2010. |
| Fowler, Microvascular and Macrovascular Complications of Diabetes, Diabetes Foundation, vol. 26, 2008. |
| Brosius, Mouse Models of Diabetic Neuropathy, JASN, vol. 20, 2009. |
| Kern, Linagliptin Improves Insulin Sensitivity, PLOSONE, vol. 7. 2012. |
| Wertheimer, et al., “Drug Delivery Systems improve pharmaceutical profile and faciliate medication adherence”, Adv. Therapy 22: p. 559-577 (2005). |
| White, John R. Jr., “Dipeptidyl Peptidase-IV Inhibitors: Phamacological Profile and Clinical Use”. Clinical Diabetes, Apr. 2008, vol. 26, No. 2, pp. 53-57. |
| Wikipedia, “Linagliptin” Sep. 12, 2015. < https://en.wikipedia.org/w/index.php? title=Linagliptin&oldid=333469979>. |
| Wikipedia, Annulation. Jun. 23, 2008, http://en.wikipedia.org/wiki/Annelation. |
| Williams-Herman, D. et al., “Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study”. Current Medical Research and Opinion, Informa Healthcare, GB, vol. 25, No. 3, Jan. 2009, p. 569-583. |
| Wirth, D. et al., “Maillard Reaction of Lactose and Fluoxetine Hydrochloride, a Secondary Amine.” Journal of Pharmaceutical Sciences, 1998, vol. 87, No. 1, pp. 31-39. |
| Witteles, R. M. et al., “Dipeptidyl Peptidase 4 Inhibition Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy.” Journal of Cardiac Failure, 2012, vol. 18, No. 10, pp. 804-809. |
| Wolff, M.E.: “Burger's Medicinal Chemistry and Drug Discovery” Fifth Edition, vol. 1: Principles and Practice, pp. 975-977, 1994, John Wiley & Sons, Inc. |
| World Health Organization (WHO). “Addendum 1 to “The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances”” Online Jun. 19, 2007, pp. 1-3, retrieved from URL: http://www.who.int/medicindedocs/index/assoc/s1414e/s1414e.pdf. |
| X-Ray Diffraction. The United States Pharmacopeia, 2002, USP 25 NF20, p. 2088-2089. |
| Yale, Jean-Francois, “Oral Antihyperglycemic Agents and Renal Disease: New Agents, New Concepts.” Journal of the American Society of Nephrology, 2005, vol. 16, Suppl. 1, Pgs. S7-S10. |
| Yamagishi, S. et al., “Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes.” Current Pharmaceutical Design, 2012, vol. 17, pp. 4379-4385. |
| Yap, W.S. et al., “Review of management of type 2 diabetes mellitus.” Journal of Clinical Pharmacy and Therapeutics, 1998, vol. 23, pp. 457-465. |
| Yasuda, et al. “E3024 3-but-2-yny1-5-methyl-2-piperazin-1-y1-3,5-dihydro-4H-imidazol [4,5-d]pyridazin-4-one tosylate, is a move, selective and competitive dipeptidyl peptidase-IV inhibitor”. European Journal of Pharmacology, vol. 548, No. 1-3, Oct. 24, 2006, p. 181-187. Abstract. |
| Yokoyama< “Prevalence of albumineria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes clinical data Management study(JDDM15)” Nephrol Dial Transplant (2009) 24: 1212-1219 Advance Access Pub 2008. |
| Yoshikawa, Seiji et al.: Chemical Abstract of Japanese Patent No. WO 2003/104229 Preparation of purinone derivatives as dipeptidylpeptidase IV (DPP-IV) inhibitors, 2003. |
| Yoshioka, S. et al., “Stability of Drugs and Dosage Forms.” Kluwer Academic Publishers, 2002, pp. 30-33. |
| Youssef, S. et al., “Purines XIV. Reactivity of 8-Promo-3,9-dimethylxanthine Towards Some Nucleophilic Reagents.” Journal of Heterocyclic Chemistry, 1998, vol. 35, pp. 949-954. |
| Zander, M. et al., “Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes.” Diabetes Care, 2001, vol. 24, No. 4, pp. 720-725. |
| Zeeuw, D. et al., “Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy.” Circulation, 2004, vol. 110, No. 8, pp. 921-927. |
| Zejc, Alfred, et al; “Badania Nad Piperazynowymi Pochodnymi Dwumetyloksantyn” Acta Polon Pharm, XXXV (1976) Nr. 4 pp. 417-421. |
| Zerilli, T. et al., “Sitagliptin Phosphate: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.” Clinical Therapeutics, 2007, vol. 29, No. 12, pp. 2614-2634. |
| Zhimei, Xiao et al., “Study progression of oral drugs for treatment of type II diabetes.” Drug Evaluation, 2004, vol. 1, No. 2, pp. 138-143. |
| Zhong, Qing et al; “Glucose-dependent insulinotropic peptide stimulates proliferation and TGF-? release from MG-63 cells,” Peptides 24 (2003) 611-616. |
| Zhu, G. et al., “Stabilization of Proteins Encapsulated in Cylindrical Poly(lactide-co-glycolide) Implants: Mechanism of Stabilization by Basic Additives.” Pharmaceutical Research, 2000, vol. 17, No. 3, pp. 351-357. |
| Zimdahl, H. et al., “Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 Inhibitor linagliptin.” Diabetologia, 2014, vol. 57, pp. 1869-1875. |
| Zimmer et al.; Synthesis of 8-Substituted Xanthines and their Oxidative Skeleton Rearrangement to 1-Oxo-2,4,7,9-tetraazaspiro[4,5]dec-2-ene-6,8, 10-triones; European Journal Organic Chemistry (1999) vol. 9 pp. 2419-2428. |
| Rosenstock, J. et al., “Triple Therapy in Type 2 Diabetes.” Diabetes Care, 2006, vol. 29, No. 3, pp. 554-559. |
| Moritoh, Y. et al., “Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.” Diabetes, Obesity and Metabolism, 2010, vol. 12, pp. 224-233. |
| EMEA Guidelines on Galvus®, 2007, pp. 1-34. |
| EMEA Guidelines on Eucreas®, 2007, pp. 1-27. |
| Yasuda, N. et al., “Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats.” The Journal of Pharmacology and Experimental Therapeutics, 2004, vol. 310, No. 2, pp. 614-619. |
| U.S. Appl. No. 15/235,575, filed Aug. 12, 2016, Inventor: Klaus Dugi. (The cited pending U.S. application is stored In the USPTO IFW system (MPEP 609.04(a)(II)(C)). |
| Kishore, Preeti MD., “Complications of Diabetes Mellitus.” Merck Manual Consumer Version, 2016, pp. 1-7. |
| Fantus, George, “Metformin's contraindications: needed for now.” Canadian Medical Association Journal, 2005, vol. 173, No. 5, pp. 505-507. |
| EU Clinical Trial Register, “A multicenter, international, rendomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk.” Aug. 19, 2015. |
| Jibiinkoka-Tenbo, Vision of Otorhinolaryngology, How to use anti-microbial drug in a patient with impairment of renal function, vol. 44, No. 3, 2001, p. 217-220. |
| Rinsho-Yakuri, Jpn. J. Clin. Pharmacol. Ther. Pharmacokinetics: excretion, 30(3) 1999. |
| Fiorucci, et al. Trends in Molecular Medicine, Targeting farnesoid X receptor for liver and metabolic disorders, 13(7), 2007, p. 298-309. |
| Morhenn, “Keratinacyte proliferation n wound healing and skin diseases”, Immunology Today, vol. 9, Issue 4, 1988, p. 104. |
| Boehringer Ingelheim Pharmceuticals, Inc. v. HEC Pharm Co., Ltd., et al., No. 15-cv-5982, United States District Court for the District of New Jersey, Dec. 8, 2016. |
| Karaliede et al., Diabetes Care, Endothelial Factors and Diabetic Nephropathy, 2011, 34, Suppl 2, p. 291-296. |
| Hansen, European Journal of Pharmacology, “The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat”, 2014, p. 254-263. |
| Ferreira, Triple Combination therapy with sitagliptin, metformin and rosiglitazone improves glycaemic control in patiens with type 2 diabetes, Diabetologixa, 2008, Suppl 1. |
| Byrn, Pharmaceutical Solids, A Strategic Approach to Regulatory Considerations, Pharmaceutical Research, 1995, vol. 12. |
| MORHENN (2), Keratinocyte proliferation in wound healing and skin diseases, Immunology Today, vol. 9, 1994. |
| Diabetes, Type 1 Diabetes-Associated Autoantibodies, 2009, vol. 52, Issue 8, p. 675-677. |
| Merck manual, 18th Edition, published Apr. 25, 2007, p. 594-598, Japanese Edition. |
| Scientific Discussion on Sifrol, EMEA, 2005, p. 1-9. |
| Scientific Discussion for Sifrol, European Public Assessment Reports, 2005, p. 1. |
| Medline Plus, “Obesity” 2013, Retrieved from internet on Aug. 22, 2013, http://www.nlm.nih.gov/medlineplus/obesity.html. |
| Meece, J. “When Oral Agents Fail: Optimizing Insulin Therapy in the Older Adult”. Consultant Pharmacist, The Society, Arlington, VA US. vol. 24, No. Suppl B, Jun. 1, 2009, p. 11-17. |
| Mendes, F.D, et al. “Recent advances in the treatment of non-alcoholic fatty liver disease”. Expert Opinion on Investigational Drugs, vol. 14, No. 1, Jan. 1, 2005, p. 29-35. |
| Merck Manual of Diagnosis and Therapy: “Obesity.” 1999, 17th Edition, Chapter 5, pp. 58-62. |
| Merck: “Initial Therapy with Janumet (sitagliptin/metformin) provided significantly greater blood sugar lowering compared to metformin alone in patients with type 2 diabetes”. Webwire.com, Jun. 8, 2009, p. 1-4. http://www.webwire.com/ViewPressRel.asp?aId=96695. |
| Mikhail, Nasser, “Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.” Expert Opinion on Investigational Drugs, 2008, vol. 17, No. 6, pp. 845-853. |
| MIMS Jan. 2009, “Sitagliptin.” pp. 152-153. |
| Nabors, Lyn O'Brien “Alternative Sweeteners.” Marcel Dekker, Inc., 2001, pp. 235, 339-340. |
| Naik, R. et al., “Latent Autoimmune Diabetes in Adults.” The Journal of Clinical Endocrinology and Metabolism, 2009, vol. 94, No. 12, pp. 4635-4644. |
| Nar, Herbert “Analysis of Binding Kinetics and Thermodynamics of DPP-4 Inhibitors and their Relationship to Structure.” 2nd NovAliX Conference: Biophysics in drug discovery, Strasbourg, France, Jun. 9-12, 2015. |
| Nathan, D. et al., “Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy.” Diabetes Care, Aug. 2006, vol. 29, No. 8, pp. 1963-1972. |
| National Program for Care Guidelines, “Type 2 Diabetes mellitus.” 2002, First Edition, pp. 1-50. |
| Nauck, M. A. et al., “Efficacy and Safety of Adding the Dipeptidyl Peptidase-4 Inhibitor Alogliptin to Metformin Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicentre, Randomised, Double-Blind, Placebo-Cotrolled Study.” Clinical Practice, 2008, vol. 63, No. 1, pp. 46-55. |
| Nauck, M. A et al., “Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Compared with the Sulfonylurea, Glipizide, in Patients with Type 2 Diabetes Inaduately Controlled on Metformin alone: A Randomized, Double-Blind, Non-Inferiority Trial.” Dlabetes Obesity and Metabolism, 2007, vol. 9, No. 2, pp. 194-205. |
| Nielsen, L., “Incretin Mimetics and DPP-IV Inhibitors for the Treatment of Type 2 Diabetes.” Drug Discovery Today, 2005, vol. 10, No. 10, pp. 703-710. |
| Nihon Ijinpo, Japan Medicinal Journal, 2001, No. 4032, p. 137. |
| Novartis AG, Investor Relations Release, “Galvus, a new oral treatment for type 2 diabetes, receives positive opinion recommending European Union approval.” Securities and Exchange Commission, Form 6-K, 2007, pp. 1-4. |
| O'Farrell, et al., “Pharmacokinetic and Pharmacodynamic Assessments of the Dipeptidyl Peptidase-4 Inhibitor PHX1149: Double-Blind, Placebo-controlled, Single-and Multiple-Dose Studies in Healthy Subjects”. Clinical Therapeutics, Excerpta Medica, Princeton, NJ, vol. 29, No. 8, 2007, p. 1692-1705. |
| Office Action for U.S. Appl. No. 10/695,597 dated May 2, 2008. |
| Oz, Helieh S., “Methionine Deficiency and Hepatic Injury in a Dietary Steatohepatitis Model.” Digestive Diseases and Sciences, 2008, vol. 53, No. 3, pp. 767-776. |
| Patani George A. et al.: “Bioisoterism : A Rational Approach in Drug Design”, Chemical Reviews, 1996, vol. 96, No. 8, pp. 3147-3176. |
| Pearson, E. R. et al., “Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas.” Diabetes, 2007, vol. 56, pp. 2178-2182. |
| Pei, Z .: “From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents” Current Opinion in Drug Discovery and Development, Current Drugs, London, GB vol. 11, No. 4, Jul. 1, 2008 pp. 512-532. |
| Pietruck, F. et al., “Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation.” Transplant International, 2005, vol. 18, pp. 483-486. |
| Pilgaard, K. et al., “The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men.” Diabetologia, 2009, vol. 52, pp. 1298-1307. |
| Plummer, C.J.G. et al., “The Effect of Melting Point Distributions on DSC Melting Peaks.” Polymer Bulletin, 1996, vol. 36, pp. 355-360. |
| Pospisilik, et al; Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates ? - Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats; Diabetes, vol. 52, Mar. 2003 pp. 741-750. |
| Poudel, Resham R., “Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin.” Indian Journal of Endocrinology and Metabolism, 2012, vol. 16, Supplement 1, pp. S41-S46. |
| Pratley, R. et al., “Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.” Current Medical Research and Opinion, 2007, vol. 23, No. 4, pp. 919-931. |
| Prescribing Information, Package insert for Leprinton tablets 100mg, Manufacturer: Tatsumi Kagaku Co., Ltd., Mar. 2003, pp. 1-3. |
| Priimenko, B. A., et al; Synthesis and Pharmacological Activity of Derivates of 6,8-Dimethyl Imidazo(1,2-f) Xanthine-(Russ.); Khimiko-Farmatsevticheskii zhurnal (1984) vol. 18, No. 12 pp. 1456-1461. |
| Radermecker, Regis et al., “Lipodystrophy Reactions to Insulin.” American Journal of Clinical Dermatology, 2007, vol. 8, pp. 21-28. |
| Rask-Madsen, C. et al., “Podocytes lose their footing.” Nature, 2010, vol. 468, pp. 42-44. |
| Rhee et al.: “Nitrogen-15-Labeled Deoxynucleosides. 3. Synthesis of [3-15N]-2′-Deoxyadenosine” J. Am. Chem. Soc. 1990, 112, 8174-8175. |
| Rosenbloom, et al., “Type 2 Diabetes mellitus in the child and adolescent”, Pediatric Diabetes, 2008, p. 512-526. |
| Rosenstock, et al., “Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component montherapy in patients with type 2 diabetes”. Diabetes, Obesity and Metabolism, Mar. 2007, vol. 9, No. 2, p. 175-185. |
| Rosenstock, et al., Sitagliptin Study 019 Groups, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin, Clinical Therapeutics, 2006, vol. 28, Issue 10, p. 1556-1568. |
| Rosenstock, J. et al., “Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia”. Diabetes, Obesity and Metabolishm, Dec. 2009, vol. 11. No. 12, p. 1145-1152. |
| Rowe, R. et al., Handbook of Pharmaceutical Excipients, Fifth Edition, Pharmaceutical Press, 2006, pp. 389-395, 449-453, and 731-733. |
| Rowe, R. et al., Handbook of Pharmaceutical Excipients, Fourth Edition, Pharmaceutical Press and American Pharmaceutical Association, 2003, pp. 323-332., 373-377, 609-611. |
| Russell-Jones, D. et al., “Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.” Diabetologia, 2009, vol. 52, pp. 2046-2055. |
| Salomon, J., et al.; Ultraviolet and g-Ray-Induced Reactions of Nucleic Acid Constituents. Reactions of Purines with Amines; Photochemistry and Photobiology (1974) vol. 19 pp. 21-27. |
| Sarafidis, P. et al., “Cardiometabolic Syndrome and Chronic Kidney Disease: What is the link?”JCMS 2006, 1: p. 58-65. |
| Sathananthan, A., et al., “Personalized pharmacotherapy for type 2 diabetes mellitus”. Personalized Medicine 2009 Future Medicine Ltd, vol. 6, No. 4, Jul. 2009, p. 417-422. |
| Sauer, R, et al. “Water-soluble phosphate prodrugs of 1-Propargyl-7-styrylxanthine derivatives, A2A-selective adenosine receptor antagonists”. Journal Med. Chem., vol. 43, Issue 3, Jan. 2000, p. 440-448. |
| Schillinger, M. et al., “Restenosis after percutaneous angioplasty: the role of vascular inflammation.” Vascular Health and Risk Management, 2005, vol. 1, No. 1, pp. 73-78. |
| Schmidt, D. et al., “Fibromatosis of Infancy and Childhood Histology, Ultrastructure and Clinicopathologic Correlation.” Zeitschrift für Kinderchirurgie, 1985, vol. 40, No. 1, pp. 40-46. |
| Schnapp, G. et al., “Analysis of Binding Kinetics and Thermodynamics of DPP-4 Inhibitors and their Relationship to Structure.” 23rd PSDI, Protein Structure Determination in Industry, Tegernsee, Germany, Nov. 8-10, 2015. |
| Schnapp, G. et al., “Analysis of binding kinetics and thermodynamics of DPPIV Inhibitors and their relationship to structure.” International Workshop: The aspect of time in drug design, Schloss Rauischholzhausen, Marburg, Germany, Mar. 24-27, 2014. |
| Schnapp, G. et al., “Comparative Enzyme Kinetic Analysis of the Launched DPP-4 Inhibitors.” American Diabetes Association 74th Scientific Sessions, Poster 1048-P, 2014. |
| Merck Index, 15th Ed., Linagliptin, 2013. |
| Janumet dosing instructions, Highlights of Prescribing information, 2008. |
| Ennis, Handbook of Pharmaceutical Granulation Technology, Theory of Granulation, 2010. |
| Houben-Weyl, Oxygen Compounds, Methods of Organic Chemistry, 1929. |
| Slotta, On Biguanides, Chem. Institute at the Univ. of Wroclaw, vol. 62, 1929. |
| Laugesen, Latent Autoimmune diabetes of the adult: current knowledge and uncertainty, vol. 10, 2015., Diabetic medicine. |
| Johansen, Diabetes Care, C-peptide Levels in latent Automimmune Diabetes in Adults treated with Linagliptin vs. Glimepiride, vol. 37, 2014. |
| Mojsov, Insulintropin: Glucagin like peptide: Lab of Molecular Endocrinology, vol. 79, 1987, p. 616-619. |
| Holst, Role on incretin hormones in the regulation of insulin, Am j. Physiol Endocrinol Metab., 2004. |
| Matsuyama, Glucagen like peptide: a ptotent glucagonostatic hormone, Diabetes Research, 1988, p. 281-288. |
| Wettergren, Truncated GLP-1, Inhibits Pancreatic and Gastric Functions in Man, 1993, p. 665-673. |
| Li, Glucagen like Peptide 1 Receptor Signaling Modulates b cell apoptosis, Journal of Biological Chem, 2003. |
| Drug Data Report, 1994, Source, Smith Kline Beechman, Treatments for Septic Shock, p. 459. |
| Horie, Biomedcentral, Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin vs. voglibose and placebo, 2009. |
| International Search report for PCT/EP2019/069126, dated Oct. 2, 2019. |
| Press, Synthesis of 5,6 Dimethoxyquinazolin-2(1-H) ones, J. Heterocyclic Chwm, 1986. |
| Adams, Pub Pharmafile, 2011, Boehringer-lilly launch diabetes drug tradjenta in US. |
| Excerpt from Orange Book of Product Tradjenta, Feb. 5, 2011. |
| Roy, Pharmaceutical Impurities, PharmSciTech, 2002. |
| Publication Boehringer Ingelheim and Lilly's New type 2 Diabetes Treatment tradjenta, 2015, p. 1-7. |
| Donelly, Vascular Complications of Diabetes, MBJ, vol. 320, 2000. |
| Smithies, The Jackson Lab, Mouse Strain Datasheet, 2019, p. 1-2. |
| American Diabetes Assoc., Diagnosis and Classification of Diabetes Mellitus, vol. 29, 2006. |
| Deshpande, American Physical Therapy Assoc., Epidemiology of Diabetes related complications, 2008, vol. 88. |
| Falanga, Lancet, Wound healing and impairment in the diabetic foot, vol. 366, 2005. |
| Who drug information, International nonproprietary Names for Pharmaceutical Substances, vol. 23, 2009. |
| Thielitz, Inhibitors of Dipeptidyl Peptidase IV and aminopeptidase N target Major Pathogenetic steps in Acne initiation, Journal of inventigative Dermatology, 2007. |
| Rai, Effect of Glycemic Control on apoptosis in diabetic wounds, Journal of Wound care, vol. 14, 2005. |
| Mcintosh, Dipeptidyl Synthase IV inhibitors, Regulatory Peptides, vol. 128, 2005. |
| Kaji, Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats, J. Gastro, 2012. |
| Gorrell, Fibroblast Activation Protein, Handbook of Proteolytic Enzymes, 3rd ed., 2013. |
| Mclennan, Molecular aspects of wound healing in diabetes, Dept. of Endocrinology, Univ of Sydney, vol. 14, 2006. |
| Pradham, Wound-healing abnormalities in Diabetes, Dept. of surgertm Harvard, Touch Briefings, 2007. |
| FDA Drug Safety Communication, FDA revises warnings regarding diabetes medicine metformin in certain patients with reduced kidney function, Apr. 8, 2016. |
| Groop, Diabetologica, 2012, vol. 55. |
| Basi, Diabetes Care, vol. 31, 2008. |
| Donnelly, BMJ, Vascular complications of diabetes, 2000. |
| Kendall, Emerging Treatments in Diabetes Care, Effects of Exenatide on Glycemic Control over 30 weeks in Patients with Type 2 Diabetes, vol. 28, 2005. |
| Sampanis, Hippokratia, Management of Hyperglcemia in patients with diabetes mellitus and chronic renal failure, vol. 12, p. 22-27, 2008. |
| Hasanato, Diagnostic Efficacy of random albumin creatinine ration, Saudi Med, J., 2016, vol. 37,. |
| Forst, The oral DPP 4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with diabetes, Diabetes Obes Metab, vol. 13, 2011. |
| US Court of Appeals for the Federal Circuit, Boehringer Ingelheim Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc., Decided Mar. 16, 2020, retrieved online http;///www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1172.Opinion.3-16-2020_1551193.pdf (last visited May 29, 2020.). |
| Ahren, Vascular Health and Risk Management, Novel combination treatment of type 2 diabetes DPP-4 inhibition plus metformin, 2008, p. 383-394. |
| Fuchs, Journal of Pharmacy and Pharmacology, Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans, 2009. |
| Linagliptin, Pub Chem, Clinical Trial Search of Japan, https://pubchem.ncbi.nlm.nih.gov/compound/10096344 dated Jun. 25, 2020. |
| Ristic, Diabetes, Obesity and Metabolism, Improved Glycemic Control with dipeptidyl peptidase-4 inhibition in patients In patients with type 2 diabetes, 2005. |
| Aschner, Emerging Treatments and Technologies, Effect of the Dipepttidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients with Type 2 Diabetes, vol. 29, 2006. |
| Levien, Diabetes Spectrum, New Drugs in Development for the Treatment of Diabetes, vol. 22, 2009. |
| Mikhail, Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials, expert Opinion on Investigational Drigs, 2008. |
| Schnapp, G. et al., “Comparative Enzyme Kinetic Analysis of the Launched DPP-4 Inhibitors.” American Diabetes Association, Abstract 1048-P, 2014. |
| Schurmann, C. et al., “The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Attenuates Inflammation and Accelerates Epithelialization in Wounds of Diabetic ob/ob Mice.” The Journal of Pharmacology and Experimental Therapeutics, 2012, vol. 342, No. 1, pp. 71-80. |
| Schwartz, M. S. et al., “Type 2 Diabetes Mellitus in Childhood: Obesity and Insulin Resistance”. JAOA Review Article, vol. 108, No. 9, Sep. 2008, p. 518. |
| Scientific Discussion, EMEA, Pramipexole, 2005, pp. 1-10. |
| Scientific Discussion: “Eucreas. Scientific discussion”. Online Oct. 2007, p. 1-27, URL:http://www.emea.europa.eu/humandocs/PDFs/EPAR/eucreas/H-807-en6.pdf. see point 2. quality aspects pp. 2-4. (EMEA). |
| Sedo, A. et al.; “Dipeptidyl peptidase IV activity and/or structure homologs: Contributing factors in the pathogenesis of rheumatoid arthritis?” Arthritis Research & Therapy 2005, vol. 7, pp. 253-269. |
| Shanks, N. et al., Are animal models predictive for humans?, PEHM, Philosophy, Ethics, and Humanaities in Medicine, 4(2), 2009, 1-20. |
| Sharkovska, Y., et al., “DPP-4 Inhibition with Linagliptin Delays the Progression of Diabetic Nephropathy in db/db Mice.” 48th EASD Annual Meeting, Berlin, Abstract 35, Oct. 2012. |
| Sheperd, Todd M. et al., “Efective management of obesity.” The Journal of Family Practice, 2003, vol. 52, No. 1, pp. 34-42. |
| Shintani, Maki, et al., “Insulin Resistance and Genes” Circulatory Sciences (1997) vol. 17, No. 12 pp. 1186-1188. |
| Shu, L. et al., “Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function.” Human Molecular Genetics, 2009, vol. 18, No. 13, pp. 2388-2399. |
| Shu, L. et al., “Transcription Factor 7-Like 2 Regulates B-Cell Survival and Function in Human Pancreatic Islets.” Diabetes, 2008, vol. 57, pp. 645-653. |
| Silverman, G. et al., “Handbook of Grignard Reagents.” 1996, Retrieved online: <http://books.google.com/books?id=82CaxfY-uNkC&printsec=frontcover&dq=intitle:Handbook+intitle:of+intitle:Grignard+intitle:Reagents&hl=en&sa=X&ei=g06GU5SdOKngsATphYCgCg&ved=0CDYQ6AEwAA#v=onepage&q&f=false>. |
| Singhal, D. et al., “Drug polymorphism and dosage form design: a practical perspective.” Advanced Drug Delivery Reviews, 2004, vol. 56, pp. 335-347. |
| Sortino, M.A. et al., “Linagliptin: a thorough characterization beyond its clinical efficacy.” Frontiers in Endocrinology, 2013, vol. 4, Article 16, pp. 1-9. |
| St. John Providence Health Center, “Preventing Obesity in Children and Teens.” Retrieved from internet on Aug. 22, 2013, http://www.stjohnprovidence.org/Health | nfoLib/swarticle.aspx?type=85&id= P07863. |
| Stahl, P.H., “Handbook of Pharmaceutical Salts” C.G. Wermuth, Wiley-VCH, 2002, pp. 1-374. |
| Standl, E. et al., “Diabetes and the Heart.” Diabetes Guidelines (DDG), 2002, pp. 1-25. |
| Sulkin, T.V. et al., “Contraindications to Metformin Therapy in Patients With NIDDM.” Diabetes Care, 1997, vol. 20, No. 6, pp. 925-928. |
| Sune Negre, J. M. “New Galenic Contributions to Administration Forms”. Continued Training for Hospital Pharmacists 3.2., (Publication date unavailable), Retrieved from internet on Feb. 23, 2011, http://www.ub.es/egmh/capitols/sunyenegre.pdf. |
| Suzuki, Y. et al., “Carbon-Carbon Bond Cleavage of a-Hydroxybenzylheteroarenes Catalyzed by Cyanide Ion: Retro-Benzoin Condensation Affords Ketones and Heteroarenes and Benzyl Migration Affords Benzylheteroarenes and Arenecarbaldehydes.” Chemical Pharmaceutical Bulletin, 1998, vol. 46(2), pp. 199-206. |
| Tadayyon, M. et al., “Insulin sensitisation in the treatment of Type 2 diabetes.” Expert Opinion Investigative Drugs, 2003, vol. 12, No. 3, pp. 307-324. |
| Takai, S. et al., “Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats.” Journal of Pharmacological Sciences, 2014, vol. 125, pp. 386-393. |
| Takeda Press Release: “Voglibose (BASEN) for the prevention of type 2 diabetes mellitus: A Randomized, Double- blind Trial in Japanese Subjects with Impaired Glucose Tolerance.” 2008, Retrieved online Jul. 6, 2015. https://www.takeda.com/news/2008/20080526_3621.html. |
| Tamm, E, et al., “Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem TM) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate”. Science Direct, Vaccine, Feb. 2005, vol. 23, No. 14, p. 1715-1719. |
| Tanaka, S. et al.; “Suppression of Arthritis by the Inhibitors of Dipeptidyl Peptidase IV,” In. J. Immunopharmac., vol. 19, No. 1, pp. 15-24, 1997. |
| Targher, G. et al., “Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients.” Diabetes Care, 2007, vol. 30, No. 5, pp. 1212-1218. |
| Taskinen, M.-R. et al., “Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.” Diabetes, Obesity and Metabolism, 2011, vol. 13, pp. 65-74. |
| Third Party Observation for application No. EP20070728655, May 13, 2013. |
| Thomas, L. et al., “BI 1356, a novel and selective xanthine beased DPP-IV inhibitor, exhibits a superior profile when compared to sitagliptin and vildagliptin.” Diabetologia, 2007, vol. 50, No. Suppl. 1, p. S363. |
| Thomas, L., “Chronic treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356[9R)-8-(3-Amino-piperidin-1-yl)-7-but-2-yny1-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models” The Journal of Pharmacology and Experimental Therapeutics, Feb. 2009, vol. 328, No. 2, pp. 556-563. |
| Thomas, Leo et al: “(R)-8-(3-Amino-piperidin-1-y1)-7-but-2-yny1-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor . . . ”Journal of Pharmacology and Experimental Therapeutics, 2008, vol. 325, No. 1, p. 177. |
| Thornber, C.W., “Isosterism and Molecular Modification in Drug Design.” Chemical Society Reviews, 1979, pp. 563-580. |
| Tounyoubyou, “Symposium-19: Future Perspectives on Incretion Therapy in Diabetes.” 2008, vol. 51, Suppl. 1, p. S-71, S19-2. |
| Tradjenta, Highlights of Prescribing Information (revised Sep. 2012). |
| Tribulova, N. et al. “Chronic Disturbances in NO Production Results in Histochemical and Subcellular Alterations of the Rat Heart.” Physiol. Res., 2000, vol. 49, No. 1, pp. 77-88. |
| Tsujihata, et al., “TAK-875, an orally available G protein-Coupled receptor 40/Free fatty acid receptor 1 Agonist, Enhances Glucose Dependent Insulin Secretion and improves both Postprandial and Fasting hyperglycemic in type 2 Diabetic rats”, J. Pharm Exp. 2011, vol. 339, No. 1, p. 228-237. |
| Tsuprykov, O. et al., Linagliptin is as Efficacious as Telmisartan in Preventing Renal Disease Progression in Rats with 5/6 Nephrectomy, 73rd Annual Meeting Science Session, ADA, Chicago, Jun. 2013. |
| Turner, R.C. et al., “Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus Progressive Requirement for Multiple Therapies (UKPDS 49)” The Journal of the American Medical Association, 1999, vol. 281, No. 21, pp. 2005-2012. |
| Uhlig-Laske, B. et al., “Linagliptin, a Potent and Selective DPP-4 Inhibitior, is Safe and Efficacious in Patients with Inadequately Controlled Type 2 Diabetes Despite Metformin Therapy”. 535-P Clinical Therapeutics/New Technology—Pharmacologic Treatment of Diabetes or Its Complications, Posters, vol. 58, Jun. 5, 2009, p. A143. |
| United Healthcare, “Diabetes.” Retrieved from Internet on Aug. 22, 2013, http://www.uhc.com/source4women/health_topics/diabetesirelatedinformation/dOf0417b073bf11OVgnVCM1000002f1Ob1Oa_.htm. |
| Van Heek, M. et al., “Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters.” Diabetes, 2001, vol. 50, pp. 1330-1335. |
| Vichayanrat, A. et al., “Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients.” Diabetes Research and Clinical Practice, 2002, vol. 55, pp. 99-103. |
| Vickers, 71st Scientific Session of the American Diabetes Association, “The DPP-4 inhibitor linagliptin is weight neutral In the DIO rat but inhibits the weight gain of DIO animals withdrawn from exenatide”, vol. 60, Jul. 2011. |
| Villhauer, E.B., “1-[[3-Hydroxy-1-adamantyl)amino]acetyl]-1-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties” Journal Med. Chem, 2003, 46, 02774-2789. |
| Villhauer, E.B., et al., “1-{2-{5-Cyanopyridin-2-yl)amino}-ethylamino}acetyl-1-1(S)-pyrrolidine-carbonitrile: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties”. Journal of Medical Chemistry, 2002, vol. 45, No. 12, p. 2362-2365. |
| Vincent, S.H. et al., “Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans.” Drug Metabolism And Disposition, 2007, vol. 35, No. 4, pp. 533-538. |
| Wang, Y. et al., “BI-1356. Dipeptidyl-Peptidase IV Inhibitor, Antidiabetic Agent.” Drugs of the Future, 2008, vol. 33, No. 6, pp. 473-477. |
| Weber, Ann E., “Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes.” Journal of Medicinal Chemistry, 2004, vol. 47, pp. 4135-4141. |
| WebMD, Autoimmune Diseases: What Are They? Who Gets Them? “What Are Autoimmune Disorders?” 2015, pp. 1-3. Retrieved online Jul. 9, 2015. http://www.webmd.com/a-to-z-guides/autoimmune-diseases. |
| Lee, Radical Approach to Diabetic Neuropathy, Kidney International, vol. 72, 2007, p. 67-70. |
| Rungby, inhibition of dipeptidyl peptidase 4 by BI 1356, a new drug for the treatment of beta cell failure in type 2 diabetes, Expert Opin. Invest. Drugs, vol. 18, 2009, p. 835-838. |
| Hahr, Management of diabetes mellitus in patients with chronic kidney disease, Clinical Diabetes and Endocrinology, vol. 10, 2015, 9 pages. |
| Duong, Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes, Clinical Pharmacokinetics, vol. 52, 2013, p. 373. |
| Bell, Prescribing for older people with chronic renal impairment, Australian Family Physician, vol. 42, 2013, 5 pages. |
| Munar, Drug dosing adjustments in patients with chronic kidney disease, AFP, vol. 75, 2007, 10 pages. |
| Laasko, Hyperglycemia and Cardiovascular Disease in Type 2 Diabetes, Diabetes, vol. 48, 1999, 6 pages. |
| Haffner, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, The N.E. J. of Medicine, vol. 339, 1996, 6 pages. |
| Calles, Type 2 diabetes, Coronary Artery Disease, vol. 10, 1999, 8 pages. |
| Marks, Cardiovascular Risk in Diabetes, Journal of Diabetes and the complications, vol. 14, 2000, 8 pages. |
| Fadini, DPP-4 inhibition has no cute affect on BNP and its N-terminal pro-hormone measured by commercial immune assays, Cardiovascualr Diabetology, vol. 16, 2017, 7 pages. |
| Mu, Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus, Diabetology, vol. 14, 2022, 9 pages. |
| McGuire, Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus, http://shjajournals.org on Mar. 18, 2023, 11 pages. |
| Clifton, Do dipeptidyl Peptidase IV inhibitors cause heart failure?, Clinical therapeutics, vol. 36, 2014, 8 pages. |
| Shiraki, The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency, Pharmcology and Pharmacotherapy, downloaded from http://academic.cup.com/eurheartj/article/43/supplement_2/ehcac544268/26746435 Mar. 18, 2023. |
| Mu, Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus, Diabetology and Diabetes Mellitus, vol. 14, 2022, 9 pages. |
| Translations of Textbook Diabetologie in Kilink and Praxis, 384 and 434, 2003, 4 pages. |
| “Betahistine diHCL CF 16 mg, tabletten,” Dutch Medicines Evaluation Board, Dated Apr. 13, 1988, Retrieved online from: <http://db.cbg-meb.nl/ords/f?p=111:3:0:SEARCH:NO::P0_DOMAIN,P0_LANG,P3_RVG1:H,EN,57626>. |
| “Betahistine diHCL CF 8 mg, tabletten,” Dutch Medicines Evaluation Board, Dated Apr. 13, 1988, Retrieved online from: <http://db.cbg-meb.nl/ords/f?p=111:3:0:SEARCH:NO::P0_DOMAIN,P0_LANG,P3_RVG1:H,EN,56227>. |
| “Sifrol 0,088 mg, tabletten,” Dutch Medicines Evaluation Board, Dated Oct. 14, 1997, Retrieved online from: <http://db.cbg-meb.nl/ords/f?p=111:3:0:SEARCH:NO::P0_DOMAIN,P0_LANG,P3_RVG1:H,EN,70120>. |
| “Sifrol 0,18 mg, tabletten,” Dutch Medicines Evaluation Board, Dated Oct. 14, 1997, Retrieved online from: <http://db.cbg-meb.nl/ords/f?p=111:3:0:SEARCH:NO::P0_DOMAIN,P0_LANG,P3_RVG1:H,EN,70121>. |
| “Sifrol 0,35 mg, tabletten,” Dutch Medicines Evaluation Board, Dated Nov. 16, 1999, Retrieved online from: <http://db.cbg-meb.nl/ords/f?p=111:3:0:SEARCH:NO::P0_DOMAIN,P0_LANG,P3_RVG1:H,EN,70673>. |
| “Sifrol 0,70 mg, tabletten,” Dutch Medicines Evaluation Board, Dated Oct. 14, 1997, Retrieved online from: <http://db.cbg-meb.nl/ords/f?p=111:3:0:SEARCH:NO::P0_DOMAIN,P0_LANG,P3_RVG1:H,EN,70122>. |
| “Sifrol 1,1 mg, tabletten,” Dutch Medicines Evaluation Board, Dated Oct. 14, 1997, Retrieved online from: <http://db.cbg-meb.nl/ords/f?p=111:3:0:SEARCH:NO::P0_DOMAIN,P0_LANG,P3_RVG1:H,EN,70124>. |
| Abstract for AU 2003280680, Jun. 18, 2004. |
| Abstract for AU 2009224546, Sep. 17, 2009. |
| Abstract in English for DE10109021, 2002. |
| Abstract in English for DE19705233, Aug. 13, 1998. |
| Abstract in English for DE2205815, 1972. |
| Abstract in English for EP0023032, 1981. |
| Abstract in English for JP 2002/348279, Dec. 4, 2002. |
| Abstract in English for JP 2003/286287, Oct. 10, 2003. |
| Abstract in English for KR20070111099, Nov. 11, 2007. |
| ACTOS Prescribing Information, 1999, pp. 1-26. |
| Adebowale, K.O. et al., “Modification and properties of African yam bean (Sphenostylis stenocarpa Hochst. Ex A. Rich.) Harms starch I: Heat moisture treatments and annealing.” Food Hydrocolloids, 2009, vol. 23, No. 7, pp. 1947-1957 |
| Ahren, B. et al., “Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes.” Diabetes Care, 2004, vol. 27, No. 12, pp. 2874-2880. |
| Ahren, Bo “Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.” Vascular Health and Risk Management, 2008, vol. 4, No. 2, pp. 383-394. |
| Ahren, BO, et al; Improved Meal-Related b-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients with Type 2 Diabetes Over 1 Year; Diabetes Care (2005) vol. 28, No. 8 pp. 1936-1940. |
| Ahren, BO; “DPP-4 inhibitors”, Best practice and research in clinical endocrinology and metabolism—New therapies for diabetes 200712 GB LNKD—DOI:10.1016/J. Beem.2007.07.005, vol. 21, No. 4, Dec. 2007, pp. 517-533. |
| Al-Masri, I.M. et al., “Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.” Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, vol. 24, No. 5, pp. 1061-1066. |
| Alter, M. et al., “DPP-4 Inhibition on Top of Angiotensin Receptor Bockade Offers a New Therapeutic Approach for Diabetic Nephropathy.” Kidney and Blood Pressue Research, 2012, vol. 36, No. 1, pp. 119-130. |
| American Association of Clinical Endocrinologists, “Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus.” Endocrine Practice, 2007, col. 13, Suppl. 1, pp. 1-68. |
| American Diabetes Association, “Standards of Medical Care in Diabetes-2008.” Diabetes Care, Jan. 2008, vol. 31, Supplement 1, pp. S12-S54. |
| Anstee, Quentin M. et al. “Mouse models in non-alcholic fatty liver disease and steatohepatitis research” (2006) International Journal of Expermental Pathology, vol. 87, pp. 1-16. |
| Augeri, D.J. “Discovery and Preclinical Profile of Saxagliptin (GMB-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes”. Journal Med. Chem, 2005, vol. 48, No. 15, p. 5025-5037. |
| Augusti, D.V. et al., “Quantitative determinatio of the enantiomeric composition of thalidomide solutions by electrospray ionizatio tandem mass spectrometry”. Chem Comm, 2002, p. 2242-2243. |
| Augustyns, K. et al., The Unique Properties of Dipeptidyl-peptidase IV (DPP IV/CD 26) and the Therapeutic Potential of DPP-IV Inhibitors, Current Medicinal Chemistry, vol. 6, No. 4, 1999, pp. 311-327. |
| Aulinger, B.A. et al., “Ex-4 and the DPP-IV Inhibitor Vildagliptin have Additive Effects to Suppress Food Intake in Rodents”. Abstract No. 1545-P, 2008. |
| Aulton, Michael E., Pharmaceutics: The Science of Dosage Form Design, Second Edition, 2002, pp. 441-448. |
| Baetta, R. et al., “Pharmacology of Dipeptidyl Peptidase-4 Inhibitors.” Drugs, 2011, vol. 71, No. 11, pp. 1441-1467. |
| Balaban, Y.H. et al., “Dipeptidyl peptidase IV (DDP IV) in NASH patients” Annals of Hepatology, vol. 6, No. 4, Oct. 1, 2007, pp. 242-250, abstract. |
| Balbach, S. et al., “Pharmaceutical evaluation of early development candidates the 100 mg-approach.” International Journal of Pharmaceutics, 2004, vol. 275, pp. 1-12. |
| Balkan, B. et al., “Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obses Zucker rates”. Diabetologia, 1999, 42, p. 1324-1331. |
| Banker, Gilbert S., “Prodrugs.” Modem Pharmaceutics Third Edition, Marcel Dekker, Inc., 1996, p. 596. |
| Bastin, R.J. et al., “Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities”. Organic Process Research and Development, 2000, vol. 4, p. 427-435. |
| Beauglehole, Anthony R., “N3-Substituted Xanthines as Irreversible Adenosine Receptor Antagonists.” Ph.D. Thesis, Deakin University, Australia, 2000, pp. 1-168. |
| Beljean-Leymarie et al., Hydrazines et hydrazones hétérocycliques. IV. Synthèses de dérives de l'hydrazine dans a série des imidazo[4,5-d]pyridazinones-4, Can. J. Chem., vol. 61, No. 11, 1983, pp. 2563-2566. |
| Berge, S. et al., “Pharmaceutical Salts.” Journal of Pharmaceutical Sciences, 1977, vol. 66, No. 1, pp. 1-19. |
| Bernstein, Joel “Polymorphism in Molecular Crystals.” Oxford University Press, 2002, p. 9. |
| Blech, S. et al., “The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans”, Drug Metabolism and Disposition, 2010, vol. 38, No. 4, p. 667-678. |
| Bollag, R.J. et al; “Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors,” Endocrinology, vol. 141, No. 3, 2000, pp. 1228-1235. |
| Borloo, M. et al. “Dipeptidyl Peptidase IV: Development, Design, Synthesis and Biological Evaluation of Inhibitors.” 1994, Universitaire Instelling Antwerpen, vol. 56, pp. 57-88. |
| Bosi, E. et al., “Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin.” Diabetes Care, 2007, vol. 30, No. 4, pp. 890-895. |
| Boulton, D.W. et al., “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-Daily Oral Doses of Saxagliptin for 2 Weeks in Type 2 Diabetic and Healthy Subjects.” Diabetes, 2007, Supplement 1, vol. 56, pp. A161. |
| Brazg, R. et al: “Effect of adding sitagliptin, a dipeptidyll peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.” Diabetes, Obesity and Metabolism, Mar. 2007, vol. 9, No. 2, Mar. 2007 pp. 186-193. |
| Brazg, Ronald, et al; Effect of Adding MK-0431 to On-Going Metforming Therapy in Type 2 Diabetic Patients Who Have Inadequate Glycemic Control on Metformin; Diabetes ADA (2005) vol. 54, Suppl. 1 p. A3. |
| Brittain, H.G., “Methods for the Characterization of Polymorphs: X-Ray Powder Diffraction,” Polymorphism in Pharmaceutical Solids, 1999, p. 235-238. |
| Number | Date | Country | |
|---|---|---|---|
| 20210121468 A1 | Apr 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61492391 | Jun 2011 | US | |
| 61421400 | Dec 2010 | US | |
| 61415545 | Nov 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13295174 | Nov 2011 | US |
| Child | 14669813 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15668819 | Aug 2017 | US |
| Child | 17122072 | US | |
| Parent | 14669813 | Mar 2015 | US |
| Child | 15668819 | US |
